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ABSTRACT 
The progressive X-linked genetic disorder Duchenne Muscular Dystrophy (DMD) is 
caused by a defect in the myofibre subsarcolemmal protein dystrophin. The malfunction of 
dystrophin leads to myofibre membrane fragility and myofibre necrosis. Currently, there is no 
cure for DMD available, which affects 1 in 3500 live male birth worldwide.  
Here, we test the hypothesis that overexpression of the hormone relaxin is able to 
reduce muscular fibrosis. For this purpose, we use conventional plasmids or adeno-associated 
viral (AAV) vectors based plasmids to express mouse relaxin 1 isoforms in mouse muscle cells 
(C2C12 cells) and in mouse muscle fibroblasts (MH cells). We assessed the expression of relaxin, 
as well as the relaxin downstream effect on fibrotic related genes, in transfected cells through 
real-time quantitative PCR or Western Blot analysis. In addition, we performed in vitro wound 
scratch assays to examine whether overexpression of relaxin decreases the migration potential 
of fibroblasts. We show that an increased expression of relaxin reduces the fibrotic response of 
muscle fibroblasts in vitro.  
On the basis of this cellular work, overexpression of relaxin may have the potential to 
reduce muscle fibrosis in in vivo models of DMD. Further studies will be carried out in mouse 
models to fully explore the potential of overexpressed relaxin as a novel anti-fibrotic therapy in 
patients suffering from DMD.   
 
 
 
 
 
 
 
 
 
6 
 
GLOSSARY OF ABBREVIATIONS 
AAV Adeno associated virus NP-40 Nonidet P-40 
Amp Ampicillin  ori Originate of replicate 
BSA Bovine serum albumin pDNA Plasmid DNA  
cDNA  complementary DNA PBS 
PCR 
PEI  
Phophaste buffered saline 
Polymerase chain reaction 
Polyethylenimine 
CO Codon optimised 
DMD  Duchenne muscular dystrophy 
DMEM Dulbecco Modified Eagle Media mRNA Messenger RNA 
DNA  Deoxyribonucleic acid mRln1 Mouse relaxin 1 
ECM Extracellular matrix  RNA Ribonucleic acid  
FBS  Fetal bovine serum rpm  Revolutions per minute 
GFP Green fluorescent protein scAAV Self-complementary AAV 
kb Kilobase Spc512 Muscle specific synthetic promoter  
kDa Kilidalton ssAAV Single stranded AAV 
LB Luria-Bertani SV40 Simian virus 40 
µ 
mRln1 
NCO 
ng 
Micro 
mouse relaxin 1 
non-codon optimised 
nanogram  
SyBr N',N'-dimethyl-N-[4-[(E)-(3-methyl-
1,3-benzothiazol-2-ylidene)methyl]-
1-phenylquinolin-1-ium-2-yl]-N-
propylpropane-1,3-diamine 
nm Nanometre TAE Tris base, acetic acid and EDTA 
buffer 
  TRE Tetracycline respond element  
  UV Ultraviolet 
    
    
    
    
    
    
    
    
    
    
    
 
 
 
    
 
 
7 
 
TABLE OF CONTENT 
CHAPTER 1: INTRODUCTION…………………………………………………….……………………………….. 13 
1.1 Gene Therapy……………………………………………………………………….…............................. 14 
     1.1.1 Overview of Gene therapy…………………..……………………………………………………..… 14 
     1.1.2 Gene therapy vectors...…………………………………………………………………………………. 15 
          1.1.2.1 Viral vectors………..………………………………………………………………………………… 15 
          1.1.2.2 Adeno-Associated Viral (AAV) vectors……………………………………………………. 17 
                1.1.2.2.1 AAV structure………………………………………………………………………………… 17 
                1.1.2.2.2 AAV serotypes……………………………………………………………………………….. 19 
     1.1.3 Gene therapy for muscle cells…………………..………………………………………………….. 19 
1.2 Skeletal muscle……………………………………………………………………………………………………. 20 
     1.2.1 Anatomy and physiology of normal skeletal muscle …..………………………………… 20 
     1.2.2 Myogenesis…………………..……………………………………………………………..………………. 21 
     1.2.3 ECM in skeletal muscle…………………………………………………………..…………………….. 23 
     1.2.4 The composition of skeletal muscle ECM…………………….………………………………… 23 
     1.2.5 The dystrophin-associated glycoprotein complex (DGC)……………………………….. 23 
1.3 Muscular dystrophy …………………..………………………………………………………………………. 24 
     1.3.1 Duchenne Muscular Dystrophy (DMD)….………………………………………………………. 25 
     1.3.2 Dystrophin………………………………………………………………………….………………………… 28 
          1.2.3.1 Overview of Dystrophin gene………………………………………………………………… 28 
          1.2.3.2 Structure of Dystrophin Protein…………………..………………………………………… 29 
          1.2.3.3 Mutation of Dystrophin in DMD ……………..………..………..…………………………. 29 
     1.3.3 Clinical and Pathological Characteristics of DMD…………………………………………… 30 
     1.3.4 Animal Model of DMD…………………………………………………………………………………… 31 
          1.3.4.1 Mdx mouse……………………………………………………………………………………………. 32 
     1.3.5 Therapeutic Approaches for DMD…………………………………………………………………. 32 
     1.3.6 Clinical Trials for DMD………………………………………………………………………………….. 34 
1.4 Wound Healing and Fibrosis……………………………………………………………………………….. 35 
     1.4.1 ECM in fibrosis …………………………………………………………………………………….………. 35 
     1.4.2 Muscle fibrosis in DMD….……………………………………………………………………………… 36 
     1.4.3 The role of relaxin in treatment of fibrosis……………………………………………………… 36 
1.5 Relaxin………………………………………………………………………………………………………………… 37 
     1.5.1 Relaxin family……………………………………………………………………………………………….. 38 
     1.5.2 Relaxin receptor and cellular pathway…………………………………………………………… 39 
     1.5.3 Animal model of relaxin………………………………………………………………………………… 40 
1.6 Aim and objective..……………………………………………………………………………………………… 41 
CHAPTER 2 MATERIAL AND METHODS…………………………………………………..…………………. 42 
     2.1 Standard Reagents…………………………………………..…………………………………………….. 43 
     2.2 Plasmids…………………………………………..……………………………………………………………… 44 
        2.2.1 Transgene Analysis…………………………………………………………………………………….. 44 
        2.2.2 Relaxin Plasmids…………………………………………………………………………………………. 44 
        2.2.3 pCI-eGFP……………………………………………………………………………………………………. 44 
     2.3 Computer Software and Bioinformatics Software…………………………………………... 46 
        2.3.1 Primer design……………………………………………………………………………………………… 46 
        2.3.2 SnapGene Software……………………….…………………………………………………………… 47 
        2.3.4 GraphPad Prism Software…………………………………………………………………………… 47 
        2.3.5 FlowJo Software (BD Falcon)…………………………………………………….………………… 47 
        2.3.6 ImageJ Software………………………………………………………………………………………… 47 
     2.4 Bacterial Cultures…………………………………..……………………………………………………….. 48 
         2.4.1 Materials…………………………………………………………………………………………………... 48 
         2.4.2 Heat Shock Transformation Plasmid into Bacteria………………………………….….. 48 
         2.4.3 Screening for Transformants……………………………………………………………………… 49 
8 
 
         2.4.4 Production of Bacterial Cultures………………………………………………………………… 49 
         2.4.5 Long-term Glycerol Bacterial Storage………………………………………………………… 49 
         2.4.6 Bacterial Stocks…………………………………………………………………………………………. 50 
         2.4.7 Amplification and Purification of Plasmid DNA…………………………………………… 50 
     2.5 Nucleic acid manipulation………..………………………………………………………………..…… 51 
         2.5.1 Materials…………………………………………………………………………………………………… 51 
         2.5.2 Determination of Nucleic Acid Concentration through Optical Density……… 51 
         2.5.3 Endonuclease Restriction Digest………………………………………………………………… 52 
         2.5.4 Analysis Restriction Digest Plasmid with Horizontal Agarose Gel 
                   Electrophoresis…………………………………………………………………………………………. 
 
53 
     2.6 Tissue Cultures……………………………..…………………………………………………………………. 54 
         2.6.1 General Tissue culture reagents….……………………………………………………………… 54 
         2.6.2 Cell Lines…………………………………………………………………………………………………… 54 
         2.6.3 Cell Culture Growth Media………………………………………………………………………… 54 
            2.6.3.1 Growth Media for Culturing Mouse Myoblast (C2C12)………………………… 55 
            2.6.3.2 Growth Media for Culturing Mouse Muscle Fibroblast (MH)………………… 55 
         2.6.4 Thawing Cells…………………………………………………………………………………………….. 55 
         2.6.5 Counting Cells with Haemocytometer (Neubauer Chamber) and Trypan        
                   Blue staining……..…………………………………………………………………………………….… 
 
55 
         2.6.6 Culturing and Maintenance Cell Lines……………………………………………………….. 56 
         2.6.7 Cryopreservation of cells……………………………………………..…………………………… 57 
     2.7 Transient Transfection Protocols………………………………………………………….………… 57 
         2.7.1 Preparation of Cells for Transfection in 6 Well Plate…………………………………… 57 
         2.7.2 Comparison the Efficiency of Different Transfection Reagent……………………. 57 
            2.7.2.1 Transfection Reagents and Ratios………………………………………………………… 57 
         2.7.3 Transient Transfection with Viafect…………………………………………………………… 58 
         2.7.4 Transient Transfection with Lipofectamine® 3000……………………………………… 59 
         2.7.5 Transient Transfection with PEI…………………………………………………………………. 60 
     2.8 Flow Cytometry………………………………………………………………………………………………. 61 
         2.8.1 Materials………………………………………………….……………………………………………….. 61 
         2.8.2 Harvest GFP Expression in Cell Cultures……………………………………………………… 61 
         2.8.3 GFP detection and analysis………………………………………………………………………… 61 
     2.9 Total RNA extraction…………………..…………………………………………………………………… 62 
     2.10 Polymerase Chain Reaction (PCR) and Reverse transcription PCR (RT-PCR)….. 62 
         2.10.1 Materials…………………………………………………………………………………………………. 62 
         2.10.2 First strand cDNA Construction for RT-qPCR….………………………………………… 62 
         2.10.3 RT-qPCR ………..………………………………………………………………………………………… 63 
             2.10.3.1 RT-qPCR mastermix preparation……………………………………………………….. 63 
             2.10.3.2 RT-qPCR set up………………………………………………………………………………….. 63 
             2.10.3.3 RT-qPCR analysis……………………………………………………………………………….. 63 
     2.11 Wound Scratch Assay……………………………..…………………………………………………….. 64 
         2.11.1 Materials…………………………………………………………………………………………………. 64 
         2.11.2 Wound scratch assay dishes labelling...……………….…………………………………... 64 
         2.11.3 Seeding cells……………………………………………………………………………………………. 65 
         2.11.4 Wound scratch………………………………………………………………………………………… 65 
         2.11.5 Transfection……………………………………………………………………………………………. 65 
         2.11.6 Microscopy imaging on wound scratch……………………………………………………. 66 
         2.11.7 Wound scratch assessment……………………………………………………………………… 66 
     2.12 Isolation of mouse organs and protein extraction…………………………….…………… 66 
         2.12.1 Materials…………………………………………………………………………………………………. 66 
         2.12.2 Dissection of mouse tissue from mouse………..………………………………………… 67 
         2.12.3 Protein extraction from frozen mouse tissue samples……………………………… 67 
     2.13 Protein extraction and quantification…………………………………………………………… 67 
9 
 
         2.13.1 Materials…….…………………………………..…………………………………..…………………. 67 
         2.13.2 Protein extraction…….…………………………………..…………………………………..……. 68 
                2.13.2.1 Protein Extraction from Cell Lysate………………………………………………… 68 
                2.13.2.2 Protein Precipitation through Supernatant with  
                                Methanol/Chloroform Methods…………………………………………………….. 
 
68 
         2.13.3 Protein quantification…………………………………..…………………………………..…….. 69 
     2.14 Western Blot………………………………………………..……………………………………………….. 70 
         2.14.1 Materials…………………………………………………………………………………………………. 70 
         2.14.2 Antibodies………………………………………………………………………………………………. 70 
                2.14.2.1 Primary Antibodies…………………………………………………………………………. 70 
                2.14.2.2 Secondary Antibodies………………………………………………………………….…. 70 
         2.14.3 Sample Preparation…………………………………………………………………………………. 71 
         2.14.4 SDS-PAGE Gel set up and Electrophoresis………………………………………………… 71 
         2.14.5 Opening Precast Gel Cassettes and transferring protein onto 
                     Nitrocellulose membrane………………………………………………………………………… 
 
72 
         2.14.6 Post-Transfer Nitrocellulose Membrane Checks and Blocking………………….. 73 
         2.14.7 Visualization of the Nitrocellulose membrane (NCB): The Odyssey Method 73 
CHAPTER 3: STUDIES ON MRNA EXPRESSION AND DOWNSTREAM EFFECT OF 
MOUSE RELAXIN 1 USING PLASMID VECTORS…………………………..……………………………… 
 
75 
     3.1 Introduction…………………………………………….………………………………………………………. 76 
     3.2 Results……………………………………………………………………………………………………….……. 76 
         3.2.1 Plasmid construct design…………………………………………………………………………… 80 
             3.2.1.1 Reporter gene design and validation…………………………………………………… 80 
             3.2.1.2 Design and validation of plasmid express mRln1 driven by Spc512 
                          (AAV based plasmid…………….……………………………………………………………… 
 
80 
             3.2.1.3 Design and validation of plasmid express mRln1 driven by Tet On 
                                    (conventional & AAV based plasmid)………………………………………………….. 
 
81 
         3.2.2 Comparison between codon optimised and native mouse relaxin 1…………… 91 
         3.2.3 Optimising transgene expression efficiency in C2C12 and MH cells with GFP 
                   Reporter system….……………………………………………………………………………………. 
 
94 
         3.2.4 Bioinformatics analysis of mouse relaxin 1 and human relaxin 2…..…………… 99 
     3.3 Discussion………………………………………………………………………………………………………… 101 
         3.3.1 Plasmid construct design and characterisation…………………………………………… 101 
         3.3.2 Comparison between codon optimised and native mouse relaxin 1…………… 102 
         3.3.3 Assessment of GFP fluorescence and detection by flow cytometry analysis  
                   in mouse myogenic cell line (C2C12) and mouse myogenic fibroblast cell 
                   line (MH)…………………………………………………………………………………………………… 
 
 
103 
         3.3.4 Bioinformatics analysis of mouse relaxin 1 and human relaxin 2 analysis…… 105 
CHAPTER 4: ANALYSIS MRLN1 TRANSCRIPT LEVEL AND PROTEIN EXPRESSION IN 
CELLS TRANSFECTED WITH VARIOUS PLASMID CONSTRUCTS…….……………………………. 
 
106 
     4.1 Introduction…………………………………………………………………………………………………….. 107 
     4.2 Result………………………………………………………………………………………………………………. 110 
         4.2.1 Gradient PCR Optimization analysis of mRln1 gene expression…………………. 110 
         4.2.2 Detection of mRln1 transcripts in C2C12 or MH cell line by RT-qPCR 
                   analysis……………………………………………………………………………………………………… 
 
112 
         4.2.3 Optimization of western blot analysis for mRln1 protein detection…………… 115 
          
         4.2.4 Sustained mRln1 transgenes expression studies: Comparison the levels of  
                   mRln1 protein expression with transfected pTet On-NCO mRln1 cultures of 
                   C2C12 and MH cell line………………………………………………………………………………. 
 
 
 
117 
     4.3 Discussion……………………………………………………………………………………………………….. 121 
         4.3.1 Gradient PCR and RT-qPCR to detect CO mRln1 & NCO mRln1…………………… 121 
         4.3.2 Western blot optimization…………………………………………………………………………. 123 
10 
 
         4.3.3 Western blot detection of mRln1 protein expression evaluation…………..…… 124 
CHAPTER 5: STUDIES ON EFFECT OF RELAXIN ON FIBROBLAST THROUGH in vitro 
SCRATCH ASSAY............................................................................................................. 
 
129 
     5.1 Introduction…………………………………………………………………………………………………….. 130 
     5.2 Result………………………………………………………………………………………………………………. 132 
         5.2.1 Effect of mRln1 on downstream fibrotic related gene expression assessed    
                   Using RT-qPCR analysis…………………………………………………………………………...... 
 
132 
         5.2.2 Wound scratch assay studies with MH cells………………………………………………… 139 
             5.2.2.1 Effect of TGF-β1 on wound closure……………..………………………………………. 139 
             5.2.2.2 Effect of mRln1 on wound closure.………………………………………………………. 142 
     5.3 Discussion……………………………………………………………………………………………………….. 145 
         5.3.1 The effect of mRln1 on downstream fibrotic related genes………………………… 145 
         5.3.2 The effect of TGF-β1 and mRln1 on wound closure in wound scratch assay… 146 
CHAPTER 6: GENERAL DISCUSSION…………………………………………………….……………………… 149 
     6.1 Project overview…..…………………………………………………………………………………………. 150 
     6.2 Limitation of the work present and relevance to the field of gene therapy for  
            DMD and muscle fibrosis…………………………………………………………………………………. 
 
151 
         6.2.1 Limitation of present work………………………………………………………………………… 152 
     6.3 Conclusion……………………………………………………………………………………………………….. 157 
REFERENCES..……………………………………………………………………………………………………………. 158 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
LIST OF FIGURES  
Figure 1.1 Figure 1 A representative illustration of wild-type adeno-associated virus (wt-
AAV) viral genome and mRNA transcript 
18 
Figure 1.2 Structure of muscle fibre, from myofibril to myofilaments to sarcomeres 21 
Figure 1.3 The illustration of dystrophin-glycoprotein complex (DGC). 24 
Figure 1.4 The schematic pathophysiological consequences in DMD patients 27 
Figure 1.5 The blue vertical line represent 79 exons in the dystrophin gene 28 
Figure 1.6 Image illustrating the full-length dystrophin protein 29 
Figure 1.7 Gower`s manoeuvre of DMD 31 
Figure 1.8 Image illustration of full-length, mini- and micro-dystrophin 33 
Figure 1.9 Scheme of Pre-Pro-Mouse Relaxin 1 Protein 38 
Figure 1.10 The illustration of Serelaxin interact with RXFP1 in mammalian heart 40 
Figure 2.1 Haemacytometer and Cell counting system 56 
Figure 2.2 The illustration shows the bottom labelling ibidi dishes 65 
Figure 2.3 The Illustration of One Gel transferring process during western blot 73 
Figure 3.1 Design and characterisation of pCi-eGFP 82 
Figure 3.2 Design and characterisation of pssAAV-Spc512-CO mRln1 vectors 83 
Figure 3.3 Design and characterisation of pssAAV-Spc512-NCO mRln1 vectors 84 
Figure 3.4 Design and characterisation of pscAAV-Spc512-CO mRln1 vectors 85 
Figure 3.5 Design and characterisation of pscAAV-Spc512-NCO mRln1 vectors 86 
Figure 3.6 Design and characterisation of pTet On-CO mRln1 vectors 87 
Figure 3.7 Design and characterisation of pTet On-NCO mRln1 vectors 88 
Figure 3.8 Design and characterisation of pssAAV-Tet On-CO mRln1/HA vectors 89 
Figure 3.9 Design and characterisation of pssAAV-Tet On-NCO mRln1/HA vectors 90 
Figure 3.10 Comparison between codon optimise and native mouse relaxin 1  92 
Figure 3.11 Comparative transfection efficiency with various transfection reagents 
(Lipofectamine p3000, PEI and Viafect) in C2C12 and MH cells 
96 
Figure 3.12 Fluorescence microscopy images with various transfection reagents in 
C2C12 cell 
97 
Figure 3.13 Fluorescence microscopy images with various transfection reagents in MH 
cell 
98 
Figure 3.14 Comparison amino acids sequence between mRln1 and hRln2 100 
Figure 3.15 Comparison protein structure between mRln1 and hRln2  101 
Figure 4.1 Figure 4.1 Gel Image indicate a gradient PCR 111 
Figure 4.2 Comparison between the mRln1 mRNA expressions with different plasmid 
construct 
113 
Figure 4.3 Gel Image of RT-qPCR amplicon targeting mRln1 114 
Figure 4.4 Ponceau S staining for transferring optimization 115 
Figure 4.5 Western blot blocking buffer optimization 116  
Figure 4.6 Western blot to detect mRln1 with HA tag antibody 118 
Figure 4.7 Western blot to detect mRln1 with mRln1 targeting antibody 119 
Figure 4.8 Western blot to detect mRln1 in C2C12 and MH cells 120 
Figure 5.1 Melting Curve of RT-qPCR targeting downstream fibrotic related genes  134 
Figure 5.2 Melting Curve of RT-qPCR targeting downstream fibrotic relate genes 135 
Figure 5.3 RT-qPCR analysis of downstream fibrosis-related genes of RNA harvested 
from C2C12 cells transfected with mRln1 expressing plasmid 
136 
Figure 5.4 Gel Image with RT-qPCR amplicon targeting downstream fibrotic relate gene 137 
Figure 5.5 RT-qPCR targeting 3 downstream fibrotic related genes affected by mRln1 in 
MH cells. 
138 
Figure 5.6 In vitro assessment of wound closure in MH cell with hrTGF-β1 140 
Figure 5.7 Representative phase contrast images of cell wound scratch assay 141 
Figure 5.8 In vitro assessment of wound closure in MH cell with hrTGF-β1 and mRln1 143 
Figure 5.9 Representative Brightfield microscopy images of wound scratch assay 144 
12 
 
Figure 6.1 Comparison between amino acid sequence of canine pre-pro-insulin and 
murine pre-pro-relaxin. 
 
153 
 
LIST OF TABLES 
 
Table 1.1 A comparison of different types of viral vectors used in gene therapy 16 
Table 1.2 Main gene therapy strategies 18 
Table 2.1 Details of plasmids used in this project  45 
Table 2.2 Details of primer used in this project 46 
Table 2.3 List of restriction enzyme enzyme used in this project 52 
Table 3.1 Rare codon analysis comparison between codon optimised mouse relaxin 1 
and native mouse relaxin 1 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
1.1 GENE THERAPY   
1.1.1 Overview of gene therapy 
The idea of gene therapy was first mentioned by Dr. Marshall Nirenberg around 1960, 
who suggested that "genetic surgery" might be a cure to treat human diseases (Nirenberg, 1967).  
Gene therapy involves the transfer of genetic material into the host, such as humans. The 
purpose of a gene therapy is to either alter the expression of a specific gene or to correct a 
mutation in a malfunctioning gene.  
The first patient, who was successfully cured through a gene therapy was a four year old 
girl, who suffered from severe immunodeficiency syndrome. In 1990, this patient received ex 
vivo a corrected version of adenosine deaminase through white blood cells. The gene therapy 
was successful and cured her disease long-term (Bordignon, et al., 1995; Sutton, R., 2018). 
However, there are also challenges to consider when conducting a gene therapy. In 1999, Jesse 
Gelsinger, who received an adenovirus vector that expressed ornithine transcarbamylase, 
suffered from a massive anaphylactic reaction, which lead to his death after four days (Sibbald, 
B., 2001). The case of Jesse Gelsinger caused a reconsideration in gene therapy and led to a 
higher safety standard.  
To date, there have been worldwide around 2600 gene therapy clinical trials approved 
or completed. Most of these studies take place either in the USA (64.9%) or in Europe (23%). 
The main focus of gene therapy are various forms of cancer (65 % of the studies), monogenetic 
diseases (11.1 % studies) and cardiovascular diseases (6.9 % of the studies). Only a few gene 
therapies have passed through clinical trials and are now available on the market; the gene 
therapy Luxturna (Spark Therapeutics) improves the vision in patients suffering from Leber 
congenital amaurosis or retinitis pigmentosa. In addition, Kymriah (Norvatis) and Yescarta (Kite 
Pharma Inc/Gilead) has been developed to treat leukemia or B-cell lymphoma, respectively 
(Gene and Cell Therapy FAQ’s, 2018). In 2012, Glybera launched their gene therapy against a 
rare lipoprotein lipase deficiency in Europe, however it was withdrawn in 2017 due to the 
enormous cost for each patients (1 million euro) (Morrison, 2015; Senior, 2017). Despite the 
15 
 
enormous therapeutic benefits of gene therapy, there are still many challenges, such as high-
costs, that have to be overcome in the future.  
 
1.1.2 Gene Therapy Vectors 
 Gene therapy is achieved by delivering genetic material to specific cells through the viral 
or non-viral systems route. In non-viral delivery systems, the genetic material is delivered into 
the cells through electroporation (genetic material is transferred into cells through high voltage), 
passive delivery (endocytosis of the genetic material into cells) or ballistic delivery (sheer 
mechanical force delivering genetic material into cells) (Gene and Cell Therapy FAQ’s, 2018).  
Non-viral vectors based gene therapy relies on the import of exogenous genetic material 
into the cell nucleus through physical or chemical systems. Non-viral vectors offer lower immune 
responses compared to viral vectors. In addition, non-viral vectors have no limitation on 
exogenous transgene capacity and are relatively easy to apply. There are several modified 
viruses available that can be used to transfer genetic material into cells. The main focus of this 
thesis are naked plasmid DNA systems (non-viral delivery). In addition, we plan to test Adeno-
Associated Virus (AAV) (viral delivery) in in vivo experiments. The AAV viral delivery systems are 
more effective to deliver genetic materials where AAV viral normally have lower immunogenic 
respond compare to other types of viral vector (Naso, et al., 2017).  
 
1.1.2.1 Viral vectors 
In viral vectors disease-causing and –associated genes are removed from the viral 
genome, only leaving genes that are important for the structure of the virus. Subsequently, 
potential therapeutic transgenes are integrated into the genome of the virus to create 
recombinant viral vectors   (Thomas et al., 2003). The common viral vector adeno-associated 
virus (AAV) and retrovirus (RV)/lentivirus (LV) vectors have been modified by removing the viral 
gene that is essential for replication (Daya & Berns, 2008). There are many properties that 
16 
 
contribute to an ideal viral vector for gene therapy such as immunological silence, easy to scale 
up production, tissue-specific targeting, capability to transduce dividing/non-dividing cells and 
the capability to integrate the transgene. The capability to integrate the transgenes into host is 
a double-edged knife where it can cause random insertional mutation mutagenesis 
(Ramamoorth and Narvekar, 2015). On the other hand, integrating transgene into the host 
genome is useful for stable long-term transgene expression therapy (Braun, et al., 2014), as it 
provides permanent transgene expression in the host. Each type of viral vector offers 
advantages as well as disadvantages (Table 1.1). More than 70% of all gene therapies in clinical 
studies are conducted using the viral vectors Adenovirus (AV), Lentivirus (LV)/ Retrovirus (RV) 
and AAV (Wiley, 2017). This suggests that viral delivery systems are for some treatments the 
more promising strategy.  
Particle 
characteristics 
Adenovirus Adeno-
associated 
virus 
Alphavirus Herpesvirus Retrovirus 
/Lentivirus 
Vaccinia virus 
Genome dsDNA ssDNA ssRNA (+) dsDNA ssRNA (+) dsDNA 
Capsid Icosahedral Icosahedral Icosahedral Icosahedral Icosahedral Complex 
Coat Naked Naked Enveloped Enveloped Enveloped Enveloped 
Virion polymerase Negative Negative Negative Negative Positive Positive 
Virion diameter 70 – 90 nm 18 – 26 nm 60 – 70 nm  150 – 200 nm 80 – 130 nm 170 – 200 X  
300 – 450 nm 
Genome size 39 – 38 kb 5 kb 12 kb 120 – 200 kb 3 – 9 kb 130 – 280 kb 
Gene Therapy 
Properties 
      
Family Adenoviridae Parvoviridae Togaviridae Herpesviridae Retroviridae Poxviridae 
Infection/tropism Dividing and 
non-diving 
cells 
Dividing and 
non-diving 
cells 
Dividing and 
non-diving 
cells 
Dividing and 
non-diving 
cells 
Dividing cells  Dividing and 
non-diving cells 
Host genome 
interaction 
Non-
integrating 
Non-
integrating 
Non-
integrating 
Non-
integrating 
Integrating Non-integrating 
Transgene 
expression 
Transient Potential long 
lasting 
Transient Potential long 
lasting 
Long lasting Transient 
Packaging 
capacity 
7.5 kb 4.5 kb 7.5 kb > 30kb 6 kb 25 kb 
Table 1.1 A comparison of different types of viral vectors used in gene therapy dsDNA: 
double-stranded DNA, ssDNA: single-stranded DNA, ssRNA: single-stranded RNA. (Gene 
Therapy Net, 2017). 
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1.1.2.2 Adeno-Associated Viral (AAV) vectors 
1.1.2.2.1 AAV structure 
Adeno-associated virus (AAV) is a single-stranded deoxyribonucleic acid virus (viral 
genome size: ~4.7 kb) that belongs to the parvoviridae subfamily (genus: Dependoparvovirus) 
(Büning et al., 2008). The AAV was firstly discovered as a contamination during AV preparation 
(Atchison, 1965). This virus has a very small size (~20nm), which is smaller than naked plasmid 
DNA. Another important feature of the AAV is that it requires another virus, which is termed 
helper virus, for its replication. Helper viruses include for example AV, herpes simplex virus or 
human papillomavirus. The unmodified genome of AAV (wild type AAV) consists of two genes: 
rep (replication) and cap (capsid) genes. Additionally, inverted terminal repeats (ITR) can be 
found N- and C-terminal of the AAV genome (Figure 1.1).  
The Inverted terminal repeat (ITRs) consists of a 125 bp long palindromic hairpin 
structure which contains recognition signals for replication and packaging into AAV particle. The 
rep gene encodes for four proteins driven by p5, p19 and p40 promoter (Qiu, & Pintel, 2008), 
which play an important role in viral DNA replication, integration and packaging. The four 
different proteins are generated through alternative splicing (Saraiva, et al., 2016). The gene 
product of the cap gene is transcribed through P40 promoter and alternatively spliced to 
produce structural proteins that form the capsid: viral protein 1 (VP1), viral protein 2 (VP2), viral 
protein 3 (VP3) and Assembly-activating protein (APP) (Sonntag, et al., 2010). In the absence of 
a helper virus, the Rep proteins, Rep78 or Rep68, bind to ITR and integrate the viral genome into 
the human chromosome 19 at the site AAVS1 (MaCarty, et al., 2004). When there is also another 
virus present, that can function as a helper virus (such as adenovirus and herpesvirus), the AAV 
will start to replicate and will produce more viral particles. Different types of elements are 
provided by adenovirus (E1a, E1b, E2a, E4 and VA RNA) or herpesvirus (DNA polymerase, 
helicase) for helper function which is absent in the AAV genome (Daya and Berns, 2008). 
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 In modified viruses, which are used in gene therapy, both the rep and cap genes are 
removed and replaced with transgenes that have gene therapy functions. A summary of the 
main strategies involved in gene therapy is shown in Table 1.2. During the AAV viral vector 
production, triple transfection of three plasmids that express: 1) rep and cap genes, 2) ITRs with 
transgenes and 3) helper genes which facilitates small scale virus production in the human 
embryonic kidney cell line (HEK293 cells) (Michael, et al., 2017). 
Types of Gene 
Therapy 
Details  
Gene addition Insert another copy of functional or modified protein to treat disease 
Gene correction Modifying genetic material through gene editing tools for gene 
correction 
Gene silencing  Reducing gene expression through RNA interference 
Reprogramming Changing the characteristic of a cell into another type of cell by adding 
one or more genes 
Cell elimination  Introduce “suicide gene” into tumour cells to induce cell death 
Table 1.2 Main gene therapy strategies. A summary of the main type of gene therapy strategies 
used therapeutically (Adapted from Gene and Cell Therapy FAQ’s, 2018). 
 
 
Figure 1.1 A representative illustration of wild-type adeno-associated virus (wt-AAV) viral 
genome and mRNA transcript. The wt-AAV viral genome containing two inverted terminal 
repeat (ITR), two ORF with rep (green) and cap (blue) genes and polyadenylation site (pA). Four 
rep genes are transcribed by the P5 promoter (Rep78 and Rep68) or P19 promoter (Rep52 and 
Rep40). The cap genes are driven by the P40 promoter to produce 4 viral proteins (VP, VP2, VP3 
and APP). (Image taken from Saraiva, et al., 2016). 
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1.1.2.2.2 AAV serotypes 
Currently, there have been 100 AAV variants identified, which can be categorised into 
twelve different serotypes. Most of these have been modified and engineered into viral vectors 
(Wang et al., 2016). AAV variants can be distinguished based on their capsid structure that also 
defines the transduction efficiency of the virus. Various types of AAV capsids bind specific 
cellular receptors and co-receptors that facilitates the viral internalization into mammalian cells 
(Chakrabarty, et al., 2013). There are few serotypes (1, 6, 7, 8 and 9) that are suitable for 
recombinant AAV (rAAV) and incorporate with the specific muscle cell targeting “promoter 
enhancer murine muscle creatine kinase (CK)” (Salva et al., 2007). Another muscle-specific 
promoter consists of a combination of the muscle creatine kinase (MCK) enhancer and the 
synthetic muscle promoter C5-12 (Wang, et al., 2008). Viral delivery systems derived from the 
serotype AAV-8 show the highest efficiency to deliver gene therapy throughout whole organisms 
(Evans et al., 2011), whereas viral vectors of the serotypes AAV1 and AAV6 are more efficient 
for local muscular gene delivery (Wang et al., 2005). In three of the DMD clinical trial involved 
in systemic delivery of micro-dystrophin with AAV-rh74 (similar to AAV-8 serotype) or AAV-9 are 
the most preferred AAV serotypes (Duan, 2018). Other serotypes of AAV such as ancestral 
reconstruct AAV Anc80 is an ancestral AAV reconstructed through bioinformatics. The AAV 
Anc80 is relate to AAV serotypes 1, 2, 8 and 9 (Zinn et al., 2015) which might be an excellent AAV 
viral vector for muscle-targeting gene therapy with lower immunogenicity. 
 
1.1.3 Gene therapy for muscle cells  
 In humans, muscles make up approximate 40% to 50% of total body weight. There are 
a wide range of proteins produced, secreted or processed in muscle cells. Various types of 
muscular targeted gene therapies have been studied, from decreasing the progression of 
muscular disorders to immunization through the delivery of an antibody that contributes to a 
passive vaccine (Paulk, et al., 2018). In addition, therapeutic delivery of the factor IX to muscle 
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cells has been proposed to be beneficial for the treatment of hemophilia (Buchlis, et al., 2012). 
The ideal of using skeletal muscle as a gene therapy target emerged when new target organs 
were studied to apply gene therapy to patients that suffer from liver diseases, such as Hepatitis 
B or C. To target a gene therapy specifically to muscle cells it is pivotal to employ a muscle-
specific promotor. Non-specific transgenes expression in non-targeted cell types might induce 
unwanted immune responses or unknown side effects (Munch, et al., 2015). Muscle-specific 
promoters include muscle creatine kinase (MCK) promoter, desmin promoter, CK6 promoter, 
Syn promoter and Spc512 promoter (Dickson, et al., 2017). These have been tested using 
luciferase activity expression. The CK6 promoter exhibits a ~twofold higher level of transgene 
expression compared to the Cytomegalovirus (CMV) promoter in muscle cells. In contrast, in 
liver cells the expression of the CK6 promoter exhibits ~42-fold lower level of transgene 
expression compared to CMV promoter. This highlights the importance of the employed tissue 
specific promoter in reducing off target effects of transgene expression on non-targeted tissue 
(Katwal, et al., 2013).   
 
1.2 Skeletal muscle 
1.2.1 Anatomy and physiology of normal skeletal muscle  
Muscle can be categorized into three types: skeletal muscle, cardiac muscle and smooth 
muscle. Skeletal muscles control voluntary movement, while cardiac and smooth muscle are 
responsible for involuntary movements. In human, there are around 640 individual skeletal 
muscles (Randolph and Pavlath, 2015). In an adult human, skeletal muscle cells are approximate 
2 to 3 cm long with a diameter of 100 µm (Alberts, et al., 2008). Skeletal muscle can be further 
categorized based on size, shape and arrangement. The main function of skeletal muscles is the 
control of movement, besides that skeletal muscles also play a role in heat regulation, breathing, 
reflexes and posture. 
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1.2.2 Myogenesis  
The development of mesodermal precursors into myoblasts (myogenic lineage) is a 
strict regulated process. Subsequently, myoblasts further differentiate and fuse together to 
form multinucleated myotubes (Lee, et al., 2017). The rod-like shaped mature myofibres are 
formed by myofibrillogenesis. Myofibres are composed of actin (thin filaments) produce I band, 
myosin (thick filaments) produce A band, titin and ECM to keep the structure (Gillies and Lieber, 
2011). Numerous myofibrils fuse together to form a sarcomere which is the basic unit of striated 
muscle (Figure 1.2). 
Satellite cells are muscle-specific stem cells located under the basal lamina of myofibers 
(Ciciliot & Schiaffino 2010). In adults, satellite cells comprise about 3 – 6% of total muscle nuclei 
in the quiescent state. When triggered by extrinsic signals, the satellite cells will become 
activated and start to proliferate (Dhawan & Rando, 2005). Satellite cells undergo asymmetric 
divisions and most of newly generated cells eventually differentiate into myoblasts to form new 
myofibers, whereas the remaining satellite cells return to quiescence. Other factors that can 
trigger the activation of satellite cells include muscle stretch, exercise, and electrical stimulation. 
Studies have been performed to analyse whether normal satellite cells can be used to treat the 
progressive muscular disorder Duchenne Muscular Dystrophy (DMD). However, none of these 
studies was successful. This is due to the limited migration ability of satellite cells and reduced 
proliferation efficiency of the injected satellite cells. In addition, most of injected satellite cells 
are shortly lost after injection. Another issue is that satellite cells that were previously grown in 
vitro show a low differentiation rate when injected into the patient (Dellavalle et al., 2007). 
Moreover, satellite cells can only be administered to a local part of the human body (Briggs & 
Morgan, 2013).  
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Figure 1.2 Structure of muscle fibre, from myofibril to myofilaments to sarcomeres. Numerous 
myofibrils form a structural unit called sarcomeres and a muscle fibre is composed of many 
sarcomere units (Figure taken from http://www2.highlands.edu). 
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1.2.3 ECM in skeletal muscle  
The extracellular matrix (ECM) of skeletal muscles plays a crucial role in various 
biological processes, such as maintenance, repair and force transmission of skeletal muscle cells. 
The composition of the ECM in skeletal muscle is tightly regulated by several enzymes. Matrix 
metalloproteinases (MMP) are responsible for the degradation of various types of ECM 
components. The activity of MMPs can be inhibited by specific tissue inhibitor of matrix 
metalloproteinases (TIMPs). The balanced interaction between MMPs and TIMPs is crucial for 
muscle matrix remodelling, cell migration and myofibre formation. The ECM forms different 
distinct structures around skeletal muscles: endomysial (surrounding individual muscle cells), 
perimysial (surrounding group of muscle cells) and epimysial (surrounding the whole muscle 
cells) (Gillies and Lieber, 2011). 
 
1.2.4 The composition of skeletal muscle ECM 
The ECM of skeletal muscles is mainly composed of collagens, which comprise about 1 
to 10 % of the total muscle mass. In adults, the main collagens found in the ECM of skeletal 
muscles are collagen type I and type III. However, other collagens (type IV, V, VI, XI, XII, XIV, XV 
and XVIII) also contribute to the development of skeletal muscles. Studies show that collagen of 
type I was mainly distributed in perimysial ECM, whereas collagen type III are more commonly 
found in endomysium and epimysium ECM (Gillies and Lieber, 2011).  
 
1.2.5 The dystrophin-associated glycoprotein complex (DGC)  
The dystrophin-associated glycoprotein complex (DGC) protein is pivotal to connect the actin 
cytoskeleton to the ECM of muscle cells. Thereby, this protein complex is involved in the 
stabilization of the skeletal muscle structure, as well as in the maintenance of the contraction 
function. As shown in Figure 1.3, the DGC comprises several different cytoplasmic (e.g. actin 
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filament, dystrophin, dystrobrevins and syntrophins), transmembrane (e.g. sarcospan), as well 
as extracellular proteins (e.g. dystroglycans and laminin). The cytoplasmic protein dystrophin is 
essential for the connection of the skeletal muscle ECM with actin filaments of the cytoskeleton. 
The ablation of dystrophin destabilizes the DGC, which leads to muscular dystrophy (Townsend, 
2014).  
 
Figure 1.3 The illustration of dystrophin-glycoprotein complex (DGC). DGC combines with 
others components help in maintain, develop and retain normal function in muscle cells. A 
variety of proteins involved in DGC can be separated into three categories based on the 
extracellular matrix, sarcolemma and cytoplasm (Fairlough et al., 2013)  
 
1.3 Muscular dystrophy (MD)  
The heterogeneous genetic disorder muscular dystrophy (MD) is characterized by 
progressive muscle weakness and atrophy. There are about 40 different types of MD described 
(Muir and Chamberlain, 2009). In addition, MD occurs also during aging and can be related to 
the conversion of satellite cells to a fibrogenic lineage (Brack, et al., 2007). In patients suffering 
from MD, muscle fiber degeneration contributes to an excess of ECM components (Kornegay, et 
al., 2012a). MD can take place in cardiac muscles, in the respiratory system, as well as in the eye, 
skin, brain, muscle and ear (Rahimov and Kunkel, 2013). Dystrophies of muscle cells are 
categorised under neuromuscular (Parkinson disease and Multiple Sclerosis), muscular 
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dystrophies (e.g. Duchenne, Becker, facioscapulohumeral, Emery Dreifuss and limb girdle), 
inflammatory myopathies (e.g. polymyositis, inclusion body mitosis and dermatomyositis), 
congenital myopathies (e.g. Minicore myopathy, Nemaline myopathy and Central core disease), 
metabolic disorders (Pompe disease, McArdle disease and glycogen storage disease) and 
mitochondrial myopathies.  
Muscular dystrophy, for example to Duchenne (DMD) or Becker muscular dystrophy (BMD), can 
be caused by a mutation in a protein that contributes to the formation of the DGC. In DMD, 
frameshift mutations lead to the absence of the dystrophin protein. In contrast to this, patients 
suffering from BMD exhibit mutations on the dystrophin gene allowing partial functional 
dystrophin protein to be produced which slows down the pathology compare to DMD. This 
explains why BMD is associated with milder symptoms compared to DMD (Kawecka, et al., 2015). 
Another form of muscular dystrophy is Limb-girdle muscular dystrophy (LGMD), which is caused 
by mutations in one of the four proteins that form the sarcoglycan complex. Similar to DMD and 
BMD, the ablation of the sarcoglyan complex causes a destabilization of the DGC (Rahimov and 
Kunkel, 2013).  
 
1.3.1 Duchenne Muscular Dystrophy (DMD)  
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disorder that 
affects 1 in 3500 live births male worldwide (Zhou and Lu, 2010). The disorder is caused by 
nonsense or frameshift mutations in the gene encoding dystrophin, which results in the ablation 
of dystrophin in skeletal and cardiac muscle (Muntoni et al., 2003). DMD is characterized by 
progressive weakness in limbs, cardiac and respiratory failure and premature death. The lack of 
dystrophin leads to a destabilization of the DGC and in consequence decreases the link between 
the cytoskeleton and the ECM of skeletal muscles (Gumerson and Michele, 2011; Malik et al., 
2012; Kawecka et al., 2015)). The deficiency of the DGC leads to a mechanical destabilization of 
muscle and eventually to myofibre necrosis and muscle wasting (Matsumura et al., 1993a). As a 
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result, a chronic inflammation occurs followed by persistent production of profibrotic cytokines, 
excessive synthesis and deposition of ECM proteins, and finally muscle fibrosis. Muscle fibrosis 
is one factor that contributes to the early death of DMD patients.  
Currently, there are various strategies to ameliorate the pathology of DMD. However, 
none of these has the potential to stop or reverse the progression of muscular dystrophy 
disorders. There are several issues of replacing the dysfunctional dystrophin protein in DMD or 
the truncated dystrophin protein BMD patients with the full functional protein. The large size of 
dystrophin makes it challenging to deliver the whole coding sequence of the gene by gene 
therapy. In addition, the functional dystrophin gene has to be delivered to skeletal and cardiac 
muscles in the whole body. Moreover, DMD and BMD patients suffer from additional secondary 
consequences related to the disease pathology including inflammation, necrosis, oxidative 
stress, ischemia and fibrosis (Figure 1.4) (Spinazzola and Kunkel, 2016). Without treatment, 
DMD patients die usually in their early twenties. However, the current available interventions, 
such as corticosteroids treatments with anti-inflammation property and increase muscle 
regeneration, are able to reduce muscle loss and prolong the lifespan of DMD patients up to 40 
years. On the other hand, corticosteroids treatments has several severe side effects, such as 
obesity, cataracts, bone fractures and behavioural changes (Hathout, et al., 2016).    
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Figure 1.4 The schematic pathophysiological consequences in DMD patients. In DMD, the absence of dystrophin protein leads to loss of function of dystrophin-
glycoprotein complex (DGC) cause sarcolemma prone to contraction-induced damage, which eventually increases the calcium and sodium influx into muscle cells. 
There are a few conditions (inflammation, necrosis, impaired regeneration and fibrosis) take place and contribute to muscle degeneration. The increase of oxidative 
stress which causes mitochondria dysfunction and eventually led to impaired metabolism. On the other hand, blood vessel defects and ischemia also take place. In 
conclusion, all the events cause by malfunction dystrophin protein contribute to muscle wasting and loss of function in DMD (Guiraud and Davies, 2017). 
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1.3.2 Dystrophin  
1.3.2.1 Overview of the Dystrophin gene 
The DMD gene is the largest gene in human body which consist of 2.4 Mbp (0.08% of 
total human genome). The gene comprises 79 exons (Kawecka et al., 2015) and is located at 
band Xp21.2 to Xp21.1 on the human X chromosome (Hoffman et al., 1987). There are seven 
different promoters that regulate the tissue-specific expression of various dystrophin isoforms 
(Dp427m, Dp427p, Dp427b, Dp160, Dp140, Dp116 and Dp71) (Figure 1.5). The isoform Dp427m 
is only present in skeletal and cardiac muscles. In some of the DMD cases, DMD patients and 
mdx mice share symptoms of a disorganised central nervous system structure, cognitive 
impairment and a decrease in the number of neurons due to the absence of Dp140 isoform 
(Dumont and Rudnicki, 2016). The Dp140 isoform dystrophin is involved in neuropsychological 
function responsible for fetal brain development, neuronal maturation and development 
(Chamove, et al., 2013).   
 
Figure 1.5 The blue vertical line represent 79 exons in the dystrophin gene. The label of natural 
occurring dystrophin isoforms is based on the molecular weight of dystrophin protein (Dp). 
Dp427 is the full length dystrophin which is produced in brain Dp427 (B), muscle Dp427 (M) and 
Purkinje cell Dp427 (P). There are other smaller isoforms which are produced from promoters 
within different introns; Dp260 is expressed in the retina, Dp140 in brain and kidney, Dp116 in 
Schwann cells. Dp71 is ubiquitously expressed in many cell types, except in muscle cells. Dp40 is 
expressed from the same promotor as Dp71, however Dp40 is only expressed in the brain. 
(McGreevy et al., 2015).   
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1.3.2.2 Structure of Dystrophin protein  
Dystrophin is a huge protein that consists of 3685 amino acids and has a size of 427 kDa 
(Figure 1.6) (NCBI, 2017). Dystrophin comprises distinct protein domains: an N-terminal actin 
binding domain, 24 spectrin-like repeats that incorporate four hinge domains, a second actin 
binding domain and a neuronal nitric oxide synthase (nNOS), as well as C-terminal a cysteine-
rich domain (CR) and a carboxy-terminal domain (CTD). The CTD binds to α and β syntrophin 
that are part of the DGC.  
 
Figure 1.6 Image illustrating the full-length dystrophin protein. Full-length dystrophin content 
includes N-terminal domain (NT), four hinge domains (H1–H4) and a rod domain consisting of 
24 spectrin-like repeats (1–24), a cysteine-rich domain (CR) and a carboxy-terminal domain 
(CTD). The dystrophin-associated protein binding on dystrophin are actin-binding domain 1 
(AB1), actin binding domain 2 (AB2), neuronal nitric oxide synthase (nNOS), dystroglycan (DG), 
syntrophin (Syn) and dystrobrevin (Dbr) (McGreevy et al., 2015) 
 
1.3.2.3 Mutation in Dystrophin in DMD  
In humans, the DMD gene has the highest mutation rate compared to other genes. This 
is due to the large size of the gene sequence. In DMD, mutations in the Dystrophin gene are 
categorized into the following groups: large genomic deletions of one to several exon (>60%), 
duplication of one or several exons (24%), missense mutation (11%) and small in-frame deletions 
(4%) (Kawecka et al. 2015). Although mutation can happen throughout the dystrophin gene, the 
majority of all mutations occur in exons 45-55, whereas less mutations occur between the exons 
2 and 19. Mutations in dystrophin lead either to the absence of Dystrophin (DMD) or to a 
truncated gene product (BMD). In BMD patients approximately half of the Dystrophin protein is 
absent, which contributes to the mild phenotype compared to DMD (England, et al., 1990). 
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1.3.3 Clinical and Pathological Characteristics of DMD 
The progression of DMD in humans is divided into four phases, the early phase, the late 
childhood phase, the adolescence phase and the adulthood phase. DMD is diagnosed by 
measuring creatine kinase (CK) levels in the blood, genetic testing or muscle biopsy. CK is used 
as an indication of muscle degeneration and children suffering from DMD show 20 to 100 higher 
CK levels in the blood compared to children, which are not affected by DMD. The first symptoms 
of DMD become obvious at the age of two to three years (end of the early phase) (Bushby et al., 
2010), with children exhibiting motor difficulties and slower movement compared to other 
children (Shi-Wen et al. 2009). Children affected by DMD struggle to stand up when lying on the 
floor and will use their hands as support. This is termed the Gower’s manoeuvre (Figure 1.7). 
 During the late childhood phase (from 6 to 13 years) patients suffer from an extreme 
loss in muscle strength, which increases the risk of falling over. Furthermore, the massive 
reduction in muscle strength limits the walking ability of the patients so that a wheelchair is 
needed as support about the age of 13 years. In the third phase, adolescence phase (from 8 to 
15 years) patients depend on wheelchairs and show spinal deformations. Additional symptoms 
include lumbar lordosis, scoliosis, kyphosis and abnormal sitting postures (Kinali et al., 2007). At 
the end of adulthood phase, at the age of around 20s to 30s years, the cardiac function of DMD 
patients is significantly reduced and leads to heart failure.  
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Figure 1.7 Gower`s manoeuvre of DMD. Patients DMD around 5 years old have difficulty in 
standing up (7) from lying on the floor (1), using the support of both hands (2 & 3) and then 
slowly rising by using their hands to support on the leg (4, 5 & 6) (Mihpatte, 2012). 
 
 
1.3.5 Animal Model of DMD 
Currently, there are around 60 animal models for DMD available (McGreevy et al., 2015). 
The most common types of DMD models that are used are in mice or dogs. These animal models 
allow the improvement of treatment strategies and the examination of new technologies. Gene 
therapy approaches mainly exploit exon skipping as a novel DMD treatment. Additionally, there 
have been new types of DMD animal models developed in rats (Nakmura et al., 2014; Larcher et 
al., 2014) and pig (Nonneman et al., 2012; Klymiuk et al., 2013). In the mdx mouse model, the 
pathology condition in muscle differ from the muscle fibrosis in DMD patients. However, 
extensive exercise aggravates the muscle fibrosis in mdx mice models and makes it more 
comparable to human patients (Pessina, 2014). In addition, treatment with fibrotic or laceration 
causes the progressive development of muscle fibrosis in mdx mice, as well as in wild type mice. 
A more suitable model for DMD, that shows similar muscular fibrosis compared to humans, are 
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the dog golden retriever muscular dystrophy (GRMD) (Kornegay et al., 2012b), pig (Klymiuk et 
al., 2013) and mouse (DMDmdx) (Larcher et al., 2014). Each animal model offers advantages and 
disadvantages, which both have to be considered, when deciding for the appropriate model 
system. The DBA2 mdx model is a poor model for cardiomyopathy compared to DMD patients, 
however, the lower hind limb muscle weight, less myofibres, more accumulation of collagen and 
severe fibrosis which have much similar pathology to DMD patients (Wells, 2018). Other types 
of mdx mouse (Cmah mdx mouse) exhibit more severe DMD symptoms compared to mdx mouse 
such as a fibrosis increase in quadriceps ,gastrocnemius and diaphragm, reduction half of the 
lifespan, speed, peak force of diaphragm and cardiac trabeculae (Yucel, et al., 2018).  
 
1.3.5.1 Mdx mouse  
In 1981, the mdx mouse model, which exhibits a mutation in exon 23 of dystrophin, 
was discovered (Bulfield, et al., 1984). The mutation is a premature stop codon in exon 23, 
which results in a malfunctional dystrophin protein and resulting in milder symptoms 
compared to DMD patients. This mouse model offers several advantages, such as low 
maintenance cost, short gestation period and large litter size. The CK response and the muscle 
necrosis progression differs in the mdx mice and in human DMD patients. However, mdx 
mouse models and human patients both show a severe fibrosis in diaphragm. For these 
reasons, the mdx mouse model have been studied extensively with around 2800 studies up to 
date (Wells, 2018).  
 
1.3.6 Therapeutic Approaches for DMD  
There are a lot of therapeutic strategies developed to ameliorate the progression of 
DMD, such direct gene replacement strategy (micro-, mini-, quasi- or full version of dystrophin), 
mutation correction strategy (exon skipping and suppression on immature termination codon), 
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supplementary indirect strategy (drugs for utrophin upregulation, antibody therapies, shRNA, 
gene editing on myostatin) and cell therapy (myoblast or stem cell transplantation) (Kawecka, 
et al. 2015). The discovery that a truncated dystrophin from BMD patients (England et al., 1990) 
that is partially functional led to the development of mini- and micro-dystrophin constructs 
(Figure 1.8) (Gregorevic et al., 2006). Duan (2018) discusses that from 1997 to 2017 more than 
25 variant of micro-dystrophin have been designed and tested, with different degrees of 
pathology reduction and force improvement. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Image illustration of full-length, mini- and micro-dystrophin. Most of the rod domain 
is removed from full-length dystrophin to generate mini-dystrophin and micro-dystrophin. 
Components such as actin-binding domain, cysteine-rich domain and C-terminal domain remain 
in mini- or micro-dystrophin. Mini-dystrophin arose from a patient with Becker muscular 
dystrophy, where the in-frame deletions lead to partially functional protein. Three different 
micro-dystrophin cDNAs have been constructed into AAV vector, to contain four rod repeats 
with hinge 1, 2 and 4 (CS1); same components as CS1 with partially delete C-terminal domain 
(delta CS1) and one-rod repeat with hinge 1 and 4 (M3). (Ke, 2011) 
 
Despite the fact short truncated DMD gene restoration shall not have the same effect 
as full length of dystrophin. In some studies, exosome offer another approach to restore full 
length of dystrophin transiently in vivo. The exosome is extracellular vesicle produced by a range 
of cell with a size >150μm. Furthermore, the exosome produced is based on the original type of 
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cells which offered some tissue-specificity that allowed cell to cell communication. One of the 
studies shown that by using exosome derived from mouse myogenic cell line (C2C12) is capable 
of transiently restoring the full-length dystrophin and improve cardiac function in mdx mouse 
heart (Su et al., 2018). Another study has shown that by using exosomes derived from 
cardiosphere-derived cells (clinical-stage cardiac progenitor cells) and injected into mdx mice 
are capable of transiently restoring the dystrophin protein in hearts but also some skeletal 
muscle (such as soleus limb muscle and diaphragm) (Aminzadeh et al., 2018). The exosome 
might offer an insight into exosome delivery with transient full length of dystrophin restoration 
as a therapy for DMD.  
 
 
1.3.7 Clinical trials for DMD  
There are a lot of ongoing, complete and terminated clinical trials available that focus 
on DMD. A summary of these clinical trials can be obtained on the clinical trial website (Clinical 
trial, 2017). These clinical trials focus on gene replacement, nonsense suppression, exon skipping 
(exon 53, 51, 45 and 44), muscle and stem cells therapy, anti-inflammatory drugs, antifibrotic 
drugs and muscle regeneration. One of these clinical trials assesses the delivery of mini-
dystrophin with AAV into patients, but only a low level of dystrophin could be detected (Mendell 
et al. 2010), which might be to an immune response towards the foreign dystrophin epitope 
(Mendell et al. 2010). Recently, the most promising results were obtained from Sapenta Phase 
I/IIa clinical trial with AAV-micro dystrophin (Sarepta, 2018). In this study, the serum CK levels 
were reduced over 87 % in patients and this was accompanied by the high presence of micro-
dystrophin (76.2 %). Another main focus in DMD clinical trials are antisense oligonucleotides 
(AON). This strategy specifically targets exon skipping on single or multiple exons to restore 
truncated dystrophin (Abdul-Razak et al. 2016). There are two exon-skipping therapies already 
approved ataluren targeting pre-mature stop codons and eteplirsen targeting exon 51 skippings 
(Verhaart and Aartsma-Rus, 2019). Although, both micro-dystrophin restoration and exon 
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skipping approaches aim to restore BMD like dystrophin might ameliorate DMD it did not restore 
the full length of dystrophin.   
 
1.4 Wound Healing and Fibrosis in muscle 
When injury take place, wound healing initiated through release of inflammatory 
mediators such as cytokines and growth factors by damaged cells (Tidball and Villalta, 2010). 
The cytokines help in processes such as proliferation and migration of the cells in the injury site. 
Fibroblasts are recruited to the injury site and get activated for extracellular matrix components 
(ECM) synthesis (Mann et al., 2011). ECM production plays a role in ECM remodelling, which 
activates satellite cell proliferation to replace the muscle cells.    
 
1.4.1 ECM in fibrosis  
Fibrosis is an uncontrollable wound-healing process that causes hardening and scar 
formation on tissue. This process is triggered by chronic tissue injury or inflammation. The 
deposition of excessive ECM proteins weaken tissue function and replaces normal parenchymal 
tissue with various types of fibrotic tissue. Different factors such as chemical, persistent infection, 
injury, radiation, allergic and autoimmune responses contribute to chronic inflammation and 
eventually result in fibrosis (Wynn, 2008). Some current treatments on fibrotic diseases (such as 
liver cirrhosis, sclerosis, cardiovascular fibrosis and idiopathic pulmonary fibrosis) focus on 
reducing the inflammatory response. Regulation of fibrosis pathway may not be the same as 
reduced inflammation, although chronic inflammation contribute to fibrosis (Wynn, 2008).   
 The main cell type responsible for fibrosis are Myofibroblasts, which are the primary 
cells involved in the production of ECM. This cell type can be generated through different ways 
such as activation of fibroblast, from residential mesenchymal cells, endothelial, fibrocytes 
(circulating fibroblast-like cells) or through epithelial cells that undergo endothelial/epithelial 
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transition (EMT). The activation of the myofibroblast contributes to autocrine secretion of 
myofibroblasts, paracrine signals from macrophages and lymphocytes, as well as to the 
interaction of pathogen-associated molecular patterns (PAMPs) with pattern recognition 
receptors on fibroblasts (Wynn, 2008). There are several factors that regulate fibrosis and might 
be good candidates to target for anti-fibrotic therapies: cytokines (TGF-β), renin-angiotensin-
aldosterone system (ANG II), angiogenic factors (VEGF), growth factors (PDGF), chemokines 
(MCP-1), caspases and acute phase proteins (SAP) (Wynn, 2008). Relaxin have been prove able 
to reduce the TGF-β (Wang et al., 2016).  
 
1.4.2 Muscle fibrosis in DMD 
The pathological pathway of muscular degeneration in DMD has been studied 
extensively. The malfunction of dystrophin protein causes a destabilization of the DGC complex, 
which makes the muscle fibre more susceptible to contraction induced damage and necrosis. 
The decline of muscle cells, which is accompanied by muscle weakness, is caused by the 
replacement of muscles with fibro-adipose tissue and extracellular matrix (ECM) components 
(Serrano and Muñoz-Cánoves, 2010).  
 
1.4.3 The role of relaxin in treatment of fibrosis  
Relaxin is a natural suppressor of age- and disease-related fibrosis. The protein hormone 
has been used to target fibrosis in various tissues and organs, including skin [scleroderma 
(Samuel et al., 2005; Seibold et al., 2000)], lung [pulmonary fibrosis (Samuel et al., 2003)], kidney 
[renal fibrosis (McDonald et al., 2003; Lekgabe et al., 2005; Danielson et al., 2006)], heart 
[cardiac fibrosis (Samuel et al., 2004, 2008; Du et al., 2003)] and liver [hepatic fibrosis (Bani et 
al., 2001; Williams et al., 2001)]. 
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In 2010, it was shown that relaxin reduces the inflammatory and fibrotic phases during 
muscle injury (Mu et al., 2010). However, it is still largely unknown how relaxin controls 
inflammation and fibrotic tissue formation (Li et al., 2004; Mu et al., 2010). Relaxin also plays a 
role in the promotion of muscle regeneration by increasing pax7 (marker of skeletal muscle 
differentiation) in positive satellite cells. Furthermore, relaxin represses the recruitment of 
neutrophils to the site of injury (Mu et al., 2010; Negishi et al., 2005). Recently, Martin, et al. 
(2018) observed that relaxin reverses inflammatory and immune signals in aged mouse hearts. 
Additionally, it could be demonstrated that relaxin is able to suppress several genes and 
signalling pathways that are involved in the inflammatory response during heart failure (Martin 
et al., 2018). In summary, it could be shown that relaxin suppresses fibrosis in various cells types.  
 
1.5 Relaxin  
Relaxin is a 6 kDa pleiotropic peptide hormone of the insulin family. It was discovered in 
1926 by Fredrick Hisaw (Hisaw, 1926). Relaxin plays a role in hemodynamic changes and 
ligament relaxation during pregnancy and parturition (Conrad, 2011). Although relaxin and 
insulin display a similar structure, they bind to different receptors and trigger different cellular 
effects.  
 
1.5.1 Relaxin family  
Relaxin is conserved from zebrafish to humans (Wilkinson et al., 2005). The three non-
allelic relaxin genes in humans (h) (relaxin 1 (hRln1), relaxin 2 (hRln2) and relaxin 3 (hRln3)) are 
encoded by different genes. It has been shown that only higher primates and humans have RLN 
1 and RLN2, while other mammals only have RLN 1 which is most similar to human RLN2 
(Wilkinson et al., 2005). In human, hRln1 and hRln2 are located on chromosome 9p24 (NCBI, 
2016). Although hRln3 was only discovered about fifteen years ago (in 2002) the phylogenetic 
analysis indicate that it is probably the ancestral relaxin peptide.    
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Despite the low sequence homology among relaxin and insulin, both of the proteins are 
classified into the same protein family. Both hormones, relaxin and insulin, are produced as pre-
pro-hormones. The pre-pro-hormone of the relaxin/insulin family contains a signal peptide (SP) 
prior to B-chain at the N-terminus (B) and an A-chain at the C terminus shown in Figure 1.9. The 
A- and the B-chain are connected through a connecting chain (C). The pro-hormone is processed 
in the Golgi apparatus and the SP, as well as the C chain, is cleaved off. The final active 
heterodimer contains an A-chain (modulating the tertiary structure of B-chains) and a B-chain 
(binding sites) (Devarakonda and Salloum, 2018).  
 
Figure 1.9 Scheme of Pre-Pro-Mouse Relaxin 1 Protein. The scheme represents the peptide 
structure of pre-pro-mouse relaxin 1 with 185 amino acids. The sequence represents signal 
peptide (SP), mature relaxin B-chain (B-chain) and A-chain (A-chain) and connecting peptide (C-
chain). The number indicates amino acids location of different segment within the pre-pro-
mouse relaxin 1 and the protein structure also refer as B-C-A protein structure.  
 
1.5.2 Relaxin receptor and Cellular pathways 
The main circulating relaxin in humans is hRln2 (Chan, et al., 2012). Relaxin binds to a 
family of G-protein coupled receptors (CPGR) also known as relaxin family peptide receptors 
(RXFPs). There are four members of RXFP, RXFP 1-4. Hsu discovered in 2002 that relaxin also 
binds to leucine-rich G protein coupled receptor receptors (LGR7 and LGR8), which are now 
termed RXFP1 and RXFP2, respectively (Hsu et al., 2002). Despite that relaxin protein can bind 
to both RXFP1 and RXFP2 receptors, some studies shown that relaxin has a higher binding 
affinity to RXFP1 (Debrah et al., 2008). In addition, the insulin like factor 3 (INSL3) also exhibits 
a low affinity to RXFP1. RXFP1 and RXFP2 are transmembrane receptors, that comprise seven 
transmembrane domains and a large extracellular domain containing leucine rich repeats 
(Devarakonda and Salloum, 2018).   
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The RXFP1 receptor belongs in the G protein-coupled receptor (GPCR) family to the 
subclass of leucine-rich repeat (LRR)-containing GPCRs. The RXFP1 receptor contains at the 
extracellular N-terminus a unique LRR domain (Figure 1.9). In addition, a LDL-A domain is 
present at the N-terminus. Aspartate and glutamate residues of the LRR domain are essential 
for the interaction with the B chain of the relaxin hormone. Additionally, the LDL-A domain and 
the extracellular loops 1 and 2 of the transmembrane domain contribute to the interaction 
between receptor and relaxin ligand (Kong et al., 2013). The binding of relaxin activates G 
proteins (α, β and γ), which in turn activate further signalling cascades.     
Treatment of human umbilical arterial smooth muscle cells and human cardiac 
fibroblasts with the human recombinant relaxin 2 drug (serelaxin), causes an increase of the 
neuronal nitric synthase (nNOS) activity. In addition, serelaxin also causes the phosphorylation 
of ERK1/2, as well as cGMP signalling (Sarwar et al., 2015). Serelaxin also increased the vascular 
endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) 2 and 9. Moreover, 
serelaxin might be able to block TGF-β signalling through Notch1.  
 
1.5.3 Animal model of relaxin 
 Knockout of relaxin in female mice causes immature mammary glands that lack milk 
production. In addition, knockout of relaxin in male mice delayed tissue maturation and growth 
in testis and prostate. Deposition of excessive collagen contributes to the pathology observed in 
male and female relaxin knockout mice (Samuel, et al., 2005a). Moreover, relaxin knockout mice 
exhibit various kinds of fibrosis, such as age related progressive fibrosis in lung, heart, kidney 
and scleroderma (Samuel, et al., 2003; Samuel, et al., 2005a; Samuel, et al., 2005b).  
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Figure 1.10 The illustration of Serelaxin interaction with RXFP1 in mammalian heart. The NO is produced by the downstream activation of βγ subunit play a crucial 
protection role. Process such as cGMP production and activation of protein kinase G (PGK) reducing reactive oxygen species (ROS) and fibrosis upon injury. The 
uncertainty pathway (green broken line). Extracellular signal regulated kinase 1/2 (Erk1/2), mitochondrial DNA (mtDNA), nitro oxide synthase (NOS), sphingosine 
kinase (Sphk1),  Transforming growth factor β (TGF-β), Transforming growth factor β receptor (TGF-β-R), (Image taken from Devarakonda and Salloum, 2018)  
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1.6 Aim and objective 
This project focuses on the hypothesis that overexpression of the peptide hormone 
relaxin is beneficial for the treatment of fibrosis in patients suffering from muscle fibrosis. Firstly, 
we will examine various delivery systems of relaxin, and non-viral & viral delivery systems were 
designed. Subsequently, several cell lines, such as mouse muscle fibroblast cell lines (MH cells), 
have been transfected with the designed constructs and the expression level of relaxin was 
assessed by real-time quantitative PCR and by western blot analysis. In addition, further in vitro 
studies have been carried to out to analyse the effects of the increased expression of relaxin on 
fibrosis-related effects. This will help to assess the anti-fibrotic potential of relaxin. The future 
of the project is to deliver a viral vector (rAAV) that expresses relaxin in a mouse model of 
muscular dystrophy (mdx mouse model) and to analyse the effects of overexpressing relaxin on 
muscle fibrosis. Increasing the expression of the anti-fibrotic hormone relaxin might represent 
a novel treatment strategy for patients suffering from various types of muscular dystrophy, such 
as DMD or BMD 
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CHAPTER 2: MATERIALS & METHODS 
2.1 Standard reagents   
Most of the general chemical reagents that were used in the experiment were 
purchased from Sigma-Aldrich and VWR (otherwise will be stated) with standard chemical 
purity graded as Analytical Reagents for analysis applications (AnalaR). All of the reagents (list 
in the table below) were dissolved in double distilled water (ddH2O), otherwise will be stated.  
Reagents Manufacturer  
Acetic acid VMR 
EDTA Sigma-Aldrich 
Glucose Sigma-Aldrich 
Glycerol Sigma-Aldrich 
HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid]  Sigma-Aldrich 
Methanol VMR 
Magnesium sulphate (MgSO4)  Sigma-Aldrich 
NP-40 Fluka Biochemica 
Paraformaldehyde (PFA)  Sigma-Aldrich 
Sodium chloride (NaCI) Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 
Tris Base  Sigma-Aldrich 
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2.2 Plasmids  
2.2.1 Transgenes Analysis  
The open reading frame (ORF) of the mouse relaxin 1 gene (NCBI, NM_011272.2) was obtained 
from NCBI and subsequently used for primer design. Sequences of the synthetic muscle specific 
promoter (Spc512) were obtained from previous plasmid constructs from RHUL Dickson lab (Li, 
1999) Most of the plasmid that were used for investigation were purchased online through 
VectorBuilder in glycerol bacterial form and stored at -80oC. Other plasmids were purchased 
from Vector Builder in Maxi prepped form, which was eluted in TE buffer and stored at -20oC 
freezer. An ampicillin resistance gene was included within the plasmid backbone, to allow for 
screening during plasmid production. 
2.2.2 Relaxin Plasmids 
This projects utilizes eight different plasmid constructs: pssAAV-Spc512-CO mRln1, 
pssAAV-Spc512-NCO mRln1, pscAAV-Spc512-CO mRln1, pscAAV-Spc512-NCO mRln1pTet On-CO 
mRln1, pTet On-NCO mRln1, pAAV-Tet On-CO mRln1 and pAAV-Tet On-NCO mRln1 (see table 5). 
The plasmids, pTet On-CO mRln1, pTet On-NCO mRln1, are conventional plasmids. In contrast 
to this, the plasmids pAAV-Tet On-CO mRln1 and pAAV-Tet On-NCO mRln1 can be later used for 
AAV constructs. Non-codon optimized variants (NCO) exhibit the wild type version of the coding 
sequence of the mouse relaxin 1 gene. Moreover, the online software VectorBuilder algorithm 
was used to construct a codon optimized (CO) sequence version of the coding sequence of the 
mouse relaxin 1 gene.  
2.2.3 pCI-eGFP 
The plasmid was kindly gifted by Dr. Susan Jarmin (RHUL Dickson lab). The plasmid 
comprises a Cytomegalovirus (CMV) promoter that is combined with green fluorescent protein 
(GFP). Additionally, a SV40 PolyA signal was included on the 3’ end.  
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Plasmid 
purchased  
Details 
pssAAV-Spc512-
CO mRln1 
A ~4.7kb construct containing muscle specific promoter (Spc512) with 
transgenes codon optimised mouse relaxin 1 (CO mRln1). The plasmid 
construct was obtained in glycerol bacterial stocks. 
pssAAV-Spc512-
NCO mRln1 
A ~4.7kb construct containing muscle specific promoter (Spc512) with 
transgenes non-codon optimised mouse relaxin 1 (NCO mRln1). The 
plasmid construct was obtained in glycerol bacterial stocks. 
pscAAV-Spc512-
CO mRln1 
A ~4.8kb construct containing muscle specific promoter (Spc512) with 
transgenes codon optimised mouse relaxin 1 (CO mRln1). The plasmid 
construct was obtained in glycerol bacterial stocks. 
pscAAV-Spc512-
NCO mRln1 
A ~4.8kb construct containing muscle specific promoter (Spc512) with 
transgenes non-codon optimised mouse relaxin 1 (NCO mRln1). The 
plasmid construct was obtained in glycerol bacterial stocks. 
pTet On-CO 
mRln1 
A ~6kb construct containing tetracycline inducible system (Tet On) with 
transgenes codon optimised mouse relaxin 1 (CO mRln1). The plasmid 
construct was obtained in glycerol bacterial stocks and large amount of 
plasmid production (Maxiprep). 
pTet On-NCO 
mRln1  
A ~6kb construct containing tetracycline inducible system (Tet On) with 
transgenes non-codon optimised mouse relaxin 1 (NCO mRln1). The 
plasmid construct was obtained in glycerol bacterial stocks and large 
amount of plasmid production (Maxiprep). 
pAAV-Tet On-CO 
mRln1 
A ~7.4kb construct containing tetracycline inducible system (Tet On) with 
transgenes codon optimised mouse relaxin 1 (CO mRln1) and two 
inverted terminal repeats (ITRs). The plasmid construct was obtained in 
glycerol bacterial stocks and large amount of plasmid production 
(Maxiprep). 
pAAV-Tet On-
NCO mRln1 
A ~7.4kb construct containing tetracycline inducible system (Tet On) with 
transgenes non-codon optimised mouse relaxin 1 (NCO mRln1) and two 
inverted terminal repeats (ITRs). The plasmid construct was obtained in 
glycerol bacterial stocks and large amount of plasmid production 
(Maxiprep). 
Table 2.1 Details of plasmids used in this project  
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2.3 Computer Softwares and Bioinformatics Software 
2.3.1 Primer design 
Primers were designed using the either the IDT or the Primer3 software 
(http://primer3.ut.ee). All primers were designed as following:  18 – 22 bp length, melting 
temperature (Tm) around 55 – 60oC, GC content around 40 – 60%, primer dimer formation shall 
be avoided,  amplicon length is around 75 - <200 nucleotide, Tm for both forward & reversed 
primer as close as possible. Primers were obtained from IDT.  
Primer details purchase 
through IDT  
Primer sequence 5’ – 3’ Tm 
(oC) 
Amplicon 
size (bp)  
Mouse Relaxin  
Exon location: 1 – 2 
FP: 5’-CCGTGAATATGCCCGTGAA-3’ 
RP: 5’-AGGCTCTGCATCTTTGTTGA-3’ 
57 
56 
139  
Codon Optimise mouse 
relaxin  
FP: 5’-GAAGACCCTGCACGACAA-3’ 
RP: 5’- TCTCCCTCTTCTTCCTGCT-3’ 
55 
56 
98 
Mouse alpha actin 2 
Exon location: 7 – 8 
FP: 5’-GAGCTACGAACTGCCTGAC-3’ 
RP: 5’-CTGTTATAGGTGGTTTCGTGGA-3’ 
56 
56 
129 
Mouse Fibronectin 1 
Exon location: 26 – 27 
FP: 5’- GAGCTATCCATTTCACCTTCAGA-3’ 
RP: 5’- TTGTTCGTAGACACTGGAGAC-3’ 
54 
54 
96  
Mouse Periostin 
Exon location: 2 – 3  
FP: 5’-CCTGTAAGAACTGGTATCAAGGT-3’ 
RP: 5’-CCTTTCATCCCTTCCATTCTCA-3’ 
57 
56 
97 
Mouse tissue inhibitor 
metalloproteinase 1 
Exon location: 2 – 4 
FP: 5’-AGACAGCCTTCTGCAACTC-3’ 
RP: 5’-CAGCCTTGAATCCTTTTAGCATC-3’ 
56 
57 
129  
Mouse tissue inhibitor 
metalloproteinase 2 
Exon location: 3 – 4 
FP: 5’-GACCTGACAAAGACATCGAGT-3’ 
RP: 5’-GCCATCTCCTTCTGCCTTT-3’ 
56 
56 
 
119 
Mouse Matrix 
metalloproteinases 9 
Exon location: 8 – 9  
FP: 5’-GACATAGACGGCATCCAGTATC -3’ 
RP: 5’-GTGGGAGGTATAGTGGGACA -3’ 
56 
53 
125 
Mouse Procollagen 1 
Exon location: 1 – 2   
FP: 5’-CGCAAAGAGTCTACATGTCTAGG-3’ 
RP: 5’-CATTGTGTATGCAGCTGACTTC -3’ 
56 
56 
134 
Mouse Rplp0 
Exon location: 5 – 6 
FP: 5’-TTATAACCCTGAAGTGCTCGA-3’ 
RP: 5’-CGCTTGTACCCATTGATGATG-3’  
52  
56 
147  
Table 2.2 Details of primer used in this project. Primer sets (forward and reverse primer) used 
for amplification specific sizes fragment of mouse gene were purchased through IDT. FP, 
forward primer; RP, reverse primer; Tm, melting temperature of primer.   
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2.3.3 SnapGene Software  
SnapGene software was used for illustration nucleotide and sequence visualization.  
 
2.3.4 GraphPad Prism Software  
The GraphPad Prism software was used to plot the graph.    
 
2.3.5 FlowJo Software (BD Falcon) 
FlowJo software was used to analyze flow cytometry data. The percentage of dead and 
live cells were determined. In addition, the level of GFP expression of single cells was assessed.  
 
2.3.6 ImageJ Software  
 Microscopy images of wound scratch assays were analysed with Image analysis ImageJ. 
The area of wound closure was highlighted and recorded in GraphPad Prism software for graph 
design and statistical analysis. 
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2.4 Bacterial Cultures 
2.4.1 Materials 
 LB agar powder (Sigma) 
 Glycerol (Sigma): 80% Glycerol stock was prepared by added 40ml of glycerol made up 
to 50ml with ddH2O.   
 LB powder (Sigma) 
 Ampicillin (Sigma): prepared as 1000X stock in ddH2O at 50mg/ml concentration, 
filtered through the 0.22µm filter (Falcon) and stored in -20oC freezer. 
 LB broth: 20g of LB powder was made up to 1000ml with ddH2O, autoclaved and stored 
at RT.  
 LB agar: 7g of LB agar powder was made up to 200ml with ddH2O. The LB agar mixture 
was autoclaved and used straight away or stored in 60oC. The LB agar mixture was 
allowed to cool down until the mixture bottle become warm and can be felt by hand. All 
the following work was carried out beside Bunsen burner, where ampicillin was added 
into the LB agar mixture. Once the LB agar mixture with ampicillin was mixed well, 
approximate 25ml of the mixture was poured into 100mm petri dish. Once the LB agar 
has solidified, the LB agar plates used for bacterial culture or stored at 4oC (not longer 
than 30 days). 
 LB SOC media: 100µl of 1M MgSO4 and 20µl of 1M glucose (0.22µm filtered) made up 
to 10ml with LB broth.   
 SCS110 (E.coli) competent cells (Agilent) 
 
2.4.2 Heat Shock Transformation plasmid into Bacteria 
The commercial competent cells SCS110 were purchased from Invitrogen and Agilent. 
The TOP10 competent cell is suitable for high-efficiency cloning and plasmid propagation, which 
is stable for high-copy-number plasmid replication. SCS110 competent cells are suitable to 
prepare plasmid DNA free of Dam or Dcm methylation, which resulted in DNA that can be 
digested with methylation-sensitive restriction enzymes. The competent cell was thawed on ice 
and plasmid DNA with concentration ranging 400 – 600ng was added to 50µl bacterial 
competent cells (SCS110). The competent cells with plasmid DNA mixture were mixed gently 
and incubated at 4oC on ice for 30 minutes. Heat shock was performed at 42oC for 30 seconds in 
laboratory water bath and allowed to recover at 4oC on ice for 10 minutes. 250µl of antibiotic-
free LB media was added to the bacterial suspension and incubated at 32oC (pAAV-based 
plasmid) or 37oC (conventional plasmid) for 1 hour shaking at 200 rpms, prior to plating in LB 
agar with antibiotics and screening for positive transformants.  
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2.4.3 Screening for Transformants 
The bacterial suspension was split into 100µl and 200µl into two separate LB agar plates, 
in an attempt to obtain the suitable amount of bacterial densities. The LB agar plates were 
placed inverted to avoid contamination and incubated overnight at 32oC (pAAV-based plasmid) 
or 37oC (conventional plasmid) with ampicillin antibody selection. On the next day, checking was 
done to see whether any bacterial colonies grew on LB agar plates or not. If the bacterial were 
grew in appropriate densities (overgrowth was avoided), each individual bacterial colony was 
picked by using sterile pipette tips and inoculated 5ml LB broth with ampicillin.       
 
2.4.4 Production of Bacterial Cultures  
After overnight incubation of bacterial suspension in the incubator at 32oC (pAAV-based 
plasmid) or 37oC (conventional plasmid), checking was done to make sure the bacterial colonies 
were grown in appropriate densities (Overgrowth of bacterial was avoided). All the following 
work was carried out near Bunsen burner, one colony was picked by using pipette tip and growth 
with 5ml LB broth with ampicillin in the bijou bottle. Once the LB broth was inoculated, it was 
incubated at 32oC (pAAV-based plasmid) or 37oC (conventional plasmid) in the incubator with 
shaking at 200 rpms. The post incubation of bacterial suspension can be used either for larger 
bacterial culture production for Maxiprep preparation or Miniprep plasmid DNA extraction. 
 
2.4.5 Long-term Glycerol Bacterial Storage   
Long-term glycerol bacterial storage was produced by mixing 750µl of the bacterial 
suspension together with 250µl of 80% sterile glycerol stock, and stored at -80oC freezer.  
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2.4.6 Bacterial stocks 
The long-term glycerol bacterial stock is used to create single bacterial colonies.  
A sterile plastic loop was used to scrape the top of the frozen bacteria stocks without 
unthaw glycerol bacteria. Single colonies of the glycerol bacterial stock, which were grown on a 
LB plate supplemented with ampicillin. Plates were incubated overnight at a suitable 
temperature at 32oC (pAAV-based plasmid) or 37oC (conventional plasmid) overnight.   
 
2.4.7 Amplification and Purification of Plasmid DNA 
 QIAprep Spin Miniprep Kit (Qiagen) 
 EndoFree Plasmid Maxi Kit (Qiagen) 
Mini-Prep was performed with Qiagen Mini-Prep kit to extract the small amount of 
plasmid DNA from the 5ml bacterial culture in LB broth for identity check through restriction-
digest mapping. Maxi Prep required 500µl of bacterial suspension to inoculate in 250ml of LB 
broth with ampicillin for a large amount of plasmid DNA extraction with Qiagen Maxi-Prep kit. 
Both Mini and Maxi prep was carried out according to manufacturer's instructions. The 
concentration of plasmid DNA was determined by using the spectrophotometer. A variety yield 
of plasmid DNA was extracted based on the amount of starting bacterial culture (5ml for 
miniprep and 250ml for maxiprep) and a range of concentration of plasmid DNA (>20µg plasmid 
DNA for miniprep and >10mg plasmid DNA for maxiprep). The plasmid DNA will be stored at -
20oC freezer or used for further analysis (restriction digest mapping, sub-cloning and 
transfection). 
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2.5 Nucleic acid manipulation  
2.5.1 Materials 
 Restriction enzymes and buffers (NEB) 
 50X TAE buffer: 242g Tris Base, 57.1ml Glacial Acetic Acid, 100ml of 0.5M EDTA pH 8.0 
were made up to 1000ml with ddH2O. The 1x TAE buffer diluted from 20ml 50X TAE 
buffer with 980ml ddH2O and stored in room temperature.  
 UltraPure Agarose powder (Bioline) 
 1000x SYBR Safe DNA gel stain (Invitrogen) 
 Gel Loading Dye, Purple (NEB) 
 DNA molecular weight markers: Hyperladders I &V (Bioline) 
 Nanodrop Spectrophotometer (ThermoFisher) 
 Digital imaging system (Vilber) 
 
2.5.2 Determination of Nucleic Acid Concentration through Optical Density 
The determination of nucleic acid concentration and purity through measuring the 
absorbance of a sample at the wavelength of 260nm and 280nm. The different form of nucleic 
acid (RNA, single-stranded DNA, double-stranded DNA), all absorb at wavelength 260nm. The 
reading at 260nm/280nm ratio value used to access nucleic acid purity with a ratio ~1.8 for DNA 
and ~2.0 for RNA. The ratio lower below this point indicate contamination might be occurred 
due present of other components (protein, reagent or compound) absorb at 280nm. The 
secondary measurement reading at 260nm/230nm ratio value used to determine purity of the 
nucleic acid with a ratio ranging from 2.0 – 2.2, lower beyond this value indicate contamination 
(EDTA, phenol, carbohydrates) may cause absorbance at wavelength 230nm. Nanodrop 
spectrophotometer was used to determine the concentration and purity of nucleic acid. Once 
the blank (1µl of ddH2O) and reagent blank (1µl of buffer dissolved nucleic acid) was set, 1µl of 
each sample was applied to the spectrophotometer. 
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2.5.3 Endonuclease Restriction Digest 
The identity of the plasmid was identified through endonuclease restriction enzyme 
digest mapping. The restriction digest targeted site within the plasmid was identified with 
SnapGene Software and details of the restriction enzyme were checked on NEB website 
(http://nebcloner.neb.com/#!/redigest). The restriction enzyme mapping was performed 
through single, double or multiple digests with a variety of restriction enzyme. Once the 
restriction enzyme needed to be used was decided, 1µg plasmid DNA was applied in each 
reaction. The restriction digest reaction is made of 1x CutSmart Buffer, restriction enzyme (~10 
units to 1µg of plasmid DNA), 1µg plasmid DNA and makeup to total 20µl with ddH2O. The 
reaction was set up as manufacturer recommended in table below. The restriction digest 
product was either analysed through agarose gel electrophoresis.  
NEB 
enzyme 
NEB buffer Restriction digest condition 
AhdI CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 65oC for 20 min 
BamHI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, No heat inactivation  
EagI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 65oC for 20 min 
EcoRI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 65oC for 20 min 
KpnI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, No heat inactivation  
MscI CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 80oC for 20 min 
NaeI CutSmart® Buffer 
100% 
37oC for 1 hour, No heat inactivation  
NcoI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 80oC for 20 min 
NdeI CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 65oC for 20 min 
NotI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 65oC for 20 min 
PvuI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, No heat inactivation  
SpeI-HF CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 80oC for 20 min 
SmaI CutSmart® Buffer 
100% 
37oC for 1 hour, heat inactivation at 65oC for 20 min 
Table 2.3 List of restriction endonuclease enzyme used in this project 
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2.5.4 Analysis Restriction Digest Plasmid with Horizontal Agarose Gel Electrophoresis 
Restriction digest profile of plasmid DNA will be analyzed through agarose gel 
electrophoresis. Either 1% or 3.5% of agarose gel (mass of agarose powder in a total volume of 
1X TAE buffer) was set up according to anticipated size fragment of restriction digest plasmid. 
The agarose mixture was microwave till completely dissolved (avoid overheating), it was cool 
down to lower temperature. 0.01% of 1000x SYBR Safe DNA gel stain (enable visualization under 
UV light) was added to the agarose mixture and mixed well prior to set up on gel tray together 
with the comb. Once the gel has solidified, it is placed into the gel tank filled with 1X TAE buffer 
and the comb was removed gently. 2µl of gel loading dye was added to 10µl of samples (Section 
2.5.3). Approximate 12 µl of samples and DNA molecular weight markers (first and last wells) 
was loaded into each well on the agarose gel. The gel was then electrophoresed at ~65V for 1 
hour (adjusted if necessary based on the run of DNA molecular weight marker and gel loading 
dye). Electrophoresis allowed quality control verification of the plasmid size determination with 
a variety of restriction digest, by direct comparison to DNA molecular weight marker. The results 
obtained were recorded by the image captured with digital imaging system (Vilber). 
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2.6 Tissue Cultures 
2.6.1 General Tissue Culture Reagents 
 Sterile PBS: 10 Phosphate-buffered salines (PBS) tablet (Oxoid) was dissolved in 
1000ml of ddH2O. The PBS solution was autoclaved at 110oC for 1 hours, the PBS 
solution was stored at room temperature (RT) once it is cool down. 
 Dulbecco`s modified Eagle`s medium (DMEM), high glucose, GlutaMAXTM 
Supplement, pyruvate (Gibco)   
 Fetal Bovine Serum (FBS) (Gibco): FBS will be heat-inactivated at 56oC for 30 minutes, 
once the FBS was cooldown and stored at -20oC freezer.   
 10x Trypsin (Sigma): 0.5% trypsin in sterile PBS was prepared in Class II Lamina flow 
hood and stored at 4oC fridge.  
 1% penicillin-streptomycin (PIS) (ThermoFisher) 
 Tissue Grade DMSO (Sigma) 
 Trypan Blue solution (Sigma)  
 Hemocytometer (Neubauer Chamber)  
 Sterile Plastic Stripettes, 5ml, 15ml, 25ml and 50ml Pipettes (Corning) 
 T175cm3, T125cm3 and Tissue Culture Flask (Corning) 
 15ml and 50ml Falcon Tube (Corning) 
 Mr. FrostyTM, Freezing Container (Thermo) 
 Cryogenic tube vial (Nunc)  
 
 
 
2.6.2 Cell Lines 
 C2C12 (ATCC) – Cells were obtained from ATCC. These cells were expanded and stored 
in liquid nitrogen. All the experiment were carried out with C2C12 cells passage <30 
cycles.  
 MH (ATCC) – Cells were obtained from ATCC. These cells were expanded and stored in 
liquid nitrogen. All the experiment were carried out with C2C12 cells passage <30 
cycles. 
2.6.3 Cell Culture Growth Media 
Growth media was prepared according to manufacturer’s instructions.  
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2.6.3.1 Growth Media for Culturing Mouse Myoblast (C2C12) 
 10% FBS DMEM with 1% Penicillin-Streptomycin (PIS): 50ml heat-inactivated FBS and 
1% PIS was added into 500ml. The preparation was carried out in Class II Lamina flow 
hood and stored at 4oC fridge. The 10% FBS DMEM was pre-heated to 37oC for 15 
minutes at water bath prior to use.   
2.6.3.2 Growth Media for Culturing Mouse Muscle Fibroblast (MH) 
 10% FBS DMEM: 50ml heat-inactivated FBS was added into 500ml. The preparation was 
carried out in Class II Lamina flow hood and stored at 4oC fridge. The 10% FBS DMEM 
was pre-heated at 37oC for 15 minutes at water bath prior to use.   
2.6.4 Thawing Cells 
Pre-warm growth media (based on different cell type) was prepared before thawing 
cells. The cells were taken from liquid nitrogen, incubated at 37oC water bath to thaw in 
approximate 2 minutes. The 1ml thawed cells was mixed with 9ml growth media in the 50ml 
falcon tube and centrifuged (Beckmann centrifuge) at 1000 rpms, 200g for 5 minutes in RT. The 
supernatant was aspirated, and cell pellet re-suspended in a small amount (~3ml) DMEM media. 
All of the cells were transferred into T125cm3 tissue culture flask that contained 15 ml of growth 
media. The cells were closely observed under the light microscope once per day to make sure 
the cell densities are not over confluence before further passage.   
2.6.5 Counting of live Cells with Haemocytometer (Neubauer Chamber)  
Cells were detached using trypsin. After more than 95 % of cells were detached, fresh 
media was added. Following this, cells were stained with Trypan blue (0.4%) solution. Trypan 
blue staining is only taken up by dead cells. For this reason, dead cells appear dark under the 
microscope. A mixture was prepared containing 5µl 0.4% trypan blue solution and 5µl of the cell 
solution and subsequently the number of viable cells was assessed with a haemocytometer 
(Neubauer chamber). The Neubauer chamber was placed under the light microscope with 10X 
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magnification.  The counting system only included the viable cells located within the middle 
square (highlight in the circle in Figure 2.1A) and count according to as left and the upper line of 
middle square (shown in Figure 2.1B). The total number of viable cells is calculated by the 
formula (Figure 2.1C), by comparing the cell count with standard cell count.  
 
 
Figure 2.1 Haemocytometer and Cell counting system (A) Visualise appearance of 
haemocytometer under the microscope. (B) Counting system within the middle square of 
haemocytometer under the microscope. (C) The formula of total cell count compared to 
standard cells count. 
 
2.6.6 Culturing and Maintenance Cell Lines 
Cell lines were grown and maintained at 37oC and 5% CO2 with suitable types of growth 
media (Section 2.6.2). When the cell growth up to ~60 – 80% confluence, cells were passaged to 
avoid overgrowth or differentiation. The old media in tissue culture flask was aspirated and flask 
washed with 1X sterile PBS. Cells were detached using trypsin. Once 95% of the cells are 
detached, it was diluted in 15ml growth media transferred into 50ml Falcon tube and 
centrifuged at 1000 rpms for 5 minutes at RT.  
 
 
 
A B 
Total cell count = Viable cell count in middle square x 2 
Standard cell count: 50 Cells Count = 5 x 105 Cells/ml 
 
C 
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2.6.7 Cryopreservation of cells 
The sub-confluent cell cultures were treated with trypsin and re-suspended in 3ml 
growth media. Cell count was accessed the viability and number of cells using a haemocytometer 
(Section 2.6.3). 900µl of re-suspended cell culture (5 x 105 cells) was top up to total volume of 
1ml with 100µl DMSO in cryotubes (appropriate labelled). The cryotube was placed in Mr. 
FrostyTM, freezing container at -80oC freezer overnight and transferred into liquid nitrogen tank 
for long-term storage on the next day.  
 
2.7 Transient Transfection Protocols 
2.7.1 Preparation of Cells for Transfection in 6 Well Plate  
Cells were plated into 6 well plate with suitable cells density by haemocytometer 
(Section 2.6.3), in order to get up to ~80% confluence prior transfection on the next day 
(adjusted if necessary based on the confluence of cell growth through observation under the 
light microscope). Cell densities needed to be placed into the 6 well plate was approximately 2 
x 105 cells. 
2.7.2 Comparison of the Efficiency of Different Transfection Reagent  
The optimization of transgene delivery into cells was investigated using 1000ng pCi-
eGFP. Different types of transfection reagents and various ratios of reagent to plasmid DNA 
were analysed.  
2.7.2.1 Transfection Reagents and Ratios 
The ratio of transfection reagent to plasmid DNA was prepared in accordance with  
manufacturer instruction. 
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Cell line Transfection Reagent Ratio Used (transfection reagent 
volume (µl): DNA mass (µg) 
C2C12 Viafect 3:1, 4:1 and 5:1 
Lipofectamine p3000 0.8:1, 1.2:1 and 1.6:1 
PEI 2:1, 3:1 and 4:1 
MH Viafect 3:1, 4:1 and 5:1 
Lipofectamine p3000 2:1, 3:1 and 4:1 
PEI 2:1, 3:1 and 4:1 
 
2.7.3 Transient Transfection with Viafect  
 Transfection Reagent Viafect (Promega) 
 Dulbecco`s modified Eagle`s medium (DMEM), high glucose, GlutaMAXTM 
Supplement, pyruvate (Gibco): The serum-free DMEM used to set up transient 
transfection mixture consist of plasmid DNA and transfection reagent.   
 
 Viafect transfection reagent is a cationic delivery agent in aqueous solution with high 
efficiency and low toxicity. Viafect was allowed to reach RT before adding to DNA to form a 
complex. The Viafect DNA complex mixture was produced by added Viafect with DNA and made 
up to 200µl total volume with serum-free growth media into Eppendorf tube as shown in the 
table below. The Viafect DNA complex was allowed to incubate in RT for 15min prior to 
transfection. During the 15 min interval, the growth media in 6 well plate with ~80% confluence 
cells were replaced with new growth media. After 15 min, 200µl of Viafect DNA complex was 
added to each well in 6 well plate through dropwise circular motion and shaking the plate gently 
to ensure maximize the cell coverage. Cells were transfected for 24 hours (total RNA extraction) 
and 48 hours (total RNA extraction and protein extraction). 
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2.7.4 Transient Transfection with Lipofectamine® 3000 
 Transfection Reagent Lipofectamine® 3000 (Invitrogen) 
 Dulbecco`s modified Eagle`s medium (DMEM), high glucose, GlutaMAXTM 
Supplement, pyruvate (Gibco): The serum-free DMEM used to set up transient 
transfection mixture consist of plasmid DNA and transfection reagent.   
     Lipofectamine® 3000 transfection reagent offers high transfection efficiency with lipid 
nanoparticle in eukaryotic cells. The Mixture 1 (Serum free DMEM and Lipofectamine® 3000) 
and mixture 2 (Serum free, 2500 ng of pDNA and Lipofectamine® P3000 reagent) was prepared 
as shown in table below were incubated for 5 minutes in room temperature (RT). Both of the 
mixture 1 and 2 were mixed together and incubated for 15 minutes in RT to form pDNA-lipid 
complex. The 250μl of transfection mixture pDNA-lipid complex was added directly to the cells 
in culture medium on each well in 6 well plate.     
 Mixture 1  Mixture 2   
Reagent DMEM (µl) Lipofectamine 
® 3000 (µl) 
DMEM (µl) pDNA (µl) P3000 (µl) 
-  
Top up to 
437.5 
35   
Top up to 
437.5 
- 14 
2:1 17.5 8.75 14 
3:1 26.25 8.75 14 
4:1 35 8.75 14 
 
 
 
 
Plate size The 
volume of 
Cells in 
Media (per 
well) 
Total Volume 
of 
Transfection 
Complex (per 
well) 
Amount of 
pDNA (per 
well) 
Amount of Viafect 
Transfection Reagent (per 
well) for various Viafect 
Transfection Reagent: DNA 
ratio 
1:3 1:4 1:5 
6-well 
plate 
2ml 200µl 2.5µg 7.5µl 10µl 12.5µl 
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2.7.5 Transient Transfection with Polyetheylenime (PEI) 
 Transfection Reagent Polyetheylenime (PEI) (Invitrogen) 
 Dulbecco`s modified Eagle`s medium (DMEM), high glucose, GlutaMAXTM 
Supplement, pyruvate (Gibco): The serum-free DMEM used to set up transient 
transfection mixture consist of plasmid DNA and transfection reagent.   
     Polyetheylenime (PEI) is a stable cation polymer allowing positively charged DNA to 
condense such that can bind to the anionic surfaces of the cell (Longo, et al. 2013). As a result, 
the DNA is transferred into the cytoplasm through endocytosis of pDNA:PEI complex. Three 
different ratio of PEI were tested with the same amount of 2500ng pDNA shown in table below 
to investigate the effect of different concentration of PEI on transfection efficiency. The 
pDNA:PEI complex was prepared as shown in table below and incubated 15 minutes in RT. The 
200μl of transfection mixture pDNA-PEI complex was added directly to the cells in culture 
medium on each well in 6 well plate. 
 
 
 
 
 
 
 
 
 
 
 
Plate size The 
volume 
of Cells 
in Media 
(per 
well) 
Total Volume 
of Transfection 
Complex (per 
well) 
Amount of 
pDNA (per 
well) 
Amount of PEI Transfection 
Reagent (per well) for various 
Viafect Transfection Reagent: 
DNA ratio 
1:2 1:3 1:4 
6-well 
plate 
2ml Top up to 200µl 2.5µg 5µl 7.5µl 10µl 
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2.8 Flow Cytometry  
2.8.1.1 Materials 
 4% Paraformaldehyde (PFA) (Sigma) 
 FACs Buffer: 500ml Sterile PBS, 2ml of 0.5 EDTA and 5ml 10% NaN3  
 FACs Bends (BD Falcon) 
 5ml round bottom snap cap FACs Tubes (BD Falcon)  
 FACs Canto II (BD Biosciences) 
 Clean and Rise Solutions (BD Falcon)  
 
2.8.2 Harvest GFP Expression in Cell Cultures 
            Flow cytometry was used to investigate and determine the cell that is expressing Green 
Fluorescent Protein (GFP) through GFP tagged pCI-GFP plasmid (Section 2.2.3). The two types of 
cells (MH cells and C2C12 cells) were seeded at 1 x 105 cells/ 6 well plate prior to transient 
transfection protocol (Section 2.7.3) with pCI-GFP plasmid. Post 48 hours transfection, the cells 
were harvested in FACs buffer into FACs tubes.  
 
2.8.3 GFP detection and analysis 
            For the purposes of flow cytometry analysis, the control cells without the GFP protein 
expression will be used as a control to compare with the cells that are transfect with the pCI-
GFP plasmid. The efficiency of the transfection was performed with the counting of GFP 
expression verified from the proportion of expressing cells in the transfection efficiency 
experiment. The efficiency of the transfection efficiency was analysed through FlowJo software 
(section 2.3.5) and expressed in the percentage of positive live cells with GFP expression over 
total cells within the gated region.   
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2.9 Total RNA Extraction 
 RNeasy mini kit (Qiagen) 
              The RNeasy mini kit was used for total RNA extraction according to manufacturer's 
instruction. The DNase was applied during the RNA extraction to eliminate DNA. RNA was eluted 
in 30µl of RNase free water. The concentration of total RNA was determined by using the 
spectrophotometer (Section 2.5.2). The total RNA will be stored in -80oC freezer or used for 
further analysis (cDNA construction and RT-qPCR). 
 
2.10 Polymerase Chain Reaction (PCR) and Reverse transcription PCR (RT-PCR)  
2.10.1 Materials  
 Go Taq G2 Flex (Promega) 
 Primers (IDT) 
 dNTP mix 100mM (Bioline) 
 2x Red mastermix (GeneSys ltd): Ready use PCR Mastermix made up with Tris-HCI 
pH8.5, 4mM MgCI2, 0.2% Tween 20®, 0.4mM dNTPs, 0.2units/µl Taq DNA polymerase 
and inert red dye & stabilizer.    
 ProFlex 3 x 32 wells PCR System (ThermoFisher)  
 LightCycler 480 plate-based real-time PCR instrument (Roche) 
 
 
2.10.2 First strand cDNA Construction for RT-qPCR  
 Oligo-p(dT)15 (Oligo dT) (Promega) 
 Random Primer (Invitrogen) 
 GoScript Reverse Transcriptase Kit (Promega) 
 Oligo dT (Promega, C1101) 
 Random Primer (Sigma, 48190011) 
 DEPC treat water (Ambion) 
 ProFlex 3 x 32 wells PCR System (ThermoFisher)  
 
The total RNA (Section 2.9) extracted from in vitro tissue culture was used as RNA 
template for cDNA construction. Approximate 1000ng of total RNA was mixed with 50µM of 
Oligo dT and 300µg Random primer made up to the total volume of 10µl with DEPC treated 
water and incubated at 70oC for 2 minutes in PCR machine (ProFlex PCR system). This initiation 
incubation step was to ensure total RNA and non-specific primers are denatured and secondary 
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structures were eliminated. The cDNA construction was performed according to the 
manufacturer’s instruction. The mixture of 4µl of reaction buffer, 2µl of 25mM MgCl2, 2µl of 
2mM dNTP, 1µl of reverse transcriptase enzyme, 6µl of ddH2O was mixed with the 10 µl initial 
incubation mixture to form a total volume of 25 µl. The next step was incubated at 25oC for 5 
mins, followed by 42oC for 60 mins, then 70 0C for 15 mins in ProFlex PCR system. The cDNA was 
stored at -20oC or further used for RT-qPCR. 
2.10.3 RT-qPCR 
 Sybr Green Master (Roche) 
 RT-qPCR primer assay (IDT) 
 DEPC-treated water (Ambion)  
 LightCycler 481 II Instrument (Roche) 
 
2.10.3.1 RT-qPCR mastermix preparation 
            The 1µl cDNA construction (section 2.10.2) was used as a template. The cDNA was diluted 
in 1:50 with DEPC water contain with each samples. The appropriate positive samples were 
chose for a series dilution (1:10, 1:100, 1:1000, 1:10000, 1:100000) with DEPC water as standard. 
On each RT-qPCR reaction, the samples was prepared as shown in table below. 
Reagent Amount needed  
Dilute cDNA 4 μl 
20x RT-qPCR primer assay  0.5 μl 
Sybr Green Master  5 μl 
DEPC-treated water Top up to 10 μl 
Total  10 μl 
  
2.10.3.2 RT-qPCR set up 
           Each of the specific target forward and reverse primer set were designed and described 
in section (2.3.1). The initiation denaturing at 95oC, follow by 35 cycles of standard amplification 
cycles conditions were set at 95oC for 15 seconds, 60oC for 15 seconds and 70oC for 15 seconds.    
 
 
64 
 
2.10.3.3 RT-qPCR analysis 
            The RT-qPCR housekeeping control GADPH gene, which is an enzyme involve in glycolysis 
break down of glucose to produce energy within the cell. The mRNA level expression of different 
target genes and normalized with mRNA level expression housekeeping genes were compared 
by using GraphPad software (section 2.3.4) and expressed in fold of changes of targeted genes 
mRNA expression level within the cells before and after transfection of relaxin plasmid. 
 
2.11 Wound scratch assay  
2.11.1 Materials 
 MH [mocha] Mouse Muscle fibroblast (ATCC CRL-2709) 
 Fetal bovine serum (FBS) (Gibco) 
 Dulbecco`s modified Eagle`s medium (DMEM), high glucose, GlutaMAXTM 
Supplement, pyruvate (Gibco) 
 Sterile PBS: 10 Phosphate-buffered salines (PBS) tablet (Oxoid) was dissolved in 
1000ml of ddH2O. The PBS solution was autoclaved at 110oC for 1 hours, the PBS 
solution was stored at room temperature (RT) once it is cool down. 
 Recombinant human Transforming growth factor β (TGF-β) protein (Abcam, ab50036)  
 Recombinant murine Interferon-γ (Preprotech, 315-05) 
 Tetracycline hydrochloride (Sigma, T7660-5G) 
 Transfection Reagent Viafect (Promega)  
 35mm high Ibidi µ dishes (Ibidi) 
 Zeiss Axio Observer D1 Microscope (Zeiss) 
 
2.11.2 Wound scratch assay dishes labelling  
After the Ibidi plate was labelled as illustrated in Figure 11 the wound scratch was 
induced close to the 3 label dots in the inner part of the dishes. The labelling allows microscopy 
images to be taken over a time course of three days.  
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Figure 2.2 The illustration shows the bottom labelling ibidi dishes. The label of 3 dots (left, 
right and middle) near middle of the inner part of the dishes. The west (W) and east (E) was 
label on the standard outer part of the dishes. The wound scratch (red line) was done near to 
the 3 label dots on the middle of inner dishes.   
 
2.11.3 Seeding Cells  
MH cells were harvested by using trypsin treatment and suspended in 10% FBS DMEM. 
1.2 x 105 of MH cells (in 400µl 10% FBS DMEM) were plated into each pre-coated collagen I 
35mm high ibidi µ dishes (Ibidi) and incubated for 1 hour at 37oC with 5% CO2. After 1 hour, 
1.6ml 10% FBS DMEM was added into the ibidi dish and the dish was incubated overnight at 
37oC with 5% CO2. On the next day, the cells were grown up to approximate 80% confluency 
and the media was replaced by 1ml 0.5% FBS DMEM (to reduce the proliferation rate of MH 
cells). After an incubation time of at least 16 hours the cells reached 95% confluence.   
 
2.11.4 Wound Scratch 
 When the cells reached 95% confluence, a linear wound scratch was induced with a p20 
pipette tip. The cells were then washed twice with 1x PBS to clear floating debris and 1 ml 0.5% 
FBS media was added into the dishes. Various treatments, such as 40ng/ml TGF-β protein 
(Abcam, ab50036), 200ng/ml interferon γ (Preprotech, 315-05), 20µl 100ng/µl tetracycline 
hydrochloride (Sigma, T7660-5G), were used.  
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2.11.5 Transfection   
 Once the wound scratch was induced, a transfection was performed according to 
section 2.7.3.  
 
2.11.6 Microscopy imaging on wound scratch 
Brightfield microscopy images were taken with low resolution (2.5x) and high resolution 
(10x) using a Zeiss microscopy (Zeiss, Axio Observer D1). Images were taken immediately after 
wound scratching (T0), after 24 (T24) and 48 hours post transfection (T48). 
 
2.11.7 Wound closure assessment 
The area of wound closure was measured by using Image J software 
(https://imagej.nih.gov/ij/). The mean percentage of the wound closure was calculated by 
comparing to wound area T0 to T48.  
 
 
2.12 Isolation of mouse organs and protein extraction 
2.12.1 Materials 
 Dissection knife 
 PAPBNI RIPA buffer: NaCI 0.15M, HEPES 0.5M, NP-40 1%, Sodium Deoxycholate (SOC) 
0.5%, SDS 10%, EDTA 0.01M, Protease inhibitor tablet 1 in 50ml (Roche). The PAPBNI 
RIPA Buffer was aliquoted into the bijou bottle with 5ml each and stored at -20oC 
freezer.  
 QIAgen Tissue Lyser   
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2.12.2 Dissection of mouse tissue from mouse 
The animal work is done according to UK animal (Scientific Procedures) Act, 1986. The 
C57BL/10 mice were bred in and maintained with standard 12 hours in light or dark cycle with 
free access to food and water in our animal facility. The dissection was performed by Dr Ngoc 
Lu Nyugen to obtain mouse kidney, prostate, testis and vas deferens. The mouse tissue samples 
were kept in -80oC freezer. 
2.12.3 Protein extraction from frozen mouse tissue samples 
Approximately 10 – 20 mg of the frozen mouse tissue samples was cut with dissection 
knife and weighed. The samples were transferred into Eppendorf tube with 1 Tungsten Carbide 
bead (3mm) and 100 µl ice cold RIPA buffer. Each sample was homogenised at 25 Hz for 2 
minutes on QIAgen Tissue Lyser in 4oC. The tube was then centrifuged at 14,000 rpm for 10 
minutes at 4oC, followed by decanting of the supernatant into fresh pre-chilled Eppendorf tube 
on ice. The protein samples were quantified or stored at -20oC. 
 
2.13 Protein extraction and quantification 
2.13.1 Materials 
 Sterile PBS: 10 Phosphate-buffered salines (PBS) tablet (Oxoid) was dissolved in 
1000ml of ddH2O. The PBS solution was autoclaved at 110oC for 1 hours, the PBS 
solution was stored at room temperature (RT) once it is cool down. 
 PAPBNI RIPA buffer: NaCI 0.15M, HEPES 0.5M, NP-40 1%, Sodium Deoxycholate (SOC) 
0.5%, SDS 10%, EDTA 0.01M, Protease inhibitor tablet 1 in 50ml (Roche). The PAPBNI 
RIPA Buffer was aliquoted into the bijou bottle with 5ml each and stored at -20oC 
freezer.  
 Benchtop microcentrifuge (Eppendorf)  
 DC Assay protein kit: Reagent A, S & B (BioRad) 
 2µg BSA standard (Invitrogen) 
 96 well plate (Corning) 
 96 well plate reader (Genbank) 
 Methanol (VMR) 
 Chloroform (Sigma) 
 Centrifuge 5810R (Eppendorf) 
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2.13.2 Protein Extraction 
C2C12 cells were cultured in 6 wells plate up to 80% confluence. The transfection 
mixture was prepared with 2.5µg of non-codon optimized relaxin plasmid, transfection reagent 
Viafect (Promega) and top up to 200µl serum-free DMEM. The ratio of transfection reagent to 
pTRE-CO/NCO mRln1 plasmid is 3:1 (Optimised ratio Viafect with the plasmid for transfection, 
data not show). 1ml of the supernatant was transferred into 1.5ml Eppendorf tube and protein 
was precipitated from supernatant, while protein extraction from cell lysate was performed with 
cells adhered on the plate. 
 
2.13.2.1 Protein Extraction from Cell Lysate 
Cells were washed with 500µl ice-cold PBS. PBS was aspirated and 100µl of PABPN1 RIPA 
buffer was added. The plate was held at 45o angle and cells were scrapped down by using bent 
200µl pipette tips. The mixture contains PABPN1 RIPA buffer and cell mixture was transferred 
into pre-chilled 1.5ml Eppendorf tube on ice with an appropriate label. The mixture was 
incubated on ice for 15 minutes and vortexed each minute. The protein lysates mixture was 
centrifuged at 13,000 rpm for 15 minutes at 4oC to pellet down the cell debris. The supernatant 
dissolved in PABPN1 RIPA buffer was transferred to another pre-chilled and labelled 1.5ml 
Eppendorf tube and stored at -20oC freezer.      
 
2.13.2.2 Protein Precipitation through Supernatant with Methanol/Chloroform Methods 
This method involves using methanol, chloroform and water to precipitate protein. The 
ratio of protein:methanol:chloroform:water is 1:4:1:3. The protein will be precipitated and form 
a layer in between of top aqueous layer of methanol contain soluble compound (e.g. nucleic 
acids, salt, detergents and reducing agents) and bottom layer consists of chloroform containing 
lipids. 1ml of growth media was used as starting material together with 4 volume water (4ml), 1 
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volume chloroform( 1ml) and 3 volume water (3ml) in 15ml falcon tube. The Falcon tube was 
centrifuged at 5000 rpms at 4oC for 10 minutes, followed by removing the top water/methanol 
mixture (disturbing on the visible cloudy white layer contain protein shall be avoided). Another 
3 volume (3ml) of methanol was added and vortex well before proceeding to another final 
centrifuge spin at 5000 rpms at 4oC for 15 minutes. The supernatant was removed and carefully 
transferred the protein pellet into 1.5ml Eppendorf tube. The protein pellet was air dry (avoid 
the protein over dry) at RT and resuspended in approximate 100µl PABPN1 RIPA buffer. The 
protein is now ready for protein quantification or storage at -20oC freezer. 
 
2.13.3 Protein Quantification 
A standard series dilution contains BSA standard and PABPN1 RIPA buffer with 0 - 2µg range of 
concentration as shown in the table below: 
Concentration (µg) 2 1.8 1.5 1.2 1 0.8 0.6 0.4 0.2 0 
PABPN1 RIPA 
buffer (µl) 
0 4 10 16 20 24 28 32 36 40 
BSA standard (µl)  40 36 30 24 20 16 12 8 4 0 
 
5µl of protein sample and 0.5 µl of each concentration of the standard series dilution 
was transferred into 96 well plate. All conditions were prepared in triplicates. All the following 
experiment was carried out in fume hood by using reagents in DC assay protein kit. 25µl of 
mixture reagent A and S (20µl reagent S was added to each 1ml of reagents A) was added to 
each sample on 96 well plate. Next, 200µl of reagent B was applied and the resultant mixture is 
agitated (observation of the color changes from yellowish into blue once reagent B was added). 
The 96 well plate was incubated at room temperature for 15 minutes. The colorimetric analysis 
was performed through 96 well plate reader (Genbank) at 750nm. A standard curve was 
calculated and subsequent to this sample protein concentrations were determined.  
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2.14 Western Blot  
2.14.1 Materials  
 NuPage® 10% Bis-Tris precast gels, 1.0mm, 15 well (ThermoFisher) 
 NuPage® 20X MES SDS Running Buffer (ThermoFisher)  
 NuPage® 10X Reducing Agent (ThermoFisher) 
 NuPage® 4x LDS Sample Buffer (ThermoFisher) 
 NuPage® Antioxidant (ThermoFisher) 
 NuPage® 20X Transfer Buffer (ThermoFisher) 
 Novex® Sharp Pre-Stained Protein Standard (ThermoFisher, LC4800) 
 XCell SureLockTM Mini-Cell Electrophoresis System (ThermoFisher) 
 X-Cell IITM Blot Module (ThermoFisher) 
 E.coli positive control whole cell lysate (Abcam ab5395)  
 Absolute Methanol (VMR) 
 Amersham Protran Premium 0.2uM Nitrocellulose blotting membrane (GE 
Healthcare)   
 Tween 20 Detergent (Sigma) 
 Marvel Milk Powder  
 Ponceau S Stain (SigmaAldrich P7170-1L)  
 Filter paper 
 Odyssey CLx (LI-COR)  
2.14.2 Antibodies 
2.14.2.1 Primary Antibodies 
Antibody name Raised in Dilution factor used Expect binds to 
HA tag (Sigma, SAB4200080-
200UL) 
Rabbit 1:5000 HA tag peptide 
sequence  
Mouse relaxin 1/Human 
relaxin 2  (Abcam, 
ab183505) 
Rabbit 1:2500 Mouse relaxin 1 
Vinculin (Sigma 
SAB4200080-200UL)  
Mouse 1:10000 Mouse vinculin  
 
2.14.2.2 Secondary Antibodies 
Antibody name Dilution factor used Expect binds to 
IRDye® 680RD Goat anti-Mouse IgG 
(H+L) [LI-COR P/N 925-68070] 
1:10000 Mouse antibody 
IRDye® 800CW Goat anti-Rabbit IgG 
(H+L)), 0.1mg [LI-COR P/N925-32211] 
1:10000 Rabbit antibody   
 
 
71 
 
2.14.3 Sample Preparation 
Sample preparation was performed according to the table below (Taken from NuPage 
Technical guide 2010) with total protein extracted from the cell lysate and precipitate from 
supernatant: 
Reagent Reduced Non-reduced 
Sample 
Reduced  
Sample x µl x µl x µl 
NuPage® 10X Reducing Agent  1 µl - 2.5 µl 
NuPage® 4x LDS Sample Buffer  2.5 µl 2.5 µl 6.25 µl 
ddH2O To 6.5 µl To 7.5 µl To 16.25 µl 
Total Volume 10 µl 10 µl 25 µl 
  
(2x) master stock was prepared according to the table above contains: various amount 
of protein sample (40 µg – 120 µg) (Suggested 15µl sample on each well in NuPage® 10% Bis-Tris 
precast gels, 1.0mm, 15 well or 25 µl sample on each well in NuPage® 4 – 12 % Bis-Tris precast 
gels, 1.0mm, 10 well ) in Eppendorf tube. In reduced condition, the reduced sample was 
prepared by NuPage® 10X Reducing Agent. All protein samples were heated at 70oC for 10 
minutes. The Novex® Sharp Pre-Stained Protein Standard was loaded into both wells at the end 
of the NuPage Bis-Tris precast gel and another well with positive control (E.coli positive control 
whole cell lysate or mouse tissue samples). 
 
2.14.4 SDS-PAGE Gel set up and Electrophoresis 
The setup conditions of electrophoresis were followed as the manufacturer 
(ThermoFisher) recommended. NuPage® 1X MES SDS Running Buffer was prepared by mixing 
50ml of NuPage® 20X MES SDS Running Buffer with 950ml ddH2O. A NuPage® Bis-Tris precast 
gels, 1.0mm, 15 well was used to resolve recombinant relaxin hormone with HA tag. The comb 
was removed gently and wells were washed with ddH2O as initiation step to prepare the gel. 
Next, the white tape on the bottom part of the precast gel was removed. The precast gel was 
placed vertical (far from the gel tension wedge) on XCell SureLockTM Mini-Cell Electrophoresis 
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System together with plastic buffer dam (near the gel tension lock). The gel tension lock was 
lock up and filled with 200ml 1X MES SDS Running Buffer (the running buffer shall cover the well 
of the gel). Double checked to make sure there was no leaking of the running buffer from upper 
buffer chamber into the lower buffer chamber. 500µl of the NuPage® Antioxidant was added 
into the upper buffer chamber. 600ml of 1X MES SDS Running Buffer was filled into lower buffer 
chamber prior to starting electrophoresis. The gel electrophoresis was set to run at 200V for 
around 40 minutes. In order to make sure was not overrun, the smallest standard protein on 
protein ladder was located around 90% end on the bottom of the gel before stopping 
electrophoresis stop.     
 
2.14.5 Opening Precast Gel Cassettes and Transferring protein to membranes 
The opening precast gel cassettes and transferring protein to the membrane was 
followed as the manufacturer (ThermoFisher) recommended. The precast gel was removed from 
the upper buffer chamber, gel knife was placed in the groove between cassette halves and lever 
the knife gently to avoid excessive pressure on the gel. The top plate was removed and allowed 
the gel to come off by gentle shaking in the container with 1X transfer buffer (prepared as shown 
in the table below). 
Reagent Reduced Sample Non-reduced 
Sample 
NuPage® Transfer Buffer (20X) 50 ml 50 ml 
NuPage® Antioxidant 1 ml - 
Methanol 100 ml 100 ml 
ddH2O 849 ml 850 ml 
Total Volume 1000 ml 1000 ml 
 
Once the gel was detached from the lower plate, the transferring set up as shown in 
Figure 2.3 (Adapted from NuPage Technical guide 2010) in X-Cell IITM Blot Module. For one gel 
transferring, 4 blotting pad, 2 filter paper and 0.2µM nitrocellulose blotting membrane size 
similar to the gel were pre-soaked in transfer buffer. All trapped air bubbles was removed by 
using roller on the surface of blotting pad and filter paper. Extra care has taken to minimize the 
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air bubble trapped in between the gel and transfer membrane. Blot module was filled to 200ml 
of transfer buffer and make sure the buffer does not leak. The lower buffer chamber was filled 
with 600ml ddH2O, placed the lid and run at 70V for 90 minutes.     
 
Figure 2.3 The Illustration of One Gel transferring process during western blot. Two blotting 
pads were placed at the bottom (cathode core) Blot module (X Cell IITM Blot Module). This was 
followed by filter paper, gel and transfer membrane. Then the roller was used to remove air 
bubble trap in between gel and transfer membrane. Then another layer of filter paper was 
added and finally two blotting pads were added on the top. The anode core was placed on the 
top of the X Cell IITM Blot Module, which is ready for Western blot transferring process.  
 
2.14.6 Post-Transfer Nitrocellulose Membrane (NCB) Checks and Blocking 
Following 90 minutes transfer, the membrane was stained with 1X Ponceau S solution 
for 5 minutes on weighing boat shaking on the shaker at 120 rpms. The stains will bind to all of 
the protein that is present in the membrane, the image was captured. The Ponceau S stains 
membrane was washed by using 0.1% PBS-Tween 20 (PBS-T) at 5 minutes intervals until no 
stains were visible. 
The nitrocellulose membrane was then blocked with different types of blocking buffer 
(5% (w/v) Marvel milk in, 3% BSA in 0.2% PBS-Tween 20 or 3% BSA in 0.1% PBS-Triton X-100) for 
1 hour in RT and shaking on the shaker at 120 rpms. The blocking step was to prevent non-
specific binding of antibody on the membrane. Once the membrane was blocked, it is incubated 
in 4oC overnight shaking on the shaker at 70 rpms with specific primary antibodies (Section 
2.12.2.1) in 5% Marvel milk 0.2% PBS-T. 
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2.14.7 Visualization of the Nitrocellulose membrane (NCB): The Odyssey Method 
After the overnight primary antibody incubation, the NCB was then subject to 4 washes 
for 10 minutes with 0.1% PBS-T in RT and shaking on the shaker at 120 rpms. The membrane 
was incubated with secondary antibody (Section 2.12.2.2) in 5% Marvel milk 0.2% PBS-T for 1 
hour in RT, shaking on the shaker at 120 rpms. The post incubation of membrane in secondary 
antibody, further 4 times washes for 10 minutes in RT and shaking on the shaker at 120 rpms. 
Throughout the secondary antibodies incubation and post-incubation membrane washes, the 
membrane was kept in the dark. The detection of fluorescence was done at 680nm 
(Housekeeping protein shown in the red fluorescence band) and 800nm (Targeting protein 
shown in the green fluorescence band) through Odyssey CLx (LI-COR). 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: STUDIES ON THE RELAXIN PLASMID DESIGN 
AND PLASMID VERIFICATIONS 
 
 
 
 
 
 
 
 
76 
 
CHAPTER 3: STUDIES ON THE RELAXIN PLASMID DESIGN AND PLASMID VERIFICATIONS  
3.1 Introduction 
Relaxin is a small (~6 kDa) pleiotropic hormone belonging to the insulin-like growth 
factor family; which plays an important role in female sex organs during pregnancy (Bathgate et 
al., 2003). In addition, relaxin inhibits the TGF-β induced transition of fibroblast to myofibroblast 
(Mookerjee et al., 2009), mediates Notch-1 inhibition of TGF-β/Smas3 signalling (Sassoli et al., 
2013) and induces MMP-9 and MMP13 expression (Ahmad et al., 2012). Relaxin supresses 
several types of disease-related fibrosis, such as pulmonary fibrosis (Samuel et al., 2003), renal 
fibrosis (Danielson et al., 2006), hepatic fibrosis (Williams et al., 2001), cardiac fibrosis (Samuel 
et al., 2008) and scleroderma (Samuel et al., 2005). In skeletal muscle, relaxin has been shown 
to be involved in MMP regulation which suppress inflammation, tissue remodelling and fibrosis 
(Formigli et al., 2005) and promotes also the mobilization of satellite cells (Mu et al., 2010). 
Adenoviral-mediated delivery of relaxin reversed cardiac fibrosis through reduction in interstitial 
collagen content (Bathgate et al., 2008) and upregulation of the expression of MMP in keloid 
fibroblasts (Lee et al., 2012). In this project, we are interested in the potential effect of mouse 
relaxin 1 (mRln1) upregulation to reduce fibrotic condition in vitro studies with mRln1 expressing 
plasmid.  
 The reporter system based on the fluorescent protein allows visualization of the protein 
in living cells. In this thesis, a Green Fluorescence Protein (GFP) reporter system is adapted for 
detecting the efficiency of transfection through GFP expression in vitro. GFP was first isolated 
from the jellyfish Aequorea victoria (Ormö et al., 1996), where the protein exhibits green 
fluorescence when exposed to blue or ultraviolet range light (Tsien, 1998). The mutant GFP also 
known as enhanced GFP (eGFP) have mutations (F64L, S65T) within the chromophore region of 
the eGFP protein to increase the fluorescence when excited at 488nm (Cormack et al., 1996). 
The eGFP exhibits ~30 fold brighter fluorescence intensity compare to wild type GFP in in vitro 
transfection investigation (Cormack et al., 1996). An advantage of GFP reporter systems is that 
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they allow a direct visualization without the use of secondary proteins or cofactors. Some of the 
applications of the GFP protein are as a reporter gene for fluorescence microscopy or live 
imaging, fluorescence-activated cell sorting, fusion tag protein, co-transfection as a control for 
transfection efficiency in in vitro, reporter gene as transgene biodistribution in vivo (Kumar and 
Pal, 2016; Gangadaran et al., 2017).  
Plasmid DNA is a circular, double stranded form of extra-chromosomal DNA that 
replicates independent compared to nuclear DNA, it is normally present in bacteria (Lodish, 
2000); plasmids are commonly found in bacteria and often carry genes beneficial to the 
organism survival (Thomas et al., 2008). In biotechnology, plasmids are used as bacterial cloning 
vectors. Some genes in the original bacterial plasmid have been replaced with transgenes for 
specific biological research purposes, such as tissue specific promoters and genes of interest 
from mammalian cells for biological research (Gill et al., 2009). The plasmid DNA eventually 
undergoes gene silence over a period of time due to the CpG methylation in promoter or histone 
modification in mammalian (How et al., 2016). The sustainability of long-term transgene 
expression is highly dependent on the promoter and others elements (polyadenylated tails 
contribute to mRNA stability, Kozak sequence for translation initiation) (Gill et al., 2009). 
Plasmids including viral vector elements (e.g. inverted terminal repeat are needed in adeno-
associated viral vector production) allow the production of viral vectors that favour long-term 
transgene expression which can be used for gene therapy (Naso et al., 2017). In this chapter 
different plasmid constructs and their level of transgene expression in vitro is investigated.  
  In mammalian expression vectors, promoter/enhancer elements are necessary to 
promote transgene expression. Currently, there are a few different types of promoter that are 
commonly used in mammalian expression system, such as viral promoters from cytomegalovirus 
(CMV), promoters from “native” human genes that exhibit high and tissue-specific transgene 
expression, as well as inducible promoters and synthetic promoters. The CMV promoter (~800bp) 
exhibits a ubiquitous and high level of transgene expression (Gray et al., 2011). In gene therapy, 
78 
 
the CMV promoter offers a strong constitutive transgene expression in vivo that will decline 
gradually over a period of time to DNA methylation (Doerfler, 2011). The CBh promoter (~800bp) 
is an improved version of the CMV promoter consisting of the CMV enhancer, chicken β-actin 
promoter and a hybrid intron (hybrid between chicken β-actin and intron of mice minute virus) 
(Gray et al., 2011). In this project, we designed plasmids with gene expression driven by a CBh 
promoter with a tetracycline inducible transcriptional activation system to control our transgene 
expression.  
Tetracycline inducible transcriptional activation systems allow the regulation of 
transgene transcription through the presence (Tet-On) or absence (Tet-Off) of antibiotic 
tetracycline or its derivations (Kallunki et al., 2019). This system originated from gram-negative 
bacteria where it is responsible for tetracycline antibiotic resistance (Rodríguez-García et al., 
2005). The presence of tetracycline activates the expression of the membrane protein TetA, 
which regulates the efflux of the antibiotic. In the absence of tetracycline the expression of TetA 
is repressed through binding of the protein TetR to the tetracycline operator tetO (Oeth et al., 
2000). The protein TetR recognizes the Tetracycline Response Element (TRE) that comprises a 7 
repeats of a length of 19 nucleotides. This system was developed to have a rapid and controlled 
transgene expression through the presence of tetracycline in mammalian HeLa cell system 
(Gossen and Bujard, 1992).  
The Tet-On system was further developed with a reverse Tet repressor (rTetR) through 
random mutagenesis of TetR at 4 different amino acids positions (E71K, D95N, L101S and 
G102D). The Tet-On system allow for transgenes expression in the presence of tetracycline, in 
contrast absence of tetracycline repress transgenes expression. During the absence of 
tetracycline, the TetR fused with KRAB silencing domain bind to the tetO to suppress transgene 
expression (T Das et al., 2016). The rTetR fused to the C-terminal of VP16 (transcriptional domain 
from Herpes Simplex virus) and became the first generation of reverse tetracycline-controlled 
transactivator (rtTA) allow transgene expression to be turn on in the presence of tetracycline 
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(Gossen et al., 1995). Improvements led to the development of the second generation of rtTA 
also known as rtTA Advanced; rtTA Advanced consists of mutations on 5 amino acid positions 
(S12G, E19G A56P, D148E and H179R), which offer higher sensitivity to tetracycline and reduce 
leaky activity in the absence of tetracycline compare to rtTA (T Das et al., 2016). In this project, 
we utilised the Tet-On system to control our transgenes expression driven by the presence of 
antibiotic. 
 In DMD gene therapy, cardiac and skeletal muscle tissue-specific promoters allow 
specific transgenes to be expressed only in these cells to avoid off-target transgene expression 
across other types of cells (Rudeck et al., 2016). The muscle-specific synthetic promoter Spc512 
offers high specificity on gene expression in muscle and cardiac cells compare to natural 
myogenic promoter (Darghia et al., 2004). The Spc512 is constructed with random assembling 
of multiple copies of 4 elements: upstream regulatory region of muscle-specific genes (MEF-1), 
promoter/enhancer regions of the myosin light chain 3 gene (MEF-2), serum response element 
(SRE) and transcription enhancer factor-1 (TEF-1) (Darghia et al., 2004). We are interested in 
utilising the Spc512 promoter to achieve high level of transgenes expression in skeletal muscle. 
 Temporary exogenous transgene expression delivery into the nucleus can be achieved 
through plasmid DNA transfection in cultured mammalian cells. The transgene is transcribed 
and translated into a specific functional protein, which is stable over a certain period of time. 
Exogenous transgene expression in gene therapy have various purposes based on the types of 
research or therapeutic effects (Naldini, 2015). We aimed for a high level of secreted hormone 
production in skeletal muscle. We hoped to improve the translation process through codon 
optimization, where we designed a codon-optimised mRln1 construct through online 
bioinformatics software. We focused on designing various plasmid constructs with either codon 
optimised mRln1 or native mRln1.  
Introduction of nucleic acids into eukaryote cells through non-viral methods is known as 
transfection. This process involves transferring the negatively charged nucleic acid into cells 
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through the negatively charged membrane. There are a range of methods (chemical, biological 
and physical) that have been developed to introduce nucleic acids into the cells. Cationic 
polymers bind to negatively charged genetic materials that form a complex prior to being taken 
up by a cell via endocytosis (Midoux et al., 2008). On the other hand, lipofection involves a 
positively charged liposome (phospholipid bilayer vesicle) to aggregate with negatively charged 
nucleic acids that merges with the cell membrane (Felgner et al., 1987). In this project, we 
focused on a comparison of three different types of transfection reagents that are chemical 
based transfection. We utilised transfection to achieve transgene expression in vitro studies. 
In this chapter, we designed plasmids to express mouse relaxin 1 variants and 
characterised all plasmids constructs and their functional elements, including promoters 
(Spc512, CBh), tetracycline inducible activating system (Tet On), presence or absence of inverted 
terminal repeat (ITR) sequences, and origins of replication through restriction digest. Next, we 
optimised the transfection efficiency through a GFP reporter system into mouse myogenic cell 
line (C2C12) and mouse myogenic fibroblast cell line (MH). These preliminary in vitro 
transfection efficiency studies will be applied to mouse relaxin 1 expressing plasmid in the two 
following chapters.   
 
3.2 Results 
3.2.1 Plasmid construct design 
All plasmid vectors that were constructed for this thesis are described in Section 2.2.    
3.2.1.1 Reporter gene design and validation 
Details of the reporter plasmid pCI-eGFP used in this thesis are shown in figure 3.1. The 
pCI-eGFP plasmid was a kind gift provided by Dickson Lab.  The reporter plasmid pCI-eGFP 
expresses the gene eGFP under control of the promoter CMV.   
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3.2.1.2. Design and validation of plasmids expressing mRln1 driven by Spc512 (AAV based 
plasmid)  
All plasmid constructs that contain mouse relaxin 1 (mRln1) were designed and 
synthesised by VectorBuilder. AAV based (contain inverted terminal repeat which allow for AAV 
viral vector production) plasmids that express mouse relaxin 1 (mRln1) under the control of 
synthetic muscle-specific (Spc512) promoter were designed. The 558 bp ORF of native mRln1 
was obtained from NCBI (NM011272.2) (native mRln1) and the sequence-optimised version of 
mRln1 (CO mRln1) was generated through VectorBuilder Codon Optimization online software. 
Two types of AAV based plasmids were designed; single-stranded AAVs (ssAAV) were named 
pssAAV-Spc512-CO mRln1 (illustrated in figure 3.2A) and pssAAV-Spc512-NCO mRln1 (illustrated 
in figure 3.3A) and self-complementary AAVs (scAAV) were named pscAAV-Spc512-CO mRln1 
(illustrated in figure 3.4A) and pscAAV-Spc512-NCO mRln1 (illustrated in figure 3.5A). The 
expression of mRln1 (CO mRln1 or NCO mRln1) cDNAs are driven by Spc512 promoter. 
 
3.2.1.3 Design and validation of plasmids expressing mRln1 driven by a Tet On system 
(conventional & AAV based plasmid) 
All plasmid constructs with mRln1 were designed and purchased online through 
VectorBuilder. Plasmids were designed with CO mRln1 or NCO mRln1 driven by a tetracycline 
inducible transcriptional activating system (Tet-On). Two of the conventional plasmids (plasmid 
that does not allow AAV viral vector production) that express mRln1 include a HA tag (HA) 
located C terminal of mRln1 driven by Tet-On system are pTet On-CO mRln1/HA (illustrated in 
figure 3.6A) and pTet On-NCO mRln1/HA (illustrated in figure 3.7A). The second set of the single-
stranded AAV based plasmids (pssAAV) are pssAAV-Tet On-CO mRln1 (illustrated in figure 3.8A) 
and pssAAV-Tet On-NCO mRln1 (illustrated in figure 3.9A).  
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Figure 3.1 Design and characterisation of pCi-eGFP. A. Map of the reporter plasmid pCi-eGFP, 
which contains a DNA sequence for enhanced Green Fluorescence Protein (eGFP). The 
plasmid was obtained from Dickson Lab. Restriction digestion was set up with 1000ng of 
plasmid DNA digested with one unit of restriction enzyme for one hour as manufacturer 
suggested. B. Detailed restriction endonuclease analysis of pCi-eGFP was used to verify the 
plasmid construct and digests run on a 1% (w/v) agarose TAE gel. The reporter plasmid pCi-
GFP was digested with different restriction enzymes, including NcoI (lane 4), PvuI (lane 5) and 
SpeI (lane 6) with expected fragment sizes produced. A positive (uncut plasmid) was included 
to be able to differentiate between digested and undigested plasmids. In addition, a negative 
control (no plasmid) was used to indicate the absence of contamination. 
A 
B Expected fragment 
sizes (bp): 
1: 10kb Ladder 
2: Uncut positive 
control 
3: Negative control 
4: NcoI (4143, 566) 
5: PvuI (3359, 1350) 
6: SpeI (4709)  
7: 10kb Ladder 
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Figure 3.2 Design and characterisation of pssAAV-Spc512-CO mRln1 vectors. A. Functional 
map of pssAAV-Spc512-CO mRln1. The plasmid was designed online and ordered through 
VectorBuilder in bacterial glycerol stocks. The specific restriction digest site is located in the 
map and methylation site (*) for certain restriction enzyme. Restriction digestion was set up 
with 1000ng of plasmid DNA digested with one unit of restriction enzyme for one hour as 
manufacturer suggested B. Detailed restriction endonuclease analysis of pssAAV-Spc512-CO 
mRln1 was used to verify the plasmid construct and digests run on a 1% (w/v) agarose TAE 
gel. The pssAAV-Spc512-CO mRln1 is analysed respectively with different restriction enzyme 
BamHI (lane 4), MscI (lane 5), NaeI (lane 6), PvuI (lane 7) and SmaI (lane 8) with expected 
fragment sizes. A positive (uncut plasmid) was included to be able to differentiate between 
digested and undigested plasmids. In addition, a negative control (no plasmid) was used to 
indicate the absence of contamination.     
 
 
 
 
A 
B Expected fragment sizes 
(bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: Negative control 
4: BamHI (4653)  
5: MscI (3351, 1302, 664, 
638)  
6: NaeI (3215, 753, 685)  
7: PvuI (3281, 1372)  
8: SmaI (3201, 1172, 258)  
9: 10kb Ladder 
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Figure 3.3 Design and characterisation of pssAAV-Spc512-NCO mRln1 vectors. A. Functional 
map of pssAAV-Spc512-NCO mRln1. The plasmid was designed online and ordered through 
VectorBuilder in bacterial glycerol stocks. The specific restriction digest site is located in the 
map. Restriction digestion was set up with 1000ng of plasmid DNA digested with one unit of 
restriction enzyme for one hour as manufacturer suggested B. Detailed restriction 
endonuclease analysis of pssAAV-Spc512-NCO mRln1 was used to verify the plasmid construct 
and digests run on a 1% (w/v) agarose TAE gel. The pssAAV-Spc512-NCO mRln1 is analysed 
respectively with different restriction enzyme BamHI (lane 4), MscI (lane 5), NaeI (lane 6), PvuI 
(lane 7) and SmaI (lane 8) with expected fragment sizes. A positive (uncut plasmid) was 
included to be able to differentiate between digested and undigested plasmids. In addition, a 
negative control (no plasmid) was used to indicate the absence of contamination.      
 
 
A 
B 
Expected fragment sizes 
(bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: Negative control 
4: BamHI (4653)  
5: MscI (3351, 1302)  
6: NaeI (3215, 753, 685)  
7: PvuI (3281, 1372)  
8: SmaI (3201, 1172, 258)  
9: 10kb Ladder 
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Figure 3.4 Design and characterisation of pscAAV-Spc512-CO mRln1 vectors. A. Functional 
map of pscAAV-Spc512-CO mRln1. The plasmid was designed online and ordered through 
VectorBuilder in bacterial glycerol stocks. The specific restriction digest site is located in the 
map and methylation site (*) for certain restriction enzyme. Restriction digestion was set up 
with 1000ng of plasmid DNA digested with one unit of restriction enzyme for one hour as 
manufacturer suggested B. Detailed restriction endonuclease analysis of pscAAV-Spc512-CO 
mRln1 was used to verify the plasmid construct and digests run on a 1% (w/v) agarose TAE 
gel. The pscAAV-Spc512-CO mRln1 is analysed respectively with different restriction enzyme 
BamHI (lane 4), MscI (lane 5), NaeI (lane 6), PvuI (lane 7) and SmaI (lane 8) with expected 
fragment sizes. A positive (uncut plasmid) was included to be able to differentiate between 
digested and undigested plasmids. In addition, a negative control (no plasmid) was used to 
indicate the absence of contamination.     
A 
B 
Expected fragment sizes (bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: Negative control 
4: BamHI (4833)  
5: MscI (3369, 1464, 826, 638)  
6: PvuI (3443, 1390)  
7: SpeI (4212, 621)  
8: SmaI (3219, 894, 429, 258)  
9: 10kb Ladder 
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Figure 3.5 Design and characterisation of pscAAV-Spc512-NCO mRln1 vectors. A. Functional 
map of pscAAV-Spc512-NCO mRln1. The plasmid was designed online and ordered through 
VectorBuilder in bacterial glycerol stocks. The specific restriction site is located in the map. 
Restriction digestion was set up with 1000ng of plasmid DNA digested with one unit of 
restriction enzyme for one hour as manufacturer suggested B. Detailed restriction 
endonuclease analysis of pscAAV-Spc512-NCO mRln1 was used to verify the plasmid construct 
and digests run on a 1% (w/v) agarose TAE gel. The pscAAV-Spc512-NCO mRln1 is analysed 
respectively with different restriction enzyme BamHI (lane 4), MscI (lane 5), PvuI (lane 6), SpeI 
(lane 7) and SmaI (lane 8). A positive (uncut plasmid) was included to be able to differentiate 
between digested and undigested plasmids. In addition, a negative control (no plasmid) was 
used to indicate the absence of contamination.      
 
 
 
A 
B 
Expected fragment sizes (bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: Negative control 
4: BamHI (4833)  
5: MscI (3369, 1464)  
6: PvuI (3443, 1390)  
7: SpeI (4212, 621)  
8: SmaI (3219, 894, 429, 258)  
9: 10kb Ladder 
87 
 
 
 
Figure 3.6 Design and characterisation of pTet On-CO mRln1 vectors. A. Functional map of 
pTet On-CO mRln1. The plasmid was designed online and ordered through VectorBuilder in 
bacterial glycerol stocks. The specific restriction site is located in the map. Restriction 
digestion was set up with 1000ng of plasmid DNA digested with one unit of restriction enzyme 
for one hour as manufacturer suggested B. Detailed restriction endonuclease analysis of pTet 
On-CO mRln1 was used to verify the plasmid construct and digests run on a 1% (w/v) agarose 
TAE gel. The pTet On-CO mRln1 is analysed respectively with different restriction enzyme 
BamHI (lane 3), KpnI (lane 4) and NotI (lane 5). A positive (uncut plasmid) was included to be 
able to differentiate between digested and undigested plasmids.  
 
 
A 
B 
Expected fragment sizes (bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: BamHI (6039) 
4: KpnI (4765, 1274) 
5: NotI (3996, 2043)  
6: 10kb Ladder  
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Figure 3.7 Design and characterisation of pTet On-NCO mRln1 vectors. A. Functional map of 
pTet On-NCO mRln1. The plasmid was designed online and ordered through VectorBuilder in 
bacterial glycerol stocks. The specific restriction site is located in the map. Restriction 
digestion was set up with 1000ng of plasmid DNA digested with one unit of restriction enzyme 
for one hour as manufacturer suggested B. Detailed restriction endonuclease analysis of pTet 
On-NCO mRln1 was used to verify the plasmid construct and digests run on a 1% (w/v) agarose 
TAE gel. The pTet On-NCO mRln1 is analysed respectively with different restriction enzyme 
BamHI (lane 3), KpnI (lane 4) and NotI (lane 5). A positive (uncut plasmid) was included to be 
able to differentiate between digested and undigested plasmids.  
 
A 
B 
Expected fragment sizes (bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: BamHI (6039) 
4: KpnI (4765, 1274) 
5: NotI (3996, 2043)  
6: 10kb Ladder  
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Figure 3.8 Design and characterisation of pssAAV-Tet On-CO mRln1/HA vectors. A. 
Functional map of pssAAV-Tet On-CO/HA mRln1. The plasmid was designed online and 
ordered through VectorBuilder in bacterial glycerol stocks. The specific restriction site is 
located in the map. Restriction digestion was set up with 1000ng of plasmid DNA digested 
with one unit of restriction enzyme for one hour as manufacturer suggested. B. Detailed 
restriction endonuclease analysis of pssAAV-Tet On-CO mRln1 mRln1/HA was used to verify 
the plasmid construct and digests run on a 1% (w/v) agarose TAE gel. The pssAAV-Tet On-CO 
mRln1/HA is analysed respectively with different restriction enzyme AhdI (lane 3) BamHI (lane 
4), EcoNI (lane 5), KpnI (lane7), MscI (lane 8), NdeI (lane 9), PvuI (lane 10) and SmaI (lane 11). 
A positive (uncut plasmid) was included to be able to differentiate between digested and 
undigested plasmids. In addition, a negative control (no plasmid) was used to indicate the 
absence of contamination.      
A 
B 
Expected fragment sizes (bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: Negative control 
4: AhdI (4172, 1937, 1319) 
5: BamHI (7428)  
6: EcoNI (7317) 
7: KpnI (7428) 
8: MscI (4077, 3351) 
 
9: NdeI (5291, 2137) 
10: PvuI (6056, 1372)  
11: SmaI (3201, 2548, 1657) 
12: 10kb Ladder  
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Figure 3.9 Design and characterisation of pssAAV-Tet On-NCO mRln1/HA vectors. A. 
Functional map of pssAAV-Tet On-NCO/HA mRln1. The plasmid was designed online and 
ordered through VectorBuilder in bacterial glycerol stocks. The specific restriction site is 
located in the map. Restriction digestion was set up with 1000ng of plasmid DNA digested 
with one unit of restriction enzyme for one hour as manufacturer suggested. B. Detailed 
restriction endonuclease analysis of pssAAV-Tet On-NCO mRln1/HA was used to verify the 
plasmid construct and digests run on a 1% (w/v) agarose TAE gel. The pssAAV-Tet On-NCO 
mRln1/HA is analysed respectively with different restriction enzyme AhdI (lane 3) BamHI (lane 
4), EcoNI (lane 5), KpnI (lane7), MscI (lane 8), NdeI (lane 9), PvuI (lane 10) and SmaI (lane 11). 
A positive (uncut plasmid) was included to be able to differentiate between digested and 
undigested plasmids. In addition, a negative control (no plasmid) was used to indicate the 
absence of contamination.      
 
A 
B 
Expected fragment sizes (bp): 
1: 10kb Ladder 
2: Uncut positive control 
3: Negative control 
4: AhdI (4172, 1937, 1319) 
 
5: BamHI (7428) 
6: EagI (6334, 585, 509) 
7: KpnI (7428) 
8: MscI (4077, 3351) 
9: NdeI (5291, 2137) 
 
10: PvuI (6056, 1372)  
11: ScaI (4774, 2654)  
12: SmaI (3201, 2548, 1657) 
13: 10kb Ladder  
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3.2.2 Comparison between codon optimised and native mouse relaxin 1 
 We utilize codon optimization of the nucleotide sequence and hoped it might increase 
the translation efficiency compare to native nucleotide sequence. The native mouse relaxin 1 
(mRln1) nucleotide sequence was obtained from NCBI (NCBI, NM011272.2). The codon 
optimised sequence was generated with the mouse relaxin 1 amino acids sequence obtained 
from Uniprot (Uniprot, P47932) and the codon optimised mRln1 (CO mRln1) sequence was 
generated with online Vectorbuilder codon optimization software (VectorBuilder). Both of the 
CO mRln1 and mRln1 nucleotide sequence was compared by using online Clustal multiple 
sequence alignment by MUSCLE 3.8 (EMBL, MUSCLE). The result suggested there are only 39.45% 
codon from mRln1 remain the same as CO mRln1, while the other 60.55% codons replaced the 
low frequency rare codon to higher frequency codon (Figure 3.10).  
 The rare codon analysis was performed with online bioinformatics GenScript rare codon 
analysis tool (GenScript). In the Vectorbuilder codon optimization (CO) mouse relaxin 1 (mRln1) 
there was an increase in Codon Adaptation Index (CAI) and GC content, while there was a 
reduced Codon Frequency Distribution (CFD) compared to the native mRln1. The ideal CAI would 
be between 0.8 and 1.0; the CAI for native mRln1 is 0.71, there was therefore an increase in CAI 
in the CO mRln1 to 1.0, suggesting the CO mRln1 had a higher chance of being expressed at a 
higher level compared to native mRln1. Next the GC content increased from 51.76% in native 
mRln1 to 66.03% in CO plasmid. The increase in the GC content lead to a reduction of CFD which 
indicated a low percentage frequency of rare codons have been replaced with higher frequency 
codons that are translated into the same amino acid. Lastly, both of the negative Cis-regulatory 
elements (CIS) element and negative repeat elements are not present in both of the native 
mRln1 and CO mRln1. In summary, an increase of the GC content and the replacement of rare 
codons allows codon replacement which is vital for codon optimization.  
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mRln1      1   ATG TCC AGC AGA TTT TTG CTC CAG CTC CTG GGG TTC TGG CTA TTG CTG AGC CAG CCT TGC  60 
           1     M   S   S   R   F   L   L   Q   L   L   G   F   W   L   L   L   S   Q   P   C  20  
CO mRln1       ATG AGC AGC AGG TTC CTG CTG CAG CTG CTG GGC TTC TGG CTG CTG CTG AGC CAG CCT TGC 
               ***   * *** **  **   ** **  *** **  *** **  *** *** **   ** *** *** *** *** *** 
 
mRln1     61   AGG ACG CGA GTC TCG GAG GAG TGG ATG GAC GGA TTC ATT CGG ATG TGC GGC CGT GAA TAT 120 
          21     R   T   R   V   S   E   E   W   M   D   G   F   I   R   M   C   G   R   E   Y  40 
CO mRln1       AGG ACC AGG GTG AGC GAG GAG TGG ATG GAC GGC TTC ATC AGG ATG TGC GGC AGG GAG TAC 
               *** **  *   **      *** *** *** *** *** **  *** **  *** *** *** **   *  **  **  
 
mRln1    121   GCC CGT GAA TTG ATC AAA ATC TGC GGG GCC TCC GTG GGA AGA TTG GCT TTG AGC CAG GAG 180 
          41     A   R   E   L   I   K   I   C   G   A   S   V   G   R   L   A   L   S   Q   E  60 
CO mRln1       GCC AGG GAG CTG ATC AAG ATC TGC GGC GCC AGC GTG GGC AGG CTG GCC CTG AGC CAG GAG 
               ***  *  **   ** *** **  *** *** **  ***   * *** **  **   ** **   ** *** *** *** 
 
mRln1    181   GAG CCA GCT CTG CTT GCC AGG CAA GCC ACT GAA GTT GTG CCA TCC TTC ATC AAC AAA GAT 240 
          61     E   P   A   L   L   A   R   Q   A   T   E   V   V   P   S   F   I   N   K   D  80 
CO mRln1       GAG CCT GCC CTG CTG GCC AGG CAG GCC ACC GAG GTG GTG CCT AGC TTC ATC AAC AAG GAC 
               *** **  **  *** **  *** *** **  *** **  **  **  *** **    * *** *** *** **  **  
 
mRln1    241   GCA GAG CCT TTC GAT ACG ACG CTG AAA TGC CTT CCA AAT TTG TCT GAA GAG CTC AAG GCA 300 
          81     A   E   P   F   D   T   T   L   K   C   L   P   N   L   S   E   E   L   K   A 100 
CO mRln1       GCC GAG CCT TTC GAC ACC ACC CTG AAG TGC CTG CCT AAC CTG AGC GAG GAG CTG AAG GCC 
               **  *** *** *** **  **  **  *** **  *** **  **  **   **     **  *** **  *** **  
 
mRln1    301   GTA CTG TCT GAG GCT CAG GCC TCG CTC CCA GAG CTA CAA CAC GCA CCT GTG TTG AGC GAT 360 
         101     V   L   S   E   A   Q   A   S   L   P   E   L   Q   H   A   P   V   L   S   D 120 
CO mRln1       GTG CTG AGC GAG GCC CAG GCC AGC CTG CCT GAG CTG CAG CAC GCC CCT GTG CTG AGC GAC 
               **  ***     *** **  *** ***  ** **  *** **  **  **  *** **  *** ***  ** *** ***  
 
mRln1    361   TCT GTT GTT AGC TTG GAA GGC TTT AAG AAA ACT CTC CAT GAT AAA CTG GGT GAA GCA GAA 420 
         121   S   V   V   S   L   E   G   F   K   K   T   L   H   D   R   L   G   E   A   E 140 
CO mRln1       AGC GTG GTG AGC CTG GAG GGC TTC AAG AAG ACC CTG CAC GAC AAG CTG GGC GAG GCC GAG 
                   **  **  ***  ** **  *** **  *** **  **  **  **  **  **  *** **  **  **  **  
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mRln1    421   GAC GGC AGT CCT CCA GGG CTT AAA TAC TTG CAA TCA GAT ACC CAT TCA CGG AAA AAG AGG 480 
         141     D   G   S   P   P   G   L   K   Y   L   D   G   S   P   P   G   L   K   Y   L 160 
CO mRln1       GAC GGC AGC CCT CCT GGC CTG AAG TAC CTG CAG AGC GAC ACC CAC AGC AGG AAG AAG AGG 
               *** *** **  *** **  **  **  **  ***  ** **      **  *** **       ** **  *** *** 
 
mRln1    481   GAG TCT GGT GGA TTG ATG AGC CAG CAA TGT TGC CAC GTC GGT TGT AGC AGA AGA TCT ATT 540 
         161     E   S   G   G   L   M   S   Q   Q   C   C   H   V   G   C   S   R   R   S   I 180 
CO mRln1       GAG AGC GGC GGC CTG ATG AGC CAG CAG TGC TGC CAC GTG GGC TGC AGC AGG AGG AGC ATC 
               ***     **  **   ** *** *** *** **  **  *** *** **  **  **  *** **  **      **  
 
mRln1    541   GCT AAA CTC TAT TGC TGA 555 
         181     A   K   L   Y   C     185                                          
CO mRln1       GCC AAG CTG TAC TGC TGA  
               **  **  **  **  *** *** 
 
Codon details  Colour Percentage (aa/full length aa) 
Nucleotide one and two are identical Red 45.4% (84aa/185 aa) 
Nucleotide two and three are identical Green 6.48% (12aa/185aa) 
No nucleotides are identical Blue 3.78% (7aa/185aa) 
Only nucleotide one is identical Yellow 0.005% (1aa/185aa) 
Only nucleotide two is identical Purple 0.01% (2aa/185aa) 
Only nucleotide three is identical Orange 0.01% (3aa/185aa) 
Nucleotides remain unchanged No Highlight  39.45% (73aa/185aa) 
   
Figure 3.10 Comparison between codon optimise and native mouse relaxin 1. The native mouse relaxin 1 (mRln1) nucleotide sequence are obtained from NCBI 
(NCBI, NM011272.2). The mRln1 amino acids sequence was obtained from Uniprot (Uniport, P49732) and the amino acids sequence was used to generated codon 
optimise mRln1 (CO mRln1) sequence with online VectorBuilder codon optimization software. The comparison between CO mRln1 and mRln1 was performed with 
NCBI blastn. Amino acid (aa) 
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 native 
mRln1 
VB CO 
mRln1 
CAI 0.71 1.0 
GC content 51.76% 66.03% 
CFD 4% 0% 
Negative CIS element 0 0 
Negative repeat elements 0 0 
Table 3.1 Rare codon analysis comparison between codon optimised mouse relaxin 1 and 
native mouse relaxin 1. The rare codon analysis was performed through GenScript online rare 
codon analysis to compare between the native mouse relaxin 1 (native mRln1) and codon 
optimised mouse relaxin 1 (CO mRln1) generate from VectorBuilder (VB). The native mRln1 
amino acid sequence was used to generate CO mRln1 through the VectorBuilder online codon 
optimization (VB CO mRln1). The codon optimization prediction analysis on Codon Adaptation 
Index (CAI) and GC content, Codon Frequency Distribution (CFD).  
 
3.2.3 Optimising transgene expression efficiency in C2C12 and MH cells with a GFP reporter 
system 
The mouse myogenic (C2C12) and mouse myogenic fibroblasts (MH) cell line was 
transiently transfected with the GFP reporter plasmid (pCi-eGFP). The GFP fluorescence intensity 
was measured by flow cytometry analysis (Figure 3.11) and fluorescence microscopy imaging 
for C2C12 (Figure 3.12) and MH (Figure 3.13). Three different types of chemical transfection 
reagents with various ratios were investigated: Liposomal based (Lipofectamine P3000, 
Invitrogen), Polyethylenimine (PEI) and non-liposomal polymer (Viafect, Promega). Transfected 
cell viability was assessed 48 hours post-transfection with flow cytometry analysis, at which MH 
viability is around 65% to 80% and C2C12 viability around 90%. It is vital to investigate how the 
presence of transfection reagent and plasmid DNA can be used without affecting the cell viability 
to maximise transfection efficiency and minimise cell viability before proceed to transfection 
experiment.   
 The transfection efficiency was measured and the eGFP fluorescence in the cells (C2C12 
and MH) are analysed by fluorescence microscopy and flow cytometry. Our investigation 
focused on comparing three different types of transfection reagents (Lipofectamine p3000, PEI 
and Viafect) and was performed to determine the optimum ratio of the transfection reagent 
(μl):one ratio plasmid DNA (1000ng) which gave the best transfection. The eGFP fluorescence 
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intensity detected with flow cytometry in C2C12 and MH cell were represent as mean±standard 
error of mean (Figure 3.11).  In C2C12, Viafect have the highest percentage of eGFP fluorescence 
in live cell where the ratio 3:1 (86.63 ± 4.45 %), 4:1 (78.30 ± 10.00 %) and 5:1 (86.93 ± 5.30 %). 
While the Lipofectamine p3000 with a ratio 0.8:1 (41.63 ± 6.73 %), 1.2:1 (53.80 ± 3.06 %) and 
1.6:1 (61.73 ± 4.61 %). The PEI with a ratio 2:1 (12.37 ± 0.75 %), 3:1 (18.80 ± 1.76 %) and 4:1 
(26.20 ± 0.53 %). The percentage of eGFP fluorescence in positive live control samples untreated 
samples mock (1.48 ± 0.43 %), presense of plasmid only (1.56 ± 0.34 %), presence of 
Lipofectamine P3000 (1.91 ± 0.24 %), presence of PEI (15.6 ± 1.57 %) and Viafect (1.957 ± 0.07 %). 
Most of the control have very low percentage of eGFP fluorescence except PEI. The eGFP 
fluorescence imaging in C2C12 cell was capture by fluorescence microscope (Figure 3.12). The 
cell viability of C2C12 cells with plasmid transfection of three different types of transfection 
reagents: Viafect (~80%), PEI (~80%) and Lipofectamine p3000 (~70%) were examined. 
Meanwhile, the presence of transfection reagents only is considered with similar cell viability 
compared to plasmid transfection which suggests that plasmid transfection does not cause harm 
to C2C12 cell viability.  
 
In MH cell, Viafect have highest percentage of eGFP fluorescence in live cell where with 
a ratio 3:1 (35.23 ± 1.86 %), 4:1 (50.2 ± 2.81 %) and 5:1 (46.37 ± 1.56 %). While the Lipofectamine 
p3000 with a ratio 2:1 (19.70 ± 0.30 %), 3:1 (19.93 ± 0.83 %) and 4:1 (21.57 ± 1.33 %). The PEI 
with a ratio 2:1 (0.15 ± 0.03 %), 3:1 (1.94 ± 0.18 %) and 4:1 (2.32 ± 2.29%). The percentage of 
eGFP fluorescence in positive live control samples untreated samples mock (0.12 ± 0.03 %), 
presense of plasmid only (0.07 ± 0.39 %), presence of Lipofectamine P3000 (0.41 ± 0.13 %), 
presence of PEI (0.05 ± 0.46   %) and Viafect (0.16 ± 0.05 %). Most of the control have near to 0% 
of eGFP fluorescence. The eGFP fluorescence imaging in MH cell was capture by fluorescence 
microscope (Figure 3.13). The cell viability of MH cells with plasmid transfection of three 
different types of transfection reagents is ~90%, which is similar with transfection reagent only. 
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Figure 3.11 Comparative transfection efficiency with various transfection reagents 
(Lipofectamine p3000, PEI and Viafect) in C2C12 and MH cells. The C2C12 cell (top) and MH 
cell (bottom) cells was transfection with plasmid pCi-GFP via transfection reagents for 48 
hours. The flow cytometry analysis of transfection efficiency expressed as percentage of green 
fluorescent protein in positive live (Left) and cell viability (Right). The ratio of transfection 
reagent to plasmid used for transfection as indicate Lipofectamine p3000 (0.8:1, 1.2:1 & 
1.6:1), PEI (2:1, 3:1 & 4:1) and Viafect (3:1, 4:1 & 5:1) with one unit plasmid DNA in C2C12 
cells, while Lipofectamine p3000 (2:1, 3:1 & 4:1), PEI (2:1, 3:1 & 4:1) and Viafect (3:1, 4:1 & 
5:1) with one unit plasmid DNA in MH cells. Graph show the mean ± standard error of mean, 
3 technical repeats. Results will be analysed by using FlowJo V10 software and result were 
plotted by using Graph Pad Prism 7.  
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Figure 3.12 Fluorescence microscopy images with various transfection reagents in C2C12 
cell. The pCi-eGFP plasmid (1000ng/well of 6-well plate) was transfected into mouse muscle-
derived fibroblasts (MH) cell with standard transfection protocol by using three different 
transfection reagents: PEI (PEI, upper panel) PEI:pDNA (μl/ng) at a ratio of 2:1, 3:1 and 4:1, 
Viafect (Via, middle panel) Viafect:pDNA (μl/ng) at a ratio of 3:1, 4:1 and 5:1 and 
Lipofectamine p3000 (P3000, lower panel) lipofectamine p3000:pDNA at a ratio of 0.8:1, 1.2:1 
and 1.6:1 respectively. The cells were visualized by Zeiss Axio Observer D1 fluorescence 
microscope 48 hours after transfection. Scale bars 100μm 
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Figure 3.13 Fluorescence microscopy images with various transfection reagents in MH cell. 
The pCi-eGFP plasmid (1000ng/well of 6-well plate) was transfected into mouse muscle-
derived fibroblasts (MH) cell with standard transfection protocol by using three different 
tranfection reagents: PEI (PEI, upper panel) PEI:pDNA (μl/ng) at a ratio of 2:1, 3:1 and 4:1, 
Viafect (Via, middle panel) Viafect:pDNA (μl/ng) at a ratio of 3:1, 4:1 and 5:1 and 
Lipofectamine p3000 (P3000, lower panel) lipofectamine p3000:pDNA at a ratio of 2:1, 3:1 
and 4:1 respectively. The cells were visualized by Zeiss Axio Observer D1 fluorescence 
microscope 48 hours after transfection. Scale bars 100μm.      
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3.2.4 Bioinformatics analysis of mouse relaxin 1 and human relaxin 2 
 A comparison was done between the mouse relaxin 1 (mRln1) amino acids sequence 
(Uniprot, P47932) and human relaxin 2 (hRln2) amino acids sequence (Uniprot, P04090) was 
obtained through Uniprot. We are particular interest to mouse relaxin 1 isoform as the protein 
sequence is a homologous protein to human relaxin 2 isoform. Our result indicate that the full-
length (pre-pro relaxin) with 185 amino acids have 48.09% similarity in the amino acid sequence 
between mRln1 and hRln2, while the mature relaxin comparison between mRln1 and hRln2 for 
B-chain is 44.83% and A-chain is 37.5% respectively (Figure 3.14). We further compared the B-
C-A protein structure between mRln1 and hRln2 (Figure 3.15), where both of the protein have 
similar structure of relaxin B chain (B), connecting peptide (C) and relaxin A chain (A) to form a 
B-C-A protein structure. The only different is the present prohormone convertase 2 targeting 
site in hRln2 but not mRln1.       
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Full length relaxin (pre-pro-relaxin) 
Relaxin B-chain  
 
Relaxin A chain  
 
Details Similarity 
Full-length mRln1 versus full-length hRln2 48.09% 
mRln1 B-chain versus hRln2 B-chain 44.83% 
mRln1 A-chain versus hRln2 A-chain 37.5% 
 
Figure 3.14 Comparison amino acid sequence between mRln1 and hRln2. The full-length 
amino acid sequence mouse relaxin 1 (mRln1) (Uniprot, P47932) and human relaxin 2 (hRln2) 
(Uniprot, P04090) was obtained through Uniprot and amino acid sequence align was 
performed through online bioinformatics software Clustal Omega (EMBL).  The conserved 
residues involve relaxin binding to relaxin receptor are R, R and I in B-chain (Blue highlight), 
glycine residues that is vital for relaxin secondary structure (Green highlight) and the same 
group of amino acid between mRln1 and hRln2 (Red highlight and star). The amino acids 
similarity comparison between amino acids sequence of full-length mRln1 versus full length 
hRln2, mRln1 B-chain versus hRln2 B-chain and mRln1 A-chain versus hRln2 A-chain are shown 
in table.      
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 Signal 
peptide 
B-chain C-chain A-chain Disulfide bond 
between 
interchain 
Disulfide bond 
between 
intrachain 
mRln1 1-22  23-57 58-156 161-185 36-171 and  
48-185  
170-175 
hRln2 1-24 25-53 56-157 162-185 35-172 and  
47-185  
171-176 
 
Figure 3.15 Comparison protein structure between mRln 1 and hRln2. The amino acids 
sequence of mouse relaxin 1 (mRln1) (Uniprot, P47932) (A.) and human relaxin 2 (hRln2) 
(Uniprot, P04090) (B.) are obtained through Uniprot, both protein are makeup of 185 amino 
acids. The detailed structure of Relaxin and the length of the amino acid chains are recorded 
in the table. The relaxin protein structure consists of relaxin B-chain (B), connecting peptide 
(C) and relaxin A-chain (A) shown as B-C-A protein structure. The pre-pro mRln1 and pre-pro 
hRln2 details was illustrated where signal peptide (without highlight), followed by B-chain 
(Yellow highlight), pro-peptide (Purple highlight) and A-chain (Blue highlight). The mature 
relaxin was consist of B-chain and A-chain connecting with 3 disulfide bond: two form 
interchain between B-chain and A-chain (Green and Red highlight) and one intrachain form 
between A-chain (Purple highlight). The prohormone convertase targeting by furin 
(ubiquitous prohormone convertase) targeting site RKKR (Grey highlight) on both relaxin, 
while prohormone convertase 2 targeting site KR (Dark green highlight). The details position 
of the amino acids present with both mRln1 and hRln2 is shown in table. 
  
 
 
 
 
 
A 
B 
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3.3 DISCUSSION 
3.3.1 Plasmid construct design and characterisation 
 In this chapter we describe the design full length design of mouse relaxin 1 cDNAs in 
conventional or AAV–based plasmid vectors. All of the plasmids have been characterised and all 
functional elements are present within the plasmids. All plasmids have been analysed through 
various restriction digests. Restriction enzymes were used that focus on crucial elements such 
as promoter, codon optimised/non-codon optimised mouse relaxin 1 and inverted terminal 
repeat (ITR).  
3.3.2 Comparison between codon optimised and native mouse relaxin 1 
Codon optimization is a methods with bioinformatics software prediction aim for higher 
protein expression compare to the native gene nucleotide sequence. The high protein 
expression is related to the CAI value that is near 1.0, where the ideal CAI >0.8 value for better 
protein expression in the specific organism (mouse in our project). The Genscript online rare 
codon analysis suggested the CAI of CO mRln1 (1.0) have increased compared to native mRln1 
(0.71). Next, the GC content is increase for CO mRln1 (14.28%) compare to NCO mRln1, where 
the GC content is ideal within a range of 30% to 70%. The rare codon analysis CFD value indicate 
the CO mRln1 (0%) are reduced compare to native mRln1 (4%), where the lower percentage 
indicate the low percentage of rare codons can increase the translation efficiency. Finally, the 
native mRln1 and CO mRln1 does not have negative Cis-regulatory elements (CIS) elements 
which negatively regulate gene expression or negative repeat elements (direct or inverted 
repeats) can affect the gene synthesis or expression. Despite the fact that there are many studies 
indicating higher protein expression can be achieved with codon optimization, it is not a 
guarantee and has to be verified through experiment. 
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3.3.3 Assessment of GFP fluorescence and detection by flow cytometry analysis in mouse 
myogenic cell line (C2C12) and mouse myogenic fibroblast cell line (MH). 
 Commercial companies have developed a range of products to allow DNA transfection 
into specific cell types. Many studies have compared transfection efficiency in different specific 
type of cell lines to maximise transfection efficiency. One study found that in transfections of 
C2C2 cells where the GFP plasmid:transfection reagent Fugene HD (a lipid-based transfection 
reagent) had a ratio 3:10, there was around a 60% to 70% transfection efficiency with 10% of 
cell death (Balcı et al., 2009). Although more nucleic acid can contribute to the transgene 
expression, conversely the high level of transfection reagent or exogenous nucleic acid may 
contribute to toxicity and reduce cell viability (Masotti et al., 2009). Therefore, it is vital to 
optimise the transfection conditions to analyse which reagent and with optimum ratio to 
plasmid shows the highest transfection efficiency.  
In this study, we evaluated a range of commercially available non-viral transfection 
reagents in single layered adherent cell lines (C2C12 and MH) with the pCi-eGFP reporter 
plasmid. The assessment of GFP fluorescence and cell viability were compared with non-
transfected control cell line. Three different types of transfection reagents were used: 
Lipofectamine P3000 (cationic liposome), PEI (cationic polymer) and Viafect (cationic lipid 
mixture with neutral lipid L-dioleoyl phosphatidylethanolamine). We focused on the parameters 
of the ratio of transfection reagents to the same amount of plasmid DNA. The GFP fluorescence 
intensity was detected 48 post-transfection through flow cytometry.  
We show that the Viafect/plasmid DNA ratio of 3:1 and 5:1 lead to a high transfection 
efficiency with ~90% GFP positive C2C12 cells and ~ 50% MH cells that were transfected with a 
Viafect/plasmid DNA ratio of 4:1 were GFP positive. In both types of cells, no signs of increasing 
toxicity were observed in the conditions that caused the highest transfection efficiency.  It must 
be addressed that in C2C12, the ratio of the transfection reagent Lipofectamine P3000 to 
plasmid DNA (0.8:1, 1.2:1 or 1.6:1) used in the investigation differed from the recommendations 
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of the manufacturers, (2:1, 3:1 or 4:1). It is therefore possible that the use of the recommended 
plasmid DNA ratios might have increased the transfection efficiency. However, in the ratio of 
1.6:1 a slight reduction in cell viability was observed and further increasing the ratio might have 
negative toxic effects. The highest transfection efficiencies were obtained with the Viafect 
transfection reagent. The Viafect transfection reagent in MH cells showed a 2 to 2.5 fold higher 
efficiency compared to Lipofectamine P3000. From the three transfection reagents tested PEI 
showed at the highest ratio (4:1) the lowest transfection efficiency, only ~25 % of the C2C12 
cells and ~5% of the MH cells were GFP positive. For these reasons, it was decided to use the 
transfection reagent Viafect for all further experiments. 
Transfection efficiency can be affected by various factors such as cell types, cell density 
during transfection, cell toxicity and amount of nucleic acid. Cell density can affect transfection 
as when cell density is too high it can inhibit cell growth, in contrast too low of a cell density led 
to a low transfection efficiency. We carried out our transfection when the cell density was 
around 90% confluent, because a 90-95% cell confluency is normally associated with high 
transfection efficiency (Dably et al., 2004). One question that remained was whether cells 
present in the culture dishes are not the same confluence when the experiment was carried out. 
Another transfection method nucleofection also enable nucleic acids to be transferred into cells 
by using voltage and reagents should also be consider in the transfection efficiency investigation 
with GFP plasmid. One study of nucleofection by LONZA found that their protocol can achieve 
~80% transfection efficiency and ~70% cell viability (LONZA, 2013), which both are lower 
compared to our results with transfection reagent Viafect.    
The optimization transfection efficiency investigation is a valid method to examine with 
much more appropriate GFP plasmids. This is because the GFP plasmids that we are using is 
driven by CMV promoter which is not the same as the promoter (Spc512 and CBh) in our 
designed mRln1 expressing plasmid. We suggested the GFP should be driven by Spc512 or pTet 
On-eGFP for much closer transfection efficiency evaluation to plasmid express mRln1.    
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Our in vitro investigation with mRln1 expressing plasmid might offer certain degree of 
similarity compared to AAV viral vector expressing mRln1, as either the plasmid or AAV viral 
vector offer delivery method of mouse relaxin 1 into mammalian cell. Therefore, it is important 
to investigate on how the mRln1 plasmid express and translate in in vitro as a proof to express 
mRln1 protein and secreted before going to next stage in vivo investigation with AAV viral vector. 
 
3.2.4 Bioinformatics analysis of mouse relaxin 1 and human relaxin 2 analysis  
Both of the relaxin protein mRln1 are equivalent to hRln2 only consist of 48.09% similar 
in the amino acids sequence. In Figure 3.14, have shown that the conserved amino acids 
sequence R, R, I are present in both mRln1 and hRln2 which bind to relaxin family peptide 
receptor 1 (RXFP1) (Bathgate et al., 2003). The relaxin protein has glycine residues within B-
chain and A-chain play a role in secondary structure.  Despite the fact that both mouse relaxin 1 
and human relaxin 2 have similar protein structure consist of 185 amino acids, hRln2 have a 
prohormone convertase targeting site KR by prohormone convertase 2 but not present in mRln1. 
There are no information on which category types of prohormone convertase are targeting at 
specific cleavage targeting amino acid sequence (LS) in mRln1 (Figure 3.15A). Our next interest 
would be investigate the effect of mouse relaxin 1 on fibrosis. 
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CHAPTER 4 ANALYSIS mRln1 TRANSCRIPT LEVEL AND PROTEIN EXPRESSION in vitro  
4.1 Introduction  
Measuring gene expression plays an important role in biological sciences research. This 
can be achieved in two ways: either by quantifying how much mRNA is transcribed, by 
determining the level of expressed protein or both. In gene augmentation therapy, high 
translation efficiency allows reduction the amount of viral vectors needed to achieve the same 
level of transgene expression and minimizes the immunotoxicity to the host (Anguela and High, 
2019). In this chapter, we investigate the transfected mouse muscle-derived fibroblast cell line 
(MH) or mouse myogenic cell line (C2C12) with either conventional based plasmid (p) or adeno 
associated viral vector (AAV) based plasmid where single-stranded AAV (pssAAV) or self-
complementary AAV (pscAAV) with either muscle tissue-specific promoter (Spc512) or improved 
version of CMV promoter (CBh) with tetracycline inducible transcriptional activation system (Tet 
On) driven to express codon optimised mouse relaxin 1 (CO mRln1) or native mouse relaxin 1 
(NCO mRln1). Here are the lists of plasmids: pssAAV-Spc512-CO mRln1, pssAAV-Spc512-NCO 
mRln1, pscAAV-Spc512-CO mRln1, pscAAV-Spc512-NCO mRln1, pTet On-CO mRln1, pTet On-
NCO mRln1, pssAAV-Tet On-CO mRln1 and pssAAV-Tet On-NCO mRln1 that we are going to used 
investigate how these plasmid effect on mRln1 transcript level and protein expression with 
different plasmid constructs expressing mouse relaxin 1 in C2C12 and MH cell.  
In different organisms, there are variations between the codons that code for the same 
amino acids (Athey et al., 2017). The replacement of rare codons to higher frequency codon to 
code for the same amino acid also known as codon usage bias may contribute improvement to 
the translation efficiency of a protein – this process is codon optimization. The codon usage bias 
contribute to favourable translational selection to the relative tRNA abundances and aim to 
increase the translation efficiency and accuracy (Plotkin and Kudla, 2011). In contrast, some 
study have shown there are no or weak effect of codon bias to the gene expression (Kudla et al., 
2009). In this project, we designed the plasmid with codon optimised version of mRln1 (CO 
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mRln1) or native mRln1 (NCO mRln1) version and compared the efficiency of expression of both 
construct via mRNA and protein level.    
    Since the development of Polymerase chain reaction (PCR) in 1983, it has been a 
common molecular biology technique used to amplify specific DNA segment through a set of 
oligonucleotide primer match 5’ and 3’ end (Mullis et al., 1986). Reverse transcription 
Polymerase Chain Reaction (RT-PCR) is a variation PCR method that combines reverse 
transcription of cellular mRNA into complement DNA (cDNA) and subsequent PCR amplification 
(Lodish et al., 2007). RT-PCR is widely applied to investigate the level of specific amount of mRNA. 
The combination of quantitative PCR (qPCR) with RT-PCR known as RT-qPCR allow monitoring of 
transcription of cDNA construct with mRNA. In qPCR, the visualizing of PCR amplification process 
utilizes DNA binding dyes (such as Sybr green or Taqman) that bind to double stranded DNA emit 
fluorescence. The two steps RT-qPCR involve two steps where the reverse transcription was 
used on the first part experiment involving construction of cDNA followed by the second part 
experiment with PCR separately (Wong and Medrano, 2005). The RT-qPCR analysis was done 
based on quantitation cycle (Cq) value. The Cq values are inverse to the amount of DNA copy 
present in the samples, as the lower Cq number contain more amount of copy of DNA is present 
in the samples. In this chapter, we exploited two step RT-qPCR to assess the level of mRln1 
expression in C2C12 and MH cells transfected with mRln1 expression plasmids.   
The mRln1 protein can be detected with mRln1 targeting antibody within the cells 
(prepro- or propeptide form) or as secreted hormone (mature form) in medium of cultured cells 
in vitro or in the plasma of in vivo models. The secreted hormone contains a signal peptide 
sequence located at the N-terminus of the pre-pro peptide, which facilitates secretion. In 
parallel, incorporation of the epitope tag together with mRln1 could facilitate detection. Epitope 
tagging involves synthesizing the recombinant protein with an epitope tag to facilitate protein 
isolation, purification, tracking and detection.  The epitope tag is engineered on either the C- or 
N-terminus of recombinant proteins normally without affecting the bioactivity of the protein 
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(Brizzard., 2008). Human influenza A hemagglutinin (HA) tag is one of the common epitope tag 
reporter systems have been widely used; it consists of HA amino acids sequence 98 – 106 
(YPYDVPDYA) from the virus (Schembri et al., 2007). We have designed the plasmid with HA tag 
located on the C-terminus of mRln1 before the stop codon and investigated the mRln1 protein 
with HA tag detection with western blot.   
Western blotting is a common technique used to separate and detect specific proteins. 
This technique involves: i) separation of the protein based on the size through sodium 
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE), ii) transfer of all the separated 
proteins from the gel to a membrane, iii) visualization of the specific protein via primary and 
secondary antibodies on the membrane (Lodish 2007 p. 98 -99). In this chapter, we particularly 
focus on the mRln1 protein detection through western blot using antibodies targeting HA tag or 
mRln1 protein. 
In this chapter, we are particularly interested in investigation two objective where the 
first is to detect the level of mRln1 expression after the cell transfected with various mRln1 
expressing plasmids with PCR. Second, we focus on using the highest mRln1 expressing plasmids 
to study on how the mRln1 protein is express after transfection with mRln1 expressing plasmids. 
We utilize western blot with either human relaxin 2 antibody (react to mouse relaxin 1, mouse 
relaxin 1 and human relaxin 2) to detect mRln1 or antibody target HA tag to detect mRln1 with 
HA tag.  
 
 
          
 
 
 
110 
 
4.2 RESULTS 
4.2.1 Gradient PCR optimization to analysis of mRln1 expression 
 Gradient PCR was set up to look for optimum annealing temperature on two different 
sets of primers, one targeting codon optimized mRln1 (CO mRln1) and the other non-codon 
optimized mRln1 (NCO mRln1). The C2C12 cells were transfected with the same amount (1000 
ng) plasmid DNA pTet On-CO mRln1 or pTet On-NCO mRln1 plasmid driven by Tet On system 
(Tet On) with 40 ng/ml tetracycline present for 24 hours prior to total RNA extraction, followed 
by cDNA construction. The cDNA construct was used as a template for gradient PCR over a range 
of annealing temperature (54oC to 61oC) with CO mRln1 primer for samples transfected with 
pTet On-CO mRln1 or NCO primer for samples transfected with pTet On-NCO mRln1. In Figure 
4.1A, the illustration show the primers targeting CO mRln1 amplicon size are 98 bp or NCO 
mRln1 amplicon size are 139 bp. The result indicate amplicon (Figure 4.1B) size produced with 
CO mRln1 primer are around 100 bp with the optimal amplification at around 55oC to 56oC, while 
the amplicon (Figure 4.1C) size produce with NCO mRln1 primer are around 139bp with highest 
amount at around 55oC to 57oC. The gel image indicates that the gradient PCR is efficient and 
has no non-specific binding to create a secondary off-target PCR product. 
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Figure 4.1 Gel Image indicate a gradient PCR. An illustration (A.) of the primer set to target 
CO mRln1 (Red bar) and NCO mRln1 (Blue bar) and the amplicons are highlighted in purple 
with Forward and Reverse primer. 600 ng of total RNA was extracted from C2C12 cells 
transfected with either pTet On-CO mRln1 or pTet On-NCO mRln1 plasmid for 24 hours 
followed by cDNA construction. The constructed cDNA was used as a template for PCR, which 
30 PCR cycles was performed with a range of gradient annealing temperature (54oC to 61oC) 
with either CO mRln1 (B.) or NCO mRln1 (C.) specific primers. The analysis of the amplicon 
was performed with separation of products on 3.5% (w/v) agarose TAE gel electrophoresed 
for 65V for 60 minutes and 70V for 40 minutes. The Ladder is a 25bp ladder (500bp to 25bp) 
and the negative control (-ve) was a control without cDNA template.  
 
 
 
 
 
A 
B 
C 
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4.2.2 Detection of mRln1 transcripts in C2C12 or MH cell line by RT-qPCR analysis 
 We investigated the expression level of mRln1 mRNA transcripts in C2C12 or MH cells 
transfected with various plasmids (pssAAV-Spc512-CO mRln1, pssAAV-Spc512-NCO mRln1, 
pscAAV-Spc512-CO mRln1, pscAAV-Spc512-NCO mRln1, pTet On-CO mRln1, pTet On-NCO 
mRln1). Subsequently, the total RNA was extracted, cDNA was synthesized and reverse 
transcription (RT)-quantitative (q) PCRs were performed. The mRNA level of mRln1 was analysed 
in RNA samples from C2C12 cells transfected with same amount (1000 ng of plasmid DNA) of six 
different plasmid construct DNA for 24 hours prior to total RNA extraction. The highest mRln1 
expression was measured by normalisation with housekeeping gene 60S acidic ribosomal 
protein (Rplp0) in C2C12 cells transfected with the pTet On-NCO mRln1 plasmid with tetracycline 
present (Figure 3.7A). Figure 4.2B shows specific melting curve with CO mRln1 primer, NCO 
mRln1 primer and Rplp0 primer indicate only one amplicon is produced.    
Some of the RT-qPCR amplicon from the same experiment shown in Figure 4.2 was run 
on agarose gel electrophoresis for further identification on the amplicon size. The gel image 
(Figure 4.3) indicate the specific band size of amplicon ~100bp with CO mRln1 and ~150bp NCO 
mRln1 targeting primer. There are certain basal level of mRln1 is expression in the C2C12 cells. 
Both of the transfected samples with either CO mRln1 or NCO mRln1 plasmids have shown 
higher mRln1 expression compare to the samples without transfection.       
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Figure 4.2 Comparison between the mRln1 mRNA expressions with different plasmid 
construct. The C2C12 cells are transfected with CO mRln1 or NCO mRln1 plasmid with 
tetracycline inducible expression system (Tet on) for 24 hours. The relative quantified mRNA 
expression of CO mRln1 or NCO mRln1 genes was compared to the level of Rplp0 
housekeeping gene shown in (A.). The melting curve of RT-qPCR of three different set of 
primer with specific melting temperature shown in (B.).   
 
B 
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Figure 4.3 Gel Image of RT-qPCR amplicon targeting mRln1. The RT-qPCR amplicon targeting 
CO mRln1 (A.) and NCO mRln1 (B.) from Figure 4.2 were used as a samples to run gel 
electrophoresis. The analysis of the amplicon was performed with 3.5% (w/v) agarose TAE gel 
for 65V for 60 minutes and 70V for 40 minutes. The samples that are untransfected (Mock), 
treated with Viafect (V), treated with both Viafect and 40ng/ml Tetracycline (VT), transfected 
samples with either CO mRln1 (A.) or NCO mRln1 plasmid (B.) (Transfected) and 25bp ladder 
(500bp to 25bp).  
 
 
 
 
 
 
 
 
 
 
B 
A 
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4.2.3 Optimization of western blot analysis for mRln1 protein detection  
 The optimization of western blotting is required to obtain optimal results for the analysis. 
We explored how the SDS-PAGE transferred onto the 2 μm nitrocellulose membrane with 
different transfer condition, followed by the Ponceau S stain to detect the total protein present 
on the membrane. This is to make sure all the protein on SDS-PAGE gel have successful transfer 
onto the membrane before proceeding to next stage. Next, we optimized the blocking 
conditions with various blocking buffers to reduce the non-specific signal that might interfere 
with the primary and secondary antibody stain. The 3% BSA 0.1% PBS Triton X100 is the optimal 
blocking condition buffer, as this condition can block most of the non-specific binding. 
 
Figure 4.4 Ponceau S staining for transferring optimization. A Ponceau S stain 0.1% (w/v) in 
5% acetic acid was apply to investigate on the protein after transferring onto 2μm 
nitrocellulose membrane. The staining of membrane was performed for 1 to 2 minutes 
followed by four round of destaining was with water until the background is clear. The protein 
samples were collected from supernatant of C2C12 cell line through methanol chloroform 
protein precipitation. A range of protein with different amount protein (40μg, 80μg and 
120μg) together with the Novex Sharp Pre-stained 3.5kDa – 260kDa protein standard 
(Thermofisher) was run on 10% Bis-Tris gel onto 2μm nitrocellulose membrane.  
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Figure 4.5 Western blot blocking buffer optimization. The protein samples was collected 
from C2C12 cells transfected with pTet On-NCO mRln1 plasmid with tetracycline present for 
24 hours through methanol chloroform protein precipitation. The protein samples are run on 
10% Bis-Tris gel and transferred to 0.2 µM nitrocellulose membrane: Novex Sharp Pre-stained 
3.5kDa – 260kDa protein standard (Thermofisher, LC5800)(L), 0.5μl E.coli cell lysate (Abcam 
ab5395) with recombinant protein express HA tag (+ve), 50μg cell lysate samples (CL) and 
50μg protein precipitation samples from culture media (S) were loaded onto each well. The 
membrane was cut into half on the size of 60kDa protein ladder. The blot was probed 
separately with primary antibody mouse anti-HA tag (1:1000) on the <60kDa membrane 
detected with secondary antibody IRDye® 800CW Goat anti-mouse IgG (LI-COR P/N 925-
32210) shown in green and mouse anti-vinculin (1:10000) on the >60kDa membrane followed 
by detection with secondary antibody IRDye 680RD Goat anti-Mouse IgG (LI-COR P/N 925-
68070) shown in red.   
 
   
 
 
 
 
 
 
117 
 
4.2.4 Sustained mRln1 transgene expression studies: Comparison the levels of mRln1 protein 
expression with transfected pTet On-NCO mRln1 cultures of C2C12 and MH cell line 
 To investigate whether the expressed mRNA of the mRln1 plasmids is translated into a 
functional protein that is secreted into the culture medium of C2C12 and MH cells we measured 
the level of mRln1 protein in the culture medium of transfected cells by western blot. For this 
study, we directly compared protein expression from codon optimised mRln1 (CO mRln1) or 
non-codon optimised mRln1 (NCO mRln1) constructs relative to the mock (cell without any 
treatment).  
The western blot analysis (Figure 4.6) was to detect mRln1 protein in C2C12 cells 
transfected with either plasmids pssAAV-Tet On-CO mRln1/HA or pssAAV-Tet On-NCO 
mRln1/HA for 24 hours with the presence of tetracycline. The result suggest that the HA tag 
antibodies were able to detect the positive control E.coli whole cell lysate with recombinant 
protein with HA tag (~49kDa) but not mRln1 with HA tag. We then try to use human relaxin 2 
targeting antibody to detect mRln1 with transfected with either plasmids pTet On-CO mRln1 or 
pTet On-NCO mRln1 in C2C12 and MH cells for 24 hours with western blot. The result in Figure 
4.7 shown that mRln1 antibody was able to detect mRln1 in both types of cells suggest the 
prepro-mRln1 (~21kDa) was detected in the cell lysate protein samples. The protein 
quantification analysis indicate the pTet On-NCO mRln1 was able to upregulate the protein 
expression of mRln1 to approximately  1.2 folds compared to the mock in both C2C12 and MH 
cells. However, the mature mRln1 was not detected in the supernatant of the C2C12 cells and 
the pTet On-CO mRln1 reduced the mRln1 expression in both types of the cells. 
Another western blot investigation was focus on the detection mRln1 in C2C12 and MH 
cells with human relaxin 2 targeting antibody. The cells were transfected with the either 
plasmids pTet On-CO mRln1 or pTet On-NCO mRln1 for 24 hours. In Figure 4.8, indicates all the 
protein samples from cell lysate in both types of the cells can detect for the present prepro-
mRln1. Western blot quantification of mRln1 shown that the cells transfected with pTet On-NCO 
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mRln1 in C2C12 was able to increase the mRln1 protein expression to approximately 1.5 folds 
compare to the mock. In contrast, the mRln1 was not able to increase the mRln1 protein 
expression in MH cells with either of the plasmids.            
 
Figure 4.6 Western blot to detect mRln1 with HA tag antibody. The C2C12 cells transfected 
with either codon optimised mouse relaxin (CO mRln1) or non-codon optimised mouse relaxin 
(NCO mRln1) with HA tag plasmid driven by tetracycline inducible promoter with tetracycline 
present for 24 hours. 40 μg of protein samples that are collected from cell lysate (CL) and 
protein precipitation from supernatant (S) are resolved by 10% Bis-Tris gel and transferred to 
0.2 µM nitrocellulose membrane. The positive control E.coli cell lysate with recombinant 
protein with HA tag (+ve, white arrow) was used and the protein ladder 3.5kDa to 260kDa (L). 
The red fluorescence represent secondary antibody targeting primary mouse vinculin 
antibody (117kDa) as housekeeping protein, while the green fluorescence represent 
secondary antibody targeting primary HA tag antibody.    
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Figure 4.7 Western blot to detect mRln1 with mRln1 targeting antibody. The C2C12 cells 
were transfected with pTet On-CO mRln1 or pTet On-NCO mRln1; while the MH cells were 
transfected with the pssAAV-Tet On-CO mRln1 or pssAAV-Tet On-NCO mRln1. The plasmid 
either codon optimised mouse relaxin 1 (CO) or non-codon optimised mouse relaxin 1 (NCO) 
plasmid driven by tetracycline inducible promoter (Tet On) with tetracycline present for 24 
hours. The pre-pro-mRln1 protein size is around 21kDa. Western blot result (A.) indicate 40μg 
of protein samples from MH cells cell lysate (CL) and C2C12 cells cell lysate, protein samples 
are precipitation from supernatant (S) are resolved by 10% Bis-Tris gel and transferred to 0.2 
µM nitrocellulose membrane. The positive control mouse prostate cell lysate samples (+ve) 
was used and the protein ladder 3.5kDa to 260kDa (L). The red fluorescence represent 
secondary antibody targeting primary mouse α-tubulin antibody (50kDa) as housekeeping 
protein, while the green fluorescence represent secondary antibody targeting primary human 
relaxin 2 antibody. The western blot quantification (B.) shown the level of mRln1 expression 
comparison between different plasmid construct transfected into MH or C2C12 cells. n = 1  
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Figure 4.8 Western blot to detect mRln1 in C2C12 and MH cells. The C2C12 and MH cells 
transfected with either codon optimised mouse relaxin (CO mRln1) or non-codon optimised 
mouse relaxin (NCO mRln1) plasmid driven by tetracycline inducible promoter with 
tetracycline present for 24 hours. The pre-pro-mRln1 protein size is around 21kDa Western 
blot result (A.) indicate 20μg of protein samples from MH cells cell lysate (CL) and 20μg of 
protein samples from C2C12 cells cell lysate are resolved by 10% Bis-Tris gel and transferred 
to 0.2 µM nitrocellulose membrane. The positive control mouse prostate cell lysate samples 
(+ve) was used and the protein ladder 3.5kDa to 260kDa. The mRln1 transcript level of sample 
transfected with either CO mRln1 or NCO mRln1 plasmid were compared to the mock (M). 
The red fluorescence represent secondary antibody targeting primary mouse α-tubulin 
antibody (50kDa) as housekeeping protein, while the green fluorescence represent secondary 
antibody targeting primary human relaxin 2 antibody.  The western blot quantification (B.) 
shown the level of mRln1 expression comparison between different plasmid construct 
transfected into MH or C2C12 cells. n = 1 or 2.  
B 
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4.3 DISCUSSION  
4.3.1 Gradient PCR and RT-qPCR to detect CO mRln1 & NCO mRln1 
 In this chapter we have investigated the expression efficiency of vectors that express 
mouse Relaxin 1 (mRln1) in C2C12 and MH cells. The plasmid constructs contained either codon 
optimised (CO) mRln1 or non-codon optimised (NCO) mRln1 to increase the expression of relaxin. 
To detect mRln1 mRNA expression RT-qPCR was carried out. Gradient RT-PCR was used to test 
whether the specific amplicon is formed from the designed primer targeting CO mRln1 or NCO 
mRln1. The gradient RT-PCR result (Figure 4.1) indicated that the amplicon was successfully 
formed with the cDNA template used. The gradient RT-PCR indicated that the optimum 
annealing temperature for the CO mRln1 primer is ~55oC to 56oC and for NCO mRln1 primer is 
~55oC to 57oC. In this way it was verified that the specific size of PCR amplicon can be obtained 
with the designed primer.  
For the RT-qPCR was set on around 60oC optimum annealing temperature as indicated 
by the IDT OligoAnalyzer analysis software. RT-qPCR result shown in Figure 4.2 suggested that 
the cells were transfected with mRln1 plasmids allow mRln1 expression could be detected. 
However, in some of the untransfected samples (mock) or control samples with treatment with 
tetracycline or treatment with both Viafect and tetracycline have some amplicon form, while 
some is not. The RT-qPCR result indicate the Cq value those mock and control samples are also 
inconsistent with most appear near to end of the PCR cycles. This might be due to the low 
amount of the native mouse relaxin 1 expression in in vitro. In Figure 4.2B, the melting curve 
shown indicates that only one single melting curve is present, which suggests that only one 
specific amplicon is amplified. All of the NCO mRln1 plasmids exhibit higher levels of mRln1 
expression compared to the CO mRln1 plasmids. The highest level of mRln1 expression was 
detected in C2C12 cells that were transfected with a pscAAV-Spc512-NCO mRln1 plasmids (24 
hours after the transfection). It is not clear why the mRln1 expression in cells transfected with 
the pscAAV-Spc512-NCO mRln1 construct is higher than in cells transfected with the pssAAV-
Spc512-NCO mRln1 construct. Despite the fact that codon optimised mRln1 was designed 
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through the VectorBuilder codon optimization online software, the expression analysis of the 
mRln1 suggests that CO mRln1 is less effective compared to the native mRln1. For further 
research, several codon optimised versions of the mRln1 shall be designed and compared to the 
native mRln1. No statistics could be carried out as the n number was 1. In the future, experiment 
repeats will be enable statistical analysis.   
The second highest mRln1 expression was detected in C2C12 cells transfected with the 
pTet On-NCO mRln1 plasmid and in the presence of tetracycline. In the absence of tetracycline, 
both the plasmids (pTet On-CO mRln1 or pTet On-NCO mRln1) exhibit a low level expression of 
mRln1 around a third level of expression compared to when tetracycline is present. Many 
studies have explored the leaky expression of the tetracycline inducible promoter system 
(Costello et al., 2019). In this project, we employed an improved version of the Tet On system 
where the hybrid TetR- Kruppel associated box (KRAB) system is used to reduce the basal 
transgene expression compare to Tet On (Szule et al., 2006). Our findings indicate in the absence 
of tetracycline, CO mRln1 and NCO mRln1 expressed mRln1. One possible investigation that 
could be carried out is to use a pTet On-eGFP plasmid to evaluate the efficiency and leakage of 
the Tet On system. Additionally, a dose dependent investigation with tetracycline is required to 
establish the optimum dosage to activate the Tet On system for mRln1 expression without 
causing toxicity to both C2C12 and MH cells.       
To further analyse the RT-qPCR amplicon from Figure 4.2, the PCR product was run on 
agarose gel electrophoresis. The gel image (Figure 4.3) shows that cells transfected either pTet 
On-CO mRln1 or pTet On-NCO mRln1 express mRln1 in the presence of tetracycline, compared 
to when tetracycline is absent. We used the untreated or transfected mock samples as a 
negative control. The results from the RT-qPCR indicate that the amplicon produced with C2C12 
samples with the presence of Viafect or treated both with Viafect and tetracycline have a high 
Cq value near the end of the total PCR cycles. The high Cq value suggest that the Viafect, 
tetracycline or both might contribute to the activation of low level of native genomic mRln1 
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expression. As low levels of mRln1 expression in the negative controls, the RT-qPCR 
quantification (Figure 4.2A) was analysed by normalising the expression of mRln1 to the 
housekeeping gene (Rplp0).   
Another issue with the performed RT-qPCR is the CO mRln1 primer set is shown to target 
the native mRln1 expression. Although the CO mRln1 forward primer (5’-
GAAGACCCTGCACGACAA-3’) is similar to the GAAAACTCTCCATGATAA at the position of 387 to 
404 with 13/18 nucleotide with native mRln1 similarity and CO mRln1 reverse primer (5’-
TCTCCCTCTTCTTCCTGCT-3’) to the TCACGGAAAAAGAGGGAGT at the position 466 to 484 with 
4/19 similarity with native mRln1.  Despite the low similarity on the CO mRln1 reverse primer, 
there are some amplicons produced at the same size by PCR amplification caused by cross 
contamination. The CO mRln1 primer should be redesigned and tested before the RT-qPCR. 
However, due to the high similarity between the nucleotide sequences of codon optimised 
mRln1 and non-codon optimised mRln1, it would be challenging to design primers only targeting 
the codon optimised mRln1 without amplifying the non-codon optimised mRln1. A possible 
method to specifically detect CO mRln1 expression is with a designed Taqman probe. Unlike Sybr 
Green, a non-specific double stranded DNA binding dye to emitted fluorescence, Taqman probes 
provide a specific fluorescent detection between the hybridization of probe and target unique 
nucleotide sequence (Arikawa et al., 2008). On the other hand, the RNA purity was measured 
using a spectrophotometer, where OD260/280 value for pure RNA is 2.1 and around 1.8 to 2.0 was 
considered acceptable and used to construct cDNA but there are no information regarding RNA 
integrity. The RNA integrity should be determined as a better measure of RNA degradation 
before any downstream application (Taylor et al., 2010).  
4.3.2 Western blot optimization  
The next focus was the detection of relaxin protein through western blot. Firstly, the 
western blot protocol was optimized. The transfer efficiency of proteins transfer from SDS-PAGE 
gel on the nitrocellulose membrane were visualising by Ponceau S stain. Although the transfer 
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process was successful, transfer could be improved to avoid air bubbles. The air bubbles was 
reduce on the following transfer process as more precaution has been taking to remove air 
bubbles between SDS-PAGE gel and nitrocellulose membrane. The optimum transfer condition 
was 30V for 90 minutes at 4oC, the result (Figure 4.4) indicates that protein sample were 
successfully transferred onto the nitrocellulose membrane. This suggests that to transfer small 
size proteins (<40kDa) lower voltages and low temperatures are preferable.   
Following this, the blocking conditions were optimized to reduce non-specific antibody 
binding. Two of the routinely used blocking buffers contain either 3% (w/v) or 5% (w/v) bovine 
serum albumin (BSA) or 5% non-fat dried milk in phosphate buffer saline (PBS). Besides that, 
there are small amounts (e.g. 0.05% (v/v) to 0.1% (v/v)) of surfactant (e.g. Tween 20 or Triton 
X100) present in the blocking buffer and in the washing buffer to further reduce background 
signalling (Alegria et al., 2009). The surfactants either prevent the antibody binding to the non-
specific proteins and/or block the hydrophobic sites on the membrane (Alegria, p. 573 - 599). 
The optimisation of the western blot blocking buffer (Figure 4.5) shows that the blocking buffer 
3% (w/v) BSA with 0.1% (v/v) Triton X100 in PBS can reduce most of the background signalling 
after primary and secondary antibody staining compared with 5% non-fat milk 0.2% Tween 20 
PBS and 3% non-fat milk 0.2% Tween 20 PBS. Although this might not be the best optimization 
for blocking buffer as we change both parameter together, however, are able to shown reduced 
background signal with one of the blocking buffer.  
 
4.3.3 Western blot detect mRln1 protein expression evaluation 
  The western blot analysis represent the protein samples (either cell lysate or 
supernatant) collected from C2C12 cells transfected with plasmids (either pTet On-CO 
mRln1/HA or pTet On-NCO mRln1/HA) for 24 hours with tetracycline present. The result in 
Figure 4.6, suggests that the HA tag antibodies only bind to the positive control E.coli whole cells 
lysate with recombinant protein with HA tag (~49kDa) but not cell lysate or proteins samples 
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with mRln1 protein with HA tag. This positive control confirms that the HA tag antibody was able 
to detect HA tagged proteins. One explanation might be that the HA tag nucleotide sequence 
might not be present or the nucleotide sequence is not correct within the designed plasmid and 
therefore further investigations into this are needed. To assess whether the HA tag nucleotide 
sequence is correct, a PCR targeting the HA tag nucleotide sequence should be carried out and 
further identified with sequencing. The epitope tagging normally designed to the N- or C 
terminus of the protein of interest might interfere with protein function, trafficking processing 
or folding (Zordan et al., 2015). Besides, the amount of protein samples loaded on the gel might 
be insufficient to be detectable, and this shall be repeated with higher amounts of protein. We 
should include an investigation with a gradient of protein concentration sensitivity to detect 
mRln1 protein (pre-pro or mature form).  
The next western blot analysis focuses on the detection of mRln1 in cells transfected 
with the following plasmids: either pTet On-CO mRln1 or pTet On-NCO mRln1 in C2C12; pssAAV-
Tet On-CO mRln1 or pssAAV-Tet On-NCO mRln1 in MH cells. The western blot result shown in 
Figure 4.7A indicates that the pre-pro mouse relaxin 1 (mRln1) with size ~21kDa can be detected 
with the human relaxin 2 targeting antibody. All of the samples that are either transfected with 
plasmids or mock cell lysate samples show mRln1 protein expression in C2C12 and MH cells. 
However, there is no detection of any form of mRln1 protein in the supernatant samples from 
C2C12 cells and MH cells (data not shown). Western blot quantification (Figure 4.7B) shows that 
the mRln1 protein is expressed more in both C2C12 and MH cells transfected with the pTet On-
NCO mRln1 compared to the pTet On-CO mRln1 with the presence of tetracycline. Transfection 
with The pTet On- CO mRln1 leads to ~20% more mRln1 protein being expressed compare to 
the mock. Both of the RT-qPCR result (Figure 4.2) and western analysis (Figure 4.7B) shows that 
the NCO mRln1 construct appears to express more mRln1 compared to CO mRln1 construct. In 
contrast, the CO mRln1 construct had around 30% lower expression level of mRln1 compared to 
the mock. The pTet On-CO mRln1 has a reduction for mRln1 expression compare to the mock in 
both C2C12 and MH cells.  
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  A similar western blot (Figure 4.8A) was performed with protein samples collected from 
another batch of C2C12 cells transfected with either pTet On-CO mRln1 or pTet On-NCO mRln1, 
and of MH cells transfected with either pssAAV-Tet On-CO mRln1 or pssAAV-Tet On-NCO mRln1 
for 24 hours prior to protein sample collection for western blot. The western blot quantification 
analysis (Figure 4.8B) shows both of the plasmids pTet On-CO mRln1 (~20%) and pTet-NCO 
mRln1 (~40%) were able to increase the level of mRln1 expression in C2C12 cells compared to 
the mock. On the other hand, both of the plasmids (pssAAV-Tet On-CO mRln1 or pssAAV-Tet On-
NCO mRln1) did not show any difference in the mRln1 expression compared to mock. Although 
similar transfection conditions with the plasmids (pTet On-CO mRln1) were investigated twice, 
the western blot results indicated that the level of mRln1 expression was not consistent. The 
second western blot result shows that the CO mRln1 construct was able to upregulate mRln1 
expression in C2C12, while the first western blot shows a reduction of mRln1 compared to mock; 
similar experiment shall be conducted for more detailed information. Plasmids pssAAV-Tet On-
CO mRln1 and pssAAV-Tet On-NCO mRln1 did not shown any effect on the mRln1 expression in 
the MH cells on the second western blot. No statistics could be carried out as the n number was 
1 or 2. In the future, more experiment repeats will enable statistical analysis.  
The rat prostate samples harvest from rat prostate contains rat pre-pro Rln1 (~21kDa) 
and rat mature Rln1 (~6.5kDa), and rat pro-Rln1 in vas deferens are detected through western 
blot (Cardoso et al., 2002). We used mouse prostate protein samples as a positive control and 
only managed to detect pre-pro mouse Rln1 form but not the pro mouse Rln1 (~16-17kDa) or 
mature mouse Rln1 (~6.5kDa) with human relaxin 2 targeting antibody raised to detect residue 
1 - 100 amino acid of human and rat relaxin 1. Although the human relaxin 2 antibody that we 
used was claimed can detect mouse relaxin 1 (mRln1), rat relaxin 1 and human relaxin 2; but we 
were not able to detect mRln1 with this antibody. It is suspected the antibody was unable to 
target the mouse relaxin 1 due to differences in the amino acid sequence. There is only 48.09% 
amino acids sequence similarity between the mouse relaxin 1 similarity and the human relaxin 
2 (Figure 3.14), this might be the reason that the human relaxin 2 targeting antibody that we 
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used in our investigation might not able to target the mature mouse relaxin 1. Another 
explanation might be due to low amount of protein loaded in western blot, as Cardoso et al., 
2002 have shown that 100ug of rat prostate was loaded in western blots. We should repeat our 
investigation with higher concentrations protein samples (for example 100μg).    
In Figure 4.6, in all samples show vinculin (cell surface protein responsible for 
cytoskeleton and adhesion) (Peng et al., 2011) was detected in all the supernatant samples, 
which suggests cell debris might be present in the supernatant. An additional step such as 
centrifugation, filtering with a 0.22μm filter (Lobb et al., 2015) or with protein size exclusion spin 
filter column (Sartorius Vivaspin turbo, 2019) could remove specific size of protein and applied 
to remove apoptotic bodies or cell debris and increase the concentration of protein samples 
from supernatant before western blot. Further investigation could be carried out with 
recombinant mature mRln1 protein as a positive control for western blot to check whether the 
antibody can detect the mature mRln1. Additionally, a gradient time course of expression could 
be investigated as the short life spans of the relaxin 1 protein of less than 4 minutes (Jung et al., 
2017) and recombinant human relaxin 2 of less than 10 minutes (Kanai et al., 2019) have been 
reported.  
It is vital to show that the expression of transgenic mouse relaxin 1 (mRln1) hormone 
can be secreted from myogenic cell line or fibroblasts cell line. Here are few suggestions 
regarding the detection of secreted mRln1 in vitro, as the RT-qPCR can detect the mRln1 mRNA 
expression indicates the successful transfection of plasmids with mRln1 mRNA upregulation in 
the C2C12 and MH cell line. The western blot shall be carried out with recombinant mRln1 
protein as a positive control with mRln1 specific targeting antibody to make sure the antibody 
that we are using was able to target mature mRln1 protein. If the antibody that we used in our 
investigation was not able to detect mature mRln1, we should try to get a mouse relaxin 1 
targeting antibody. Apart from that, Cardoso et al., 2010 have shown that mature rat relaxin 1 
(~6.5kDa) was able to detect in 100μg of rat prostate samples, which suggest the amount of 
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supernatant samples (maximum 40μg) that we used is lower (100μg) compared to Cardoso 
(Cardoso, et al., 2010). Besides, a more sensitive ELISA method can be applied to detect a low 
amount of mRln1 protein. Finally, a time course detection of mRln1 mRNA or secreted mRln1 
after transfection with mRln1 express plasmids shall be investigated, as the mRln1 hormone 
have a short half-life less than 10 minutes. This might provide an idea on when the protein will 
be secreted from the cell.        
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CHAPTER 5 STUDIES DOWNSTREAM EFFECT OF RELAXIN AND in in vitro WOUND SCRATCH 
ASSAY  
5.1 INTRODUCTION 
Activated fibroblasts play a vital role in the wound healing process through the 
production, deposition and reconstruction of the extracellular matrix (ECM) (Kendell and 
Feghali-Bostwick, 2014). During the wound healing process, fibroblasts migrate to the injured 
site and become activated or parenchymal cells on the injured site undergo epithelial or 
endothelial mesenchyme transition into myofibroblast for ECM component synthesis (Quaggin 
and Kapus, 2011). In the normal wound healing process, fibroblast activity is reduced to basal 
level when the wound is healed, however this process is not regulated in some events such as 
chronic inflammation or fibrosis (Thomas, 2011). In fibrosis, the excessive number of fibroblast 
and ECM components have caused the hardening and replacement of the parenchyma cells 
which affect their normal function. In DMD, muscle regeneration does not keep up the pace with 
the muscle degradation as dystrophic muscle is more susceptible to damage cause by motion 
and are surrounded with fibrosis and inflammation (Verhaart and Aastsma-Rus, 2019). In this 
chapter, we focus on utilising wound scratch assays to observe how the presence of mRln1 
affects the migration rate of mouse muscle-derived fibroblast (MH cells).  
In vitro scratch assays utilise a direct, simple and inexpensive protocol involving 
observation of cell migration in response to a scratch wound induced in a confluent monolayer 
of cells and subsequently, cells will start to migrate and fill up the “scratch” gap (Liang et al., 
2007). The type of cell used in this experiment is either sheets of cells (such as endothelial and 
epithelial cells) or loosely connected populations (such as fibroblasts cells). Cell migration rate 
is captured with microscopy images over a specific period of time (for example microscopy 
imaging after wound scratch, 24 hours and 48 hours post wound scratch) throughout the 
experiment. The wound scratch assay investigates how different types of treatments (such as 
drug treatment, phosphorodiamidate morpholino oligomer or plasmid transfection) affect cell 
migration rates. The limitations of this technique are that large amount of cells are required and 
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the experiment has a long duration (~5 days in total). In contrast, the advantage of the wound 
scratch assay are that it is easy to set-up and does not require additional expensive equipment 
(equipment remains the same as standard tissue culture work).  
Transforming growth factor – β1 (TGF-β) is a multifunctional cytokine involved in 
processes such as growth, proliferation, differentiation, apoptosis and wound healing 
(Massagué, 2012). In skeletal muscle and other type tissues fibrosis (liver, kidney and lung), TGF-
β is the primary pro-fibrotic signal (Ceco and McNally, 2013). TGF-β1 will bind to the TGF-β 
receptor II and activate the SMAD2 and SMAD3 signalling pathway and lead to the 
transcriptional activation of downstream pro-fibrotic genes such as collagen I (Hu et al., 2018). 
Li and colleagues have shown that exogenous TGF-β1 treatment in C2C12 cell led to increase in 
TGF-β secretion act an autocrine manner, where it contributes to reduce expression of myogenic 
proteins (Li, et al., 2004). Besides, TGF-β is also the key regulator for fibroblast activation to 
become myofibroblasts, the main cell type that synthesises ECM components during wound 
healing and fibrosis (Akhmetshina et al., 2012). In contrast, interferon-γ (IFN-γ) inhibits TGF-β 
signalling, collagen I expression (Kähäri et al., 1990) and reduces the activation and migration of 
fibroblasts (Bansel et al., 2012). Therefore, we investigated the effect of TGF-β1, IFN-γ, mRln1 
gene addition on the migration rate of MH cells with the wound scratch assay.    
We also investigated the downstream effect of upregulation of mRln1 mRNA expression. 
The downstream pro-fibrotic related genes of interest were alpha smooth muscle actin (Acta2), 
Collagen I (Col1a1), Fibronection 1 (Fn1), matrix metallopeptidase 9 (MMP9), Periostin (Postn), 
Tissue inhibitor of metalloproteinases 1 (TIMP1) and Tissue inhibitor of metalloproteinases 2 
(TIMP2). The ECM components (Col1a1, Fn1 and Postn) are synthesised by fibroblasts, while 
Acta2 is the surface marker which is upregulated in myofibroblasts compared to fibroblasts 
(Baun and Duffy, 2011). The balance of ECM component production is regulated by MMPs 
(degrading enzymes can breakdown various ECM components) and TIMPs (neutralizing enzyme 
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that inhibits MMP activity); these enzymes therefore play a vital role in wound healing and 
fibrosis (Kalluri, 2016).   
 In this chapter, we describe the effects of mRln1 upregulation via plasmid transfection 
with mRln1 expressing plasmid on downstream pro-fibrotic genes at the level of transcription in 
C2C12 and MH cell lines. In addition, we also look into how mRln1 upregulation affects the 
migration rate of MH cells via wound scratch assay. Our in vitro studies provide an insight into 
how mRln1 upregulation might contribute to reducing muscle fibrosis.   
 
5.2 RESULTS 
5.2.1 Effect of mRln1 on downstream fibrotic related gene expression assessed using RT-
qPCR analysis   
We investigated the effect of upregulation of mRln1 expression using plasmid 
transfection with pTet On-NCO mRln1 plasmids into C2C12 and MH cells. C2C12 or MH cells 
were transfected with 1000ng of pTet On-NCO mRln1 plasmids with the presence of 200ng/ml 
tetracycline for 24 hours. Subsequently, total RNA was extracted and 600ng of total RNA was 
used for cDNA synthesis and RT-qPCR. The Acta2 was used as a cell surface marker of 
myofibroblasts, while Col1a1, Postn and Fn1 as the extracellular matrix (ECM) component, 
MMP9 as the metalloproteinase capable to degrade ECM, TIMP1 and TIMP2 are 
metalloproteinase inhibitor.  
In C2C12 cells, RT-qPCR analysis (Figure 5.3) has shown a slight reduction in the 
transcript level of Acta2 after transfected with pTet On-NCO mRln1 plasmid with tetracycline 
presence. The other 5 downstream genes Col1a1, Fn1, MMP9, Postn and TIMP2 have remained 
at a similar transcription level as the mock (C2C12 without transfection). There is a 1 folds 
increase of transcript level of TIMP1 after transfection compared to untransfected mock sample. 
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The amplicons formed through RT-qPCR were analysed with a melting curve (Figure 5.1 
and Figure 5.2) suggested only one amplicon is formed with Acta2 primer, Col1a1 primer, Fn1 
primer, MMP9 primer, Postn primer, TIMP1 primer and TIMP2 primer and Rplp0 primer. The 
amplicon was further analysed by using agarose gel electrophoresis to examine specificity of 
amplicon size and stringency. Figure 5.4 shows a representative gel image, where the specific 
band size of the amplicon with primers targeting Acta2 (~129bp), Fn1 (~96bp), Col1a1 (~134bp), 
MMP9 (~125bp), Postn (~97bp), TIMP1 (~129bp), TIMP2 (~119bp) and Rplp0 (~147bp) can be 
seen. There were primer dimers formed with the TIMP2 targeting primer set which are 
suspected to be primer-dimers (Figure 5.2B) in non-template control samples with a melting 
peak at lower temperature and the identity was further confirmed through agarose gel 
electrophoresis (Figure 5.4D left) with a band size <50bp.    
The RT-qPCR analysis (Figure 5.5) indicate the transcript levels of three targeted genes 
(Acta2, Fn1 and Postn). The total mRNA samples were from MH cell transfection with pTet On-
NCO mRln1 for 48 hours in the presence of 200ng/ml tetracycline. When in the presence of 
human recombinant Transforming growth factor β1 (hrTGF-β1), the transcript level of the Acta2 
was slightly reduced, Fn1 increased and Postn remained unchanged when compared to mock 
(MH cell without transfection). In contrast, the cells transfected with pTet On-NCO mRln1 with 
tetracycline presence have reduced mRNA expression of three of the targeted genes compared 
to mock. The pTet On-NCO mRln1 is the plasmid that able to express highest mRln1 expression 
compare to other mRln1 plasmids construct (Section 2.2.2) that we designed. Finally, we 
observed that the transfected mRln1 expressing plasmids can reduce the mRNA expression of 
three target genes (Acta2, Fn1 and Postn) even with the presence of hrTGF-β1.   
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Figure 5.1 Melting Curve of RT-qPCR targeting downstream fibrotic related genes. The RT-
qPCR melting curve analysis indicates amplicons are produced at specific melting curve peak 
with 4 downstream fibrotic related primer targeting Acta2 (A. Blue peak), Col1a1 (B. Blue 
peak), Fn1 (A. Red peak) and Postn (B. Red peak). The one specific melting curve peak 
indicates there is only one specific amplicon that is formed with primers through RT-qPCR.    
 
 
 
A 
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Figure 5.2 Melting Curve of RT-qPCR targeting downstream fibrotic relate genes. The RT-
qPCR melting curve analysis indicates amplicon are produced at specific melting curve peak 
with 3 downstream fibrotic relate primer targeting MMP9 (A. Blue peak), TIMP1 (A. Red 
peak), TIMP2 (B. Blue peak on left) and housekeeping gene Rplp0 (B. Blue peak on right). The 
one melting curve peak indicates there is only one specific amplicon formed with primers 
through RT-qPCR. There are amplicons formed on the non-template control (without cDNA) 
with TIMP2 primer set (B. grey peak on left).       
 
 
 
 
 
A 
B 
136 
 
 
Figure 5.1 RT-qPCR analysis of downstream fibrosis-related genes of RNA harvested from 
C2C12 cells transfected with mRln1 expressing plasmid. The mouse muscle myogenic cells 
(C2C12) were transfected with pTet On-NCO mRln1 plasmid in the presence 200ng/ml 
tetracycline hydrochloride for 24 hours prior to total RNA extraction, cDNA construction and 
qPCR. The mRNA expression of 7 downstream fibrotic related genes (Acta2, Col1a1, Fn1, 
MMP9, Postn, TIMP1 & TIMP2) was relatively quantified against the expression level of Rplp0 
housekeeping gene in untransfected C2C12 cells (Mock) and transfected MH cells with pTet 
On-NCO mRln1 plasmid (Transfected). Data are the mean ± SEM of three repeats in one 
independent experiment. n = 1.  
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Figure 5.4 Gel Image with RT-qPCR amplicon targeting downstream fibrotic relate genes. 
The size of RT-qPCR amplicon targeting Acta2 (A. left), Col1a1 (A. right), MMP9 (B. left), Fn1 
(B. right), Postn (C. left), TIMP1 (C. right), TIMP2 (D. left) and Rplp0 (D. right) from Figure 5.1 
electrophoresed on a 3.5% (w/v) agarose TAE gel for 65V for 60 minutes and 70V for 40 
minutes. The samples shown are untransfected C2C12 cells without any treatment (Mock), 
transfected with pTet On-NCO mRln1 with the presence of tetracycline (Transfected), non-
template control (NTC) and 25bp DNA ladder (500bp to 25bp). There are primer dimer are 
formed with the NTC samples with TIMP2 primer.  
A 
B 
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Figure 5.5 RT-qPCR targeting 3 downstream fibrotic related genes affected by mRln1 in MH 
cells. The mouse muscle derived fibroblast (MH) cells are transfected with pTet On-NCO 
mRln1 plasmid with the presence 200ng/ml tetracycline hydrochloride for 24 hours prior to 
total RNA extraction, follow by cDNA construction and RT-qPCR. The relative quantified mRNA 
expression of 3 downstream fibrotic related genes (Acta2, Fn1 and Postn) was compared to 
the level of Rplp0 housekeeping gene. The untransfected MH cells (Mock), presence of 
40ng/ml hrTGF-β1 (TGF), transfected MH cells with pTet On-NCO mRln1 plasmid with the 
presence of tetracycline (mRln1) and transfected MH cells with pTet On-NCO mRln1 plasmid 
with the presence of tetracycline and 40ng/ml hrTGF-β1 (mRln1+TGF). Data are the mean ± 
SD of one independent experiment (n = 1, 2 – 3 technical repeats). 
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5.2.2 Wound scratch assay studies with MH cells 
The wound scratch assay was carried out as shown in the represent of the schematic 
timeframe (Figure 5.6A).    
5.2.2.1 Effect of TGF-β1 on wound closure. 
We assessed the effect of 40 ng/ml human recombinant transforming growth factor β1 
(hrTGF-β1) on cell migration of MH cells after a wound scratch. We were also interested in 
whether the presence of 200 ng/ml of murine recombinant interferon γ (mrIFN-γ) is a TGF-β1 
inhibitor would reduce the effect of TGF-β1 on MH cell migration. A wound scratch was 
performed and the cells scratch closure assessed for 48 hours with treatment of either 40 ng/ml 
hrTGF-β1, or 200 ng/ml of mrIFN-γ and both after the wound scratch was induced. The 
microscopy imaging was captured with the area of wound closure on day 0 (T0), day 1 (T24) and 
day 2 (T48) and percentage of wound closure is shown in Figure 5.6B. The presence of TGF-β1 
resulted in around ~68% wound closure after 48 hours; no treatment (mock) showed similar 
wound closure (around ~71%). The presence of hrTGF-β1 also showed the highest wound 
closure (~30%) between the day 1 (T24) and day 2 (T48) after the wound scratch compared with 
other samples. On the other hand, the presence of mrIFN-γ had the lowest (~41%) wound 
closure after 48 hours. Finally, the presence of both 40 ng/ml TGF-β1 and 200 ng/ml mrIFN-γ led 
to ~40% wound closure after 48 hours. The treatment with either only tetracycline or 
transfection reagent (Viafect) resulted in a wound closure of ~57% on both treatments. The 
representative phase contrast microscopy images of the wound gaps before and after treatment 
are shown in Figure 5.7. 
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Figure 5.6 In vitro assessment of wound closure in MH cell with hrTGF-β1. A. Schematic 
timeframe of wound scratch assay. On day 1, mouse muscle derived fibroblast (MH) cells were 
seeded onto Ibidi dishes (1.2 x 105 cells per well) with 10% FBS media. On the second day, the 
MH cells were grown to around 80% - 90% confluency and the media was replaced with 0.5% 
FBS media to minimise cell proliferation. On the third day, the wound scratch was induced 
with 20μl pipette tips followed by plasmid transfection, treatment or both and microscopy 
imaging as Day 0 (T0). The microscopy imaging was performed on day 1 (T24) and day 2 (T48) 
after the wound scratch. B. The percentage of wound closure with MH cells transfected with 
pTet On-NCO mRln1 plasmids over a period of 48 hours. The wound was induced on day 0 
(T0) and together with different treatment with the presence of 40ng/ml human recombinant 
transforming growth factor β1 (hrTGF-β1), presence of 200ng/ml murine recombinant 
interferon γ (mrIFN-γ) or presence of both hrTGF-β1 and IFN-γ. The wound closure was 
captured with microscopy imaging on day 1 (T24) and day 2 (T48). The area of wound closure 
was highlighted with ImageJ and the result shown indicate the percentage of area wound 
closure. MH cells with no treatment (Mock), MH cells treated with 100ng/μl tetracycline (Tet), 
MH cells with the presence of transfection reagent Viafect (Viafect), MH cells with the 
presence of 40ng/ml hrTGF-β1 (TGF), MH cells with the presence of 200ng/ml mrIFN-γ (IFN) 
and MH cells with the presence of both 40ng/ml hrTGF-β1 and 200ng/ml mrIFN-γ (IFN+TGF). 
Data are the mean ± SD of one independent experiment (n = 1, 2 – 3 technical repeats). 
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Figure 5.7 Representative phase contrast images of cell wound scratch assay. The microscopy 
imaging was captured after wound scratch induction and different treatment on day 0 (T0). The 
microscopy imaging was captured again on 48 hours (T48) after wound scratch induction. The 
representative bright field microscopy images of control without treatment (mock), presence of 
200ng/ml Tetracycline hydrochloride (T+), presence of transfection reagent Viafect (V), 
presence of 40 ng/ml transforming growth factor β1 (B), presence of 200 ng/ml mrIFN-γ (Y) and 
presence of both 40 ng/ml hrTGF-β1 and 200 ng/ml mrIFN-γ (BY). There are morphological 
changes with TGF-β1 treatment (elongated cell shape) compare to mock (round cell shape). 
Scale bar = 100μm. 
 
 
5.2.2.2 Effect of mRln1 on wound closure 
We assessed the effect of the presence of 40 ng/ml hrTGF-β1 on cell migration of MH 
cells with a wound scratch assay. We were also interested whether the transfection of 1000 μg 
of pTet On-NCO mRln1 plasmids reduced the effect of hrTGF-β1 on MH cell migration. A wound 
scratch assay was carried out for 48 hours with the treatment of either 40 ng/ml hrTGF-β1, 
transfected with mRln1 plasmid or both after the wound scratch was induced. The microscopy 
imaging was captured to assess the area of wound closure on day 0 (T0), day 1 (T24) and day 2 
(T48) and percentage of wound closure is shown in Figure 5.8. The presence of the either hrTGF-
β1 treatment or tetracycline resulted in around ~93% of wound closure after 48 hours, while no 
treatment (mock) had around ~82% wound closure. The presence of hrTGF-β1 also showed the 
highest wound closure (~53%) between the day 1 (T24) and day 2 (T48) after the wound scratch 
was compared with other samples. On the other hand, the presence of mRln1 had the lowest 
wound closure (~54%) after 48 hours. Finally, the presence of both 40 ng/ml TGF-β1 and 
mRln1led to wound closure 76%. The representative Brightfield microscopy images of the 
wound gaps before and after treatment are shown in Figure 5.9. 
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Figure 5.8 In vitro assessment of wound closure in MH cell with hrTGF-β1 and mRln1. A 
wound scratch assay with mouse muscle derived fibroblast cells (MH) transfected with pTet 
On-NCO mRln1 plasmids with tetracycline presence over a period of 48 hours was carried out. 
The wound was induced on day 0 (T0) and together with different treatments with the 
presence or absence of hrTGF-β1. The wound closure was captured with microscopy imaging 
on day 1 (T24) and day 2 (T48). The area of wound closure was highlighted with ImageJ and 
the result shown indicates the percentage area of wound closure. MH cells with no 
transfection or treatment (Mock), MH cells with the presence of 40ng/ml human recombinant 
transforming growth factor β1 (hrTGF-β1) (TGF), MH cells with the presence of 100ng/μl 
tetracycline (Tet), MH cells transfected with pTet On-NCO mRln1 plasmid and the presence of 
100ng/μl tetracycline (Tet+mRln1) and MH cells transfected with pTet On-NCO mRln1 plasmid 
and the presence of both 100ng/μl tetracycline & 40ng/ml hrTGF-β1 (TGT+Tet+mRln1). Data 
are the mean ± SD of one independent experiment (n=1, 2 – 3 technical repeats).  
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Figure 5.9 Representative Bright field microscopy images of wound scratch assay. The 
microscopy imaging was captured after wound scratch induction and different treatment on day 
0 (T0). The microscopy imaging was captured again on 48 hours (T48) after wound scratch 
induction. The representative bright field microscopy images of control without treatment 
(mock), presence of 200ng/ml Tetracycline hydrochloride (Tet), presence of 40ng/ml 
transforming growth factor β1 (hrTGF-β1), transfected with plasmid pTet On-NCO mRln1 & 
presence of 200ng/μl tetracycline hydrochloride (Tet+mRln1), transfected with plasmid pTet 
On-NCO mRln1 & presence of 40ng/ml hrTGF-β1 (mRln1+hrTGF-β1) and transfected with 
plasmid pTet On-NCO mRln1 & presence of both 200ng/ml tetracycline hydrochloride, 40ng/ml 
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hrTGF-β1 (Tet+mRln1+hrTGF-β1). There are morphological changes with TGF-β1 treatment 
(elongate cell shape) compare to mock (round cell shape). Scale bar = 100μm. 
 
5.3 DISCUSSION 
5.3.1 The effect of mRln1 on downstream fibrotic related genes and wound scratch assay
  
 In this chapter, we tried to evaluate on the effect of mRln1 expression in C2C12 and MH 
cell line by transfecting pTet On-NCO mRln1 plasmids in the presence of tetracycline. RT-qPCR 
methods were able to provide an insight into how upregulations of mRln1 have an effect on the 
transcript level of downstream fibrotic related genes. Li and colleagues (Li et al., 2004) have 
shown the expression of Acta2 and Fn1 protein increase after 8 hours of treatment with 
exogenous hrTGF-β1. While our investigation was carried out for 24 hours, our results do not 
seem to match theirs, with a slight reduction on the transcript level of Acta2 and Fn1. Further 
investigations such as investigation of the protein level of Acta2 and Fn1 should be considered 
for more information. Our results showed a 1-fold increase of the TIMP1 transcript level after 
mRln1 upregulation for 24 hours. The TIMP1 mRNA upregulation might link to the suppression 
activity of MMP9, where the TIMP1 is an inhibitor to MMP9 (Morgan et al., 2010). Besides, high 
levels of MMP9 in C2C12 cells have been shown in improving the migration rate (Morgan et al., 
2010). On the other hand, a gradient of time course of investigation can be performed on how 
upregulation of mRln1 at different time point. We should also investigate the effect of TGF-β1 
presence in cells transfected with mRln1 expressing plasmid or both in C2C12. Li and colleagues 
shown the presence of TGF-β1 can reduce the myogenic protein expression (such as myogenin, 
myoD and desmin) and increase Acta2, Fn1 protein expression (Li et al., 2004). Overall we have 
shown that the mRln1 upregulation in C2C12 cells can reduce the transcript level of Acta2 and 
Fn1.    
  The downstream fibrotic related genes (Acta2, Fn1 and Postn) transcript level is reduced 
with the mRln1 upregulations compared to mock. This results suggested mRln1 can reduce 
expression of the myofibroblast cell surface marker (Acta2), and also reduces the transcript level 
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of ECM components (Fn1 and Postn). In contrast, the presence of TGF-β1 can increase the 
transcript level expression of Fn1, while Acta2 and Postn remain similar compared to mock. It is 
not sure why the effect of TGF-β does not affect Acta2 and Postn expression. Our result have 
shown the effect of hrTGF-β1 can be reduced with the mRln1 upregulation. Our results are 
similar to Zanotti et al., (2016) who report that the presence of pirfenidone (anti-fibrotic drug) 
can reduce the transcript level of Fn1 in primary mdx active myofibroblasts. Further 
investigation on the protein level of the three genes mentioned earlier or other related proteins 
shall be examined for more accurate outcome on the effect of mRln1. A gradient of TGF-β1 dose 
treatment and duration of treatment shall be investigated further on the transcript level or 
protein expression of downstream fibrotic related genes. Overall, we have shown that the mRln1 
upregulation might reduce the activity of TGF-β1. However, no statistics could be carried out as 
the n number was 1 or 2. In the future, experiment repeat with more n number will enable 
statistical analysis. 
  
 
5.3.2 The effect of TGF-β1 and mRln1 on wound closure in wound scratch assay 
To determine the effects of the TGF-β1 on MH cells with wound scratch, we applied 
exogenous hrTGF-β1 in the culture media. Our results indicate that hrTGF-β1 can increase the 
speed of wound closure compared to untreated samples; in contrast the presence of IFN-γ 
reduced the rate of wound closure. When both hrTGF-β1 and IFN-γ are present in the culture 
medium of MH cells in wound scratch assay, the activity of hrTGF-β1 is inhibited due to the 
presence of IFN-γ. On the other hand, the upregulation of mRln1 is capable in reducing the effect 
of TGF-β1. This is further supported by the fact that mRln1 might contribute with its anti-fibrotic 
property. In the future, investigations shall be focused on related proteins affected by the mRln1 
upregulation. On the other hand, the collagen content in the culture media and intracellular 
collagen content might be an interesting point to look into as this can indicate the amount of 
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ECM production and secretion. The TGF-β1 has been shown here to change the morphology of 
MH cells in both wound scratch assay investigation; further investigation such as gene and 
protein expression (α-SMA as a biomarker of myofibroblast or ECM secretion) comparison with 
MH cell would be interesting. Apart from that, a concentration gradient shall be investigated 
with a range of doses of TGF-β1 and IFN-γ with MH cells for optimum response. 
There are few challenges during the wound scratch assay experiment, where it is 
difficult to split the cells in a well even distributed manner on ibidi dishes. Next, the wound 
scratch induced manually with the pipette tip is not consistent; it could be improved with a more 
consistent automatic wound induction system (Incucyte) across 96-wells plate (Roddy et al., 
2016). In order to improve the accuracy of data collect, microscopy live-imaging provide video 
camera recording on wound scratch assay such as more consistent imaging on the same fix 
targeting location microscopy imaging at specific time point or with continued microscopy video 
recording system (Roddy et al., 2016). Although latest technology can improve the outcome of 
wound scratch assays, limitations such as different cell densities due to the accumulation of cells 
at the side of wound scratch might not be able to overcome (Vang and Jenssen, 2018). On the 
other hand, the sample size shall be increased for the experiment.  
In conclusion, our data indicate that the mRln1 upregulation is able to reduce MH cell 
migration rate and the mRNA expression of downstream fibrotic related genes. However, the 
mRln1  protein might not expressed so well, we should therefore try to compare our transfection 
with mRln1 expressing plasmids to the presence of mouse recombinant relaxin 1 protein as a 
positive control in in vitro investigation or western blot. Apart from that, it is important to show 
mouse relaxin 1 receptor (RXFP1) is presence in both MH and C2C12 cells. This demonstrates 
the mRln1 upregulation might be a potential treatment for muscle fibrosis in Duchenne 
muscular dystrophy. On top of that, relaxin has been shown to have other beneficial effects: 
reduced inflammation in cardiovascular diseases, control MMP expression and promote satellite 
cell mobilization in muscle healing. In muscular dystrophies, muscle fibrosis and inflammation is 
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an unregulated process which contributes to the second pathology. Further in vitro studies 
regard using primary mdx myogenic, muscle-derived fibroblasts or both types of cells shall be 
investigated before proceeding to in vivo. 
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Chapter 6: GENERAL DISCUSSION  
6.1 Project overview 
Many studies have shown that skeletal muscle is capable of synthesizing and correct 
processing of a variety of proteins (Kessler et al., 1996). Skeletal muscle targeting gene therapy 
is also considered to be the first regulatory approval of gene therapy (Sarcar et al., 2019). We 
aim to use adeno-associated viral vector as a vehicle to deliver mouse relaxin 1 (mRln1) isoform 
as a muscle targeting gene therapy to reduce muscle fibrosis in DMD. In this thesis, we evaluated 
the potential of mouse relaxin 1 expression to reduce muscle fibrosis through an in vitro study 
using mRln1 plasmid delivery. We were particularly interested in investigating the hypothesis 
that muscle-derived mRln1 secretion acts in an autocrine and paracrine manner and could 
potentially reduce the activation of muscle-derived fibroblasts in response to a fibrotic stimulus. 
In the following investigation, experimental data were assessed: 
In Chapter 3, we have showed the mRln1 plasmids construct are designed and 
verification the identity of the plasmid. The transfection efficiency is highest with transfection 
reagent Viafect in C2C12 and MH cells. In Chapter 4, our results suggested that the mRln1 mRNA 
expression with RT-qPCR analysis show that mRln1 transcript level is express with mRln1 
plasmids construct with codon optimised mRln1 (CO mRln1) or non-codon optimised mRln1 
(NCO mRln1). The highest mRln1 mRNA expression was shown with plasmids pTet On-NCO 
mRln1, a NCO mRln1 plasmid driven by the tetracycline-inducible promoter (Tet-On). Next, the 
pre-pro-mRln1 protein (~21kDa) was detected with the cell lysate samples was success detected 
via western blot, but the mRln1 targeting antibody cannot detect any mature form of mRln1 
protein in the cell culture medium.  
In Chapter 5, we demonstrated that the downstream effects of mRln1 upregulation in 
C2C12 and MH cells. The RT-qPCR targeting 7 downstream fibrotic relate genes (Acta2, Col1a1, 
Fn1, MMP9, Postn, TIMP1 and TIMP2) in C2C12 cell. Our result suggested the mRln1 
upregulation can reduce the transcript level of Acta2 and Fn1, increase TIMP1 expression in 
C2C12 cell. On the other hand, the RT-qPCR analysis indicate a reduce in 3 downstream fibrotic 
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relate genes (Acta2, Fn1 and Postn) in MH cell. Furthermore, the effect of the presence of TGF-
β1 (a pro-fibrotic factor) can be reduced with the mRln1 upregulation and lower the expression 
of the three downstream fibrotic relate genes. Next, we utilize wound scratch with MH cells 
shown that the migration rate is reduced with the presence of IFN-γ or transfected with mRln1 
expressing plasmids. In contrast, TGF-β1 increase the migration rate of MH cells and lead to a 
10% more on wound closure. The effect of both IFN-γ (TGF-β1 inhibitor) and upregulations of 
mRln1 can also inhibit the effect of the presence of TGF-β1 on the migration rate of MH cells.  
 
6.2 Limitation of the work present and relevance to the field of gene therapy for DMD and 
muscle fibrosis 
6.2.1 Limitation of present work 
In the current project, we performed an in vitro investigation in a mouse myogenic cell 
line (C2C12) and a mouse muscle-derived fibroblast cell line (MH). Although we show 
upregulation of mRln1 mRNA expression from mRln1 express plasmids in C2C12 and MH cells 
through RT-qPCR, we are unable to show mature mRln1 protein is secreted into the culture 
medium using western blot. We suggest that further investigation using western blotting with 
another specific mouse relaxin 1 antibody instead of the human relaxin 2 targeting antibody we 
had used, loading higher protein amounts and using mRln1 recombinant protein as a positive 
control might contribute to the success of secreted mRln1 detection. Further investigation could 
focus on the change in level of downstream fibrotic related protein (such as Acta2, Col1a1, Fn1, 
MMP9, Postn, TIMP1 and TIMP2), and intracellular and soluble collagen content as a result of 
relaxin expression.  
We suspect the mRln1 protein expressed from both the codon and non-codon optimized 
constructs may not secreted into the cell culture media. Both of the codon and non-codon 
optimized mRln1 constructs are based on the native mRln1 amino acids sequence (Uniprot, 
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P47932).  We have tried to relate insulin with relaxin as both of these proteins share similar B-
C-A protein structures. A study has shown that mature insulin is not secreted from muscle 
targeting gene therapy; mature insulin is only secreted by pancreatic β cell due to the presence 
of a specific group of prohormone convertase that can cleave and remove the insulin pro-
peptide (Niessen et al., 2012). In both canine modified insulin (Niessen et al., 2012) and human-
modified insulin (Shaw et al., 2002) have shown that mutation on original prohormone 
convertase 3 targeting site and prohormone convertase 2 targeting site into furin (ubiquitous 
prohormone convertase) targeting site has to allow modified canine and human insulin secreted 
in C2C12 cell (Figure 6.1 top). Although we try to investigate which prohormone convertase 
might be responsible for the LS amino acids sequence (C-terminal of B-chain and N-terminal of 
pro-peptide of mRln1) cleavage and compared with some of the secretome protein, there is no 
information regarding the cleavage of amino acids sequence or types of prohormone convertase 
targeting it. Therefore, we propose modification of the original prohormone convertase 
targeting site in the native mRln1 amino acids sequences in between the end of B-chain and 
before pro-peptide with a furin cleavage site might contribute to the pro-peptide cleavage 
(Figure 6.1 bottom), resulting in mature mRln1 secretion in the myogenic cell line.  
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Figure 6.1 Comparison between amino acid sequence of canine pre-pro-insulin and murine 
pre-pro-relaxin. The canine pre-pro-insulin (cppl) (top) have two cleavage site target by 
prohormone convertase 2 (PC2) and prohormone convertase 3 (PC3). The mutate cppl are 
generate through 4 amino acids mutation (Red) which allow cleavage by furin (ubiquitous 
prohormone convertase) (Niessen et al., 2012). The murine pre-pro-relaxin 1 (mppr) (bottom) 
have two cleavage site target by unknown prohormone convertase (?) and furin. The mutate 
mppr are generate through 4 amino acids mutation (Red) which allow both cleavage site 
target by furin.   
 
Both the C2C12 and MH cell lines are normal cell line from mouse, which is different 
compared to myogenic and fibroblasts from both mdx mouse and DMD patient. Further in vitro 
investigation should be focus on much closer murine H2kb mdx myoblast cell line (Morgan et al., 
1994) and isolating primary muscle-derived fibroblasts/myofibroblasts from mdx mice. A study 
has shown that quiescent fibroblasts can be activated to become active fibroblasts 
(myofibroblasts) during circumstances (such as wound healing or stress) to proliferate and 
promote secretion of extracellular matrix component (ECM); activated fibroblasts can be 
reversible to become quiescent fibroblast or undergo apoptosis (Kalluri, 2016). However, the 
activated fibroblast in cancer or fibrosis can be irreversible in cancerous/fibrosis activated 
fibroblasts with ability to enhanced secretion and proliferation (Kalluri, 2016). On the other hand, 
the high level of transforming growth factor-β (TGF-β) from macrophages cause 
fibro/adipogenic progenitors to differentiate into myofibroblasts in mdx mice might also be 
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considered as a source of activating fibroblasts (Lemon et al., 2015). One study has shown that 
the TGF-β1 kinase inhibitor is able to reverse the proliferating cardiac myofibroblasts but not 
non-proliferating cardiac myofibroblasts (Driesen et al.,2019).  It is interesting to investigate 
whether the irreversible activated muscle derived fibroblasts from mdx mice or DMD exhibit the 
similar characteristic or not. The investigation on the effect of mRln1 on irreversible 
myofibroblasts can provide insight into a much closer characteristic of myofibroblast in DMD.  
The manual wound scratch assay provides only limited detail on the migration rate of 
the mouse muscle-derived fibroblasts (MH cell). By using primary mdx muscle fibroblast for 
wound scratch assay which has the morphology and activity much closer in DMD compare to 
control mouse muscle-derived fibroblasts (MH cells). Although the wound scratch assay is a 
cheap, easy and direct technique, it is hard to produce a consistent result (Grada et al., 2017). 
Other limitations of wound scratch assay is absence of cell to cell adhesion and lack of 
extracellular matrix effect (Stamm et al., 2016). Besides, the wound scratch does not represent 
the actual wound (Grada et al., 2017) or muscle fibrosis in DMD (Kharraz et al., 2014). It is 
unlikely that wound scratch assay with just limited observation on cell migration of fibroblasts 
can provide a full complex picture on the interaction between different types of cells and 
extracellular matrix in DMD.  
In the 2D cell culture system involved in the wound scratch assay, the limitation is that 
the single monolayer cell line has more contact with medium and plastic compared to 3D in vivo 
structure (Antoni et al., 2015). Skeletal muscle wound healing or fibrosis is a complex process 
involving the interaction of multiple types of cells (such as myogenic cells, fibroblasts, 
myofibroblasts and leukocyte) with various elements such as chemokines, cytokines, growth 
factors and inflammatory mediators (Kharraz et al., 2014). TGF-β improved myogenesis in 3D 
muscle cell cultures but not in the 2D monolayer muscle cell culture, where both of the 
myogenin gene expression and myotube formation was reduced (Krieger et al., 2018). This study 
has shown an example of the limitations of the 2D in vitro model is not as accurate 3D in vitro 
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model which is similar to in vivo. Besides, the presence of more than one of the elements (such 
as chemokines, cytokines, growth factors and inflammatory mediators) in the culture media of 
3D  in vitro model during the investigation might contribute to much more closely mimic 
environment that takes place in Mdx mice or DMD patients (Kalluri, 2016).  
On top of that, exosome derived from muscle fibroblasts of DMD patients have an 
elevated miRNA-199a-5p (a pro-fibrotic miRNA) which can promote the activation of fibroblasts 
(Zanotti et al., 2018). The presence of muscle-derived exosome from muscle fibroblast promotes 
myofibroblasts phenotype such as Acta2 expression, cell proliferation and collagen production. 
This might suggest the factors such as miRNA might also affect the muscle fibrosis as well as 
other elements (such as chemokines, cytokines, growth factors and inflammatory mediators). 
Therefore it is important to test the effect of mRln1 upregulation with a much more suitable in 
vitro 3D model with pro-fibrotic secretome and various elements that contribute to muscle 
fibrosis to give a much closer cellular environment to DMD patients (Krieger et al., 2018).  
 In fibrosis, there are many strategies targeting for a single factor that have been involve 
in either extracellular or intracellular factors. Most of the anti-fibrosis strategy focus on the 
inhibition of growth factors, cytokine, MMP and fibrotic relate miRNA (March et al., 2018). One 
of the main target is transforming growth factor β (master regulator for fibrosis) was the focus. 
The TGF-β1 contribute to the activation of fibroblast to promoter ECM production which is one 
of the main pathology in fibrosis. The TGF-β1 inhibition (such as halofuginone), suppression 
(such as decorin) antagonist (such as tumor necrosis factor-α) strategy have been adapted in 
order to target TGF-β1 to reduce fibrosis in multiple types of tissue fibrosis (Lichtman et al., 
2016).  
Connective tissue growth factor (CTGF) is a matricellular matrix protein that is 
upregulated in relation to fibrosis in several chronic diseases. In fibrosis, CTGF promote the 
proliferation of fibroblast to produce more extracellular matrix (ECM) component. Studies have 
shown that over expression of CTGF can induce skeletal muscle to produce ECM in in vivo 
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(Morales et al., 2011). Besides, it suggested CTGF have been related to the downstream action 
on TGF-β to exacerbate pro-fibrotic effects (Mori et al., 1999). On the other hand, Morales et al 
2013 also showed that the FG-3019 suppression on CTGF does not affect the TGF-β, pERK1/2 
and p38 signalling in mdx mouse. FG-3019 (Pamrevlunab) is a neutralizing antibody target CTGF 
for and can ameliorate muscle fibrosis in mdx mice, reduce fibrosis in different types of tissue 
(liver, cardiac and lung) (Morales et al., 2013) and currently waiting for Phase II clinical trial in 
DMD (Fibrogen, 2019). In one of the in vivo study have shown that the co-treatment of TGF-β 
and CTGF cause fibrosis compare to injection with either one of TGF-β or CTGF. (Wang et al., 
2011). Furthermore, the TGF-β and CTGF immunohistochemical staining of muscle biopsy 
samples from DMD patients (age between 3 to 13) indicate both integral optical density value is 
around 115 times more intense compare to normal (Song et al., 2017).  By summary some of 
the study on CTGF, we suggested to set up in vitro and in vivo study that is similar to fibrosis with 
co-treatment of TGF-β and CTGF together with treatment to inhibit both TGF-β and CTGF.  
The pro-fibrotic miRNA have also been study as a strategy to target in order to reduce 
fibrosis. The studies on miRNA that is involved in fibrosis are such as miR-21 (pro fibrotic role) 
and miR-29 (anti-fibrotic role) dysregulation in muscle fibrosis (Zanotti et al., 2015), miR-125 
involve in cardiac fibroblast activation (Zanotti et al., 2018), both miR-208a and miR34 relate to 
cardiac fibrosis (March et al., 2018), miR-17-5p upregulated in fibrosis (Meng et al., 2016b). The 
fibrotic miRNA can reduce the fibrotic-related mRNA expression of fibrotic tissue and should 
compare with muscle fibrosis in DMD.  
One of the current published study have shown that by utilizing cell therapy with 
leukemia inhibit factor (LIF) expression in leukocyte progenitors into dystrophin mouse (Welc et 
al., 2019). The LIF is a member of interleukin-6 class cytokine which exhibit either promote or 
inhibit process such as cell growth, proliferation or differentiation (Nicola and Babon, 2015). The 
transplantation of LIF expressing leukocyte progenitor cell can reduce the fibrosis pathology by 
not favour macrophages for CD163+/CD206 phenotype and decrease T helper cells type 2 (Th2) 
157 
 
cytokines production in muscle (Welc et al., 2019), resulting in inhibit TGF-β signalling. This study 
can provide an insight into how the macrophage and T helper cells involve in muscle fibrosis.  
The early detection of the first symptom of DMD in patient play a vital role to start the 
treatment before fibrosis and inflammation take place in dystrophic muscle (Cordova et al., 
2018). As the first symptoms start around two to three years old should be noticed with early 
detection (Bushby et al., 2010). Besides, the early dystrophin restoration therapy could minimise 
the pathology of DMD and maximise the effect of therapeutic therapy. One of the key is the 
timing to performed therapy for DMD, where the treatment should be started before a plateau 
in muscle loss around four to six years old is recommended (Sienkiewicz et al., 2015).   
 
6.3 CONCLUSIONS  
Introduction of muscle targeting as an autocrine, paracrine or endocrine manner with 
transgene expression offer a therapeutic effect in gene therapy can eliminate repeated 
administration or daily intake of a therapeutic protein, including Duchenne Muscular Dystrophy. 
Our project hopes to focus on gene addition for mouse relaxin 1 secretion via muscle to reduce 
muscle fibrosis. We aim to reduce the muscle fibrosis in DMD with relaxin might combine with 
other anti-fibrotic strategy to target one of the secondary pathologies of DMD. In future we 
hope that our work on systemic mouse relaxin 1 expression with AAV in muscle targeting gene 
therapy should be investigate much more details in 3D models or in vivo models for more 
information regarding reducing fibrosis before as a supportive therapy together with other 
strategy target other secondary pathology and the main primary dystrophin restoration multiple 
factors combinational therapy to cure DMD. In conclusion, DMD research is moving forward with 
some clinical trials to target primary and secondary pathology represents data collection toward 
better treatment. An ideal combinational therapy that able targeting both primary and 
secondary pathology as early as possible would be most likely provide maximise therapeutic 
effect to DMD. 
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